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ABSTRACT 
Mathematical Modeling of Malaria: Theories of Malaria Elimination  
Geoffrey Louis Chi-Johnston 
 
This dissertation describes the development and application of a new mathematical model for simulating 
the progression of Plasmodium falciparum infections in individuals with no malarial acquired immunity. 
The model allows for stochastic simulation of asexual and sexual parasitemias as well as the onset of 
fever and human to mosquito infectivity on a daily time scale. The model components for the asexual and 
sexual stages were developed elsewhere but are here extended to allow for simulation of the full range of 
dynamics observed in a subset of malaria therapy patients. As a first application of the model, I calculate 
the human component of malarial R0, the basic reproductive number. I then compare this value to those 
from three other models and describe how this quantity can be used to model malaria transmission. The 
second application of the model incorporates the effects of drug treatment on progression of infection by 
utilizing modeled pharmacokinetic and pharmacodynamic properties of a variety of antimalarials. I utilize 
a stage specific proportional killing model for sexual stages, informed from recent in vitro data. The 
relationship of effect sizes to treatment coverage and type of treatment in both early and late treatment 
seeking settings is calculated. In the third chapter, I consider the economic and epidemiological 
ramifications of antimalarial and rapid diagnostic subsidization for malaria control. For the 
epidemiological modeling I utilize a semi-mechanistic model of the spread of drug resistance 
parameterized from historical malaria mortality data; for the economic model I consider the effect of 
rapid diagnostics on the intensive and extensive margins of antibiotics and antimalarials, as well as the 
benefits to improved targeting of both. I find that rapid diagnostic testing is justified given our baseline 
assumptions for areas with low proportions of malarious individuals among all treatment-seekers, but that 
caution is necessary before deployment worldwide. For antimalarial subsidization, we find that this is a 
cost-effective method for reducing mortality in developing countries, though efforts to delay the onset and 
slow the spread of resistance are urgently needed. 
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Preface 
Malaria is a disease that is as old as the human species. It has taken countless lives over 
thousands of years and plagues developing counties to the present day, exacting a severe human 
and economic toll. The disease is caused by infection with one of five species in the genus 
Plasmodium: P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. The first of these 
species is the most virulent, responsible for the vast majority of deaths per year, mostly among 
African children. 
Malaria was thought for ages to have been caused by ‘bad air’ emanating from 
marshlands.1 It was not until malarial parasites were first observed by Alphonse Laveran in 1880 
that the etiologic agent of malaria was identified.2 Further, the mechanism of transmission of 
malaria was unproven until 1897, when Ronald Ross discovered malaria parasites in mosquito 
midguts. After this discovery, serious control efforts began to be formulated, applying ancient 
techniques such as swamp draining, bed nets, and improved sanitation. Ronald Ross himself 
further contributed to malaria control efforts by formulating mathematical models describing the 
equilibrium dynamics of malaria in human and mosquito populations. 
As the World Wars raged, understanding of malaria steadily improved, and new drugs for 
treatment of malaria were developed, such as chloroquine. The insecticidal properties of DDT 
were discovered in 1939, allowing for mass spraying of wide areas to eliminate or severely 
reduce mosquito populations. Further, from 1950-1952 the malariologist George MacDonald was 
modifying and building upon the mathematical work that Ross had pioneered.3 The model that 
he developed, called the Ross-MacDonald model, as well as the insights he gleaned from 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 http://www.cdc.gov/malaria/about/history/laveran.html 
2 ibid. 
3 Smith D., et al., “Ross, Macdonald, and a Theory for the Dynamics and Control of Mosquito-
Transmitted Pathogens,” PLoS Pathog 8(4): e1002588. 
	   x 
working with Ross, were then pressed into service during the first Global Malaria Eradication 
Program (GMEP).  
The GMEP, begun in 1955, was an effort to eliminate malaria from many parts of the 
world outside of Africa, and was successful in many places. However, the project lost steam and 
by the early 1970s was abandoned, never having made a serious attempt to eliminate malaria in 
Africa (though significant pilot projects were run in Pare-Taveta from 1957-1959 and in Garki, 
Nigeria from 1969-1976). After this program was abandoned, efforts toward controlling malaria 
languished. Resistance to the first-line antimalarial, chloroquine, and the second-line 
antimalarials, such as sulphadoxine-pyrimethamine, spread widely; further, resistance to DDT 
began to spread as well. By the 1990s malaria was resurging throughout Africa and Southeast 
Asia and the number of deaths was approaching two million per year. 
Not all is gloom and doom, however. In the early 2000s researchers perfected the use of 
artemisinin derivatives, a newly-discovered class of highly potent antimalarials, and artemisinin-
based combination therapies were deployed worldwide. Relying on these new antimalarial 
combinations, along with pyrethroid treated bed nets and insecticide spraying, massive 
improvements in controlling malaria mortality and morbidity were achieved, and by the end of 
the century significant progress had been made. 
However, this progress, although impressive, is tenuous. Antimalarial and insecticide 
resistance are once again on the horizon, and funding sources are drying up as recessions slow 
economic growth worldwide. Progress toward an antimalarial vaccine has proved difficult, and 
money for vaccine development is scarce. In order to make the best use of limited resources, 
mathematical models may once again be relied upon to help direct control efforts. Further, 
	   xi 
models are needed to help predict how resistance might arise and how its spread might be 
limited. 
In this dissertation, we describe two papers that apply recently developed modeling 
techniques to help improve the modeling and mapping of malaria transmission. In Chapter 1, we 
describe the parameterization of a new within-host model of the development of malaria 
infection. We utilize this model to predict the infectivity of human populations in the absence of 
preimmunity. The model was parameterized using malaria therapy data, in which individuals 
with tertiary syphilis were infected with P. falciparum in order to induce a fever. The net human 
infectivity that we calculate is a critical component of the R0, or basic reproductive number, for 
malaria. We then compare our predicted net infectivity to the net infectivity predicted by other 
malaria models. Our improved estimate was used to inform recent malaria mapping work of the 
worldwide R0 for malaria.4 
For Chapter 2, we analyze the effectiveness of artemisinin-based combination therapies 
as well as new antimalarial combinations at reducing malaria transmission. Specifically, we 
utilize our within-host model as well as the pharmacokinetics and pharmacodynamics of a 
variety of antimalarials to predict how drug treatment would reduce net human infectivity. We 
simulate treatment in two different treatment-seeking contexts (early and late treatment), 
corresponding to observed patterns of treatment in Thailand and Myanmar, respectively. We find 
that malaria control efforts benefit from gametocytocidal treatments (treatments that kill the 
sexual forms of the parasite). However, there is only a 1.5-fold increase in reduction in 
transmission that is achieved from adding gametocytocidal drugs to artemisinin-based 
combination therapies in the early treatment setting (less in the late treatment setting). This 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 Gething, P. et al., “A new world malaria map: Plasmodium falciparum endemicity in 2010,” Malaria J., 
10:378.	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reduction needs to be weighed against the costs of such drugs, as well as possible side effects. 
We also develop a framework that allows for comparing the transmission reductions achievable 
from different drug combinations to those from improving treatment coverage and/or treatment 
seeking behavior. This framework will allow for a cost-benefit analysis of whether to focus on 
introducing a new drug or improving existing delivery mechanisms in a given area. 
In Chapter 3, we predict how subsidies for artemisinin-based combination therapies and 
rapid diagnostic testing will affect malaria mortality using epidemiological and economic 
modeling. For the epidemiological modeling we used historical trends in malaria mortality to 
understand the impact of first-line drug resistance on mortality during the period of 1980-2005 
and projected the possible impacts of artemisinin resistance using these trends. For the economic 
modeling we considered how rapid diagnostic testing might affect the intensive and extensive 
margins of antibiotic and antimalarial usage and how rapid diagnostic testing results might be 
used to improve antibiotic and antimalarial targeting. We found that rapid diagnostic testing is 
justified in areas where there are relatively low proportions of malarious individuals among all 
treatment-seeking individuals. If we incorporate the benefits of reduced overtreatment using 
rapid diagnostics for delaying the onset of artemisinin resistance, the net effects of rapid 
diagnostics might recommend their usage worldwide. However, given the uncertainties involved, 
we state that a risk-averse social planner would deploy rapid diagnostic testing in a limited 
number of regions give our baseline parameter assumptions and the lack of confidence in the 
benefits of overtreatment for delaying resistance. Regarding antimalarial subsidization, we find 
that this is a cost-effective method for reducing mortality in developing countries; however, 
serious effort needs to be employed to delay the onset and slow the spread of resistance.  
	   xiii 
The results described in this thesis form the basis for a more through understanding of 
theories of elimination and eradication. In order to proceed with such a campaign, mathematical 
models are useful tools to help guide control efforts, and the results herein have helped and will 
continue to help improve model predictions and estimates. Further, the within-host modeling 
framework described here is an ideal tool to help predict how drug resistant malaria might 
spread, and efforts are ongoing to utilize results from such modeling efforts. Our results 
concerning antimalarial and rapid diagnostic subsidization show the need for caution before 
deploying these interventions worldwide, given the large number of feedbacks and uncertainties 
that are associated with these policies. We hope that we might continue to build upon the results 
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Background: Human malaria is caused by infection with one of five species of parasites of the 
genus Plasmodium. Anopheles mosquitoes are the primary host of Plasmodium and transmit 
parasites by biting their intermediate hosts, humans. Modeling transmission thus requires an 
analysis of parasite development in both mosquitoes and humans. The mosquito-borne 
components of transmission are described by their vectorial capacity. The components of 
transmission describing human infectivity to mosquitoes over time are less well understood. 
Methods and Findings: We have developed and analyzed a comprehensive simulation model of 
P. falciparum within-host malarial infection and transmission in immunologically-naïve humans. 
Our model incorporates the entire lifecycle of P. falciparum, starting with the asexual blood 
stage forms responsible for disease, the onset of symptoms, the development and maturation of 
sexual stage forms (gametocytes) that are transmissible to Anopheles mosquitoes, and human to 
mosquito infectivity. These model components were parameterized from malaria therapy data 
and from a range of other studies to simulate individual infections such that the ensemble is 
statistically consistent with the full range of patient responses to infection. Human infectivity 
was modeled over the course of untreated infections and the effects were examined in relation to 
transmission intensity expressed in terms of the basic reproductive number R0. We then 
compared our model results to implicit calculations of human infectiousness from three other 
studies. 
Conclusions: We find that mean human infectivity varies from 7.2 fully infectious days in the 
model of Okell et al., ~32 days using the current model, 45 days in the Garki model, and 94 days 
in the model of Lawpoolsri et al. This ten-fold difference reflects a diversity of modeling 
assumptions as well as the possible effects of immunity on transmission. Our current model 
3
	  provides a credible estimate of the human component of R0 and a sound basis for quantifying the 
effect sizes of antimalarial drugs. Further, the novel mechanistic modeling framework described 
here will enable careful studies into theories of eradication allowing for variation in infection 
responses within a human population. 
4
	  Introduction 
Approximately 2.5 billion people live in areas whose native ecology permits transmission of 
Plasmodium falciparum [1]. This range encompasses an incredible diversity of settings, from the 
arid Sahel to the jungles of the Congo; from rice paddies of India to the refugee camps of 
Western Thailand; indeed, malaria was once transmitted Central Park, London, and to the edge 
of the Arctic Circle. Efforts have been ongoing to map the historical and current limits of this 
transmission [1-3]; however, applications of these maps are complicated by the diversity of 
vectors in such areas, the state of the health systems, and the levels of human immunity and the 
extent of control efforts that are applied.  
Epidemiologists have long recognized the importance of developing mathematical 
techniques to quantify the extent of disease transmission in an area. The most important 
mathematical parameter for theories of eradication is R0, the basic reproductive number [4]. This 
value represents the number of secondary cases that an index case would generate in a 
population without previous exposure to the disease. For malaria, R0 has been expressed as the 
product of the vectorial capacity (i.e. the number of infectious bites that would eventually arise 
from all the mosquitoes that bite a fully infectious human on a single day), the duration of 
infectious period, and the efficiency of transmission. Vectorial capacity can be estimated directly 
over time by mosquito capture [5,6]. Changes in vectorial capacity can also be inferred from 
rapid changes in malaria endemicity corresponding to weather shocks [7] and less reliably from 
long-term endemicity responses to changing climate [3,8,9]. Statistical models have been 
developed that allow for prediction of vectorial capacity and malaria endemicity given other 
covariates such as the periodicity and intensity of rainfall, temperature, vegetation, etc. [10]. 
5
	  However, the human component of malaria transmission is more difficult to quantify, in 
part, because net infectiousness varies over the course of an infection. There are at least three 
aspects of human biology that affect human to mosquito infectiousness: immunity that is 
generated over the course of a single infection, the multiplicity of infection of a given host, and 
malaria-specific immunity acquired by repeated infections over time. The extent and 
mechanisms by which humans acquire immunity over time to malaria infections is a matter of 
current investigation and debate, with no consensus on the functional relationship between 
acquired immunity and progression of subsequent infection [11-13]. It is also not clear how 
infectious multiply-infected individuals are over time, though some estimates have been made 
that found no interaction among multiply-infected individuals in Africa [14].  
Malaria elimination, however, is based on conditions of low endemicity, when the latter 
two types of human response to infection are less relevant than the first [15,16]. In areas of 
naturally low endemicity, or in areas of previously high endemicity where control measures have 
been effective and preimmunity has waned over time [6,11], population immune responses will 
be similar to those observed in malaria-naïve individuals. Indeed, R0 itself is defined as the 
number of secondary infections among a non-infected population and serves as a threshold 
criterion for transmission: if the R0 of an area is below 1, the disease will eventually become 
extinct; if above 1, the disease will spread. 
Given the recent gains that have been made against malaria [17,18] public health and 
malaria experts have been increasingly promoting the agenda of malaria elimination and drawing 
up campaigns to reduce transmission [19,20]. To assess the likelihood of eliminating malaria 
from an area, quantitative approaches involve determining the intensity of interventions needed 
to eventually bring this value to less than 1, either through simulation or through estimation of R0 
6
	  and control effect sizes. For such calculations, it is important that human component of 
transmission be carefully quantified.  
In order to simulate the range of human responses to malaria and calculate their 
infectiousness on to mosquitoes, we developed a stochastic, mechanistic model that incorporates 
within-host infections and human to mosquito infectivity. This framework simulates the 
progression of blood-stage parasitemia after emerging from the liver, as well as conversion of 
asexual forms to sexual forms (gametocytes), onset of symptoms, and human to mosquito 
infectiousness. Molineaux and Dietz first developed the asexual and gametocyte components of 
our model from malaria therapy data, in which individuals with tertiary syphilis were infected 
with P. falciparum to induce a fever and clear the syphilis [21-23]. This framework has been 
used to simulate the effects of vaccines on transmission [21-25]. However, their original model 
required that the parameters be fitted to an individual patent’s case history before simulation. We 
have extended their work by choosing stochastic distributions for parameters that allow for 
within-host simulations that generate an ensemble consistent with the observed population of 
infections. 
Once we developed this model, we quantified the levels of human to mosquito infectivity 
over time and isolated the host-related determinants of the basic reproductive number, R0. This 
novel analysis of R0 allowed us to analyze overlooked aspects of transmission relevant for 
elimination campaigns. Predictions were compared to outputs derived from other models 
[15,26,27]. We find that mean human infectivity varies from 7.2 fully infectious days in the 
model of Okell et al., ~32 days using the current model, 45 days in the Garki model, and 94 days 
in the model of Lawpoolsri et al. Our modeling work provides the most careful estimate yet of 
the distribution of human responses to malaria infection and the mean human contribution to R0 
7




Plasmodium falciparum, the parasite that causes the deadliest form of human malaria, has a 
complex life-cycle that presents both challenges and opportunities for controlling malaria 
transmission [28]. Parasites enter the blood through the bite of an Anopheles mosquito and travel 
to the liver where they develop and replicate. Upon emerging from the liver, parasites then enter 
the blood as merozoites, which infect red blood cells, develop, replicate, burst from the infected 
cell, and then repeat the cycle of blood-stage infection. Some of these infected red blood cells 
sequester in the microvasculature to develop further and differentiate into sexual stages 
(‘gametocytes’). Once mature, these gametocytes enter the bloodstream [29]. Mature male and 
female gametocytes are then primed to form gametes and mate in the Anopheles mosquito 
following blood meal ingestion. 
Model Description 
We chose to utilize and extend a previously developed mechanistic modeling framework to 
reproduce the entire range of dynamics exhibited in the malaria therapy data, an extensive 
dataset describing deliberate malaria infections induced under clinical conditions. Our model 
simulates an infection by extending, combining, or modifying previously published models of: 1) 
bloodstream infections with the replicating asexual parasite forms; 2) onset of symptoms; 3) 
production and bloodstream dynamics of gametocytes; 4) the net infectiousness to mosquitoes as 
a function of gametocyte densities.  
1. Bloodstream Infections with Asexual Parasites 
8
	  Asexual parasitemia was modeled as a system of discrete (two-day time interval) difference 
equations previously elaborated by Molineaux et al. [21], which was also extended by Smith et al. 
[25]. The model simulates parasite densities in 50 different subpopulations aggregated by var 
gene expression type; switching occurs among the types in response to immune pressure. 
Asexual parasitemias are regulated by three immune responses: an innate immune response that 
establishes an upper limit for parasite density, a PfEMP1 variant-specific response that regulates 
short-term periodic oscillations in density and a variant-transcending immune response that 
causes a steady log-linear decrease in density over time, clearing the infection. We do not 
simulate deaths from malaria as these are so few as to not significantly impact overall 
transmission. 
The data used to parameterize this model comes from malaria therapy, in which 
individuals with tertiary syphilis and with no malaria preimmunity were inoculated with single 
strains of P. falciparum in order to induce a fever and clear the infection [30,31]. In their original 
study [21], the model parameters were fitted to individual patient parasitemias to produce a best 
fit valid for that patient. Our implementation of this model utilizes random distributions for the 
case-fitted parameters affecting infection duration and the maximum level of parasitemia. Table 
1 illustrates the changes in our model from the published parameters. 
Our asexual model parameter distributions were chosen so that the model duration of 
infection matches the duration observed in malaria therapy [32] and so that the maximum 
parasitemias would follow a truncated lognormal distribution with a maximum parasitemia of 
approximately 10% (the maximum percent parasitemia observed was 11.7 over 1000 runs) [14]. 
The model as implemented here is thus stochastic, producing a unique sequence of asexual 
9
	  parasitemias that mimics the dynamics of parasitemias observed in malaria therapy. The quality 
of model fit is described below. 
2. Onset of Symptoms 
Because we are also utilizing this model to simulate drug treatment in low-transmission areas 
(described in a companion study), treatment-seeking behavior is an important consideration. In 
the absence of diagnostic testing, fever may serve as an indicator of infection for both patient and 
clinician [33,34]. We allowed for the first onset of fever to serve as a trigger for treatment of 
infections. In order to predict when this fever occurs, we utilized the work done by Dietz et al. 
[35] who fitted probability distributions to the onset of fever as observed in malaria therapy data. 
In our model, all patients were assumed to be symptomatic and to experience a fever that began a 
variable number of days before reaching maximum parasitemia. To determine the day of first 
fever following emergence of parasites from the liver into the blood stream (taken as time zero), 
we used the uniform distribution based on an individual’s maximum asexual parasitemia as 
identified by Dietz et al. [25,35]. 
3. Gametocyte production and blood stream dynamics 
We derived our gametocyte model from previous work by Eichner et al. and Diebner et al. 
[22,23]. This model of gametocyte development calculates daily percentages of gametocyte-
infected red blood cells (i.e. gametocytemia) at each stage of development [29]. In human hosts 
gametocytes are produced by asexual parasites that commit to sexual development while in the 
host red blood cells. The sexual forms develop through five stages (I-V) over the course of 12-14 
days. The first stages sequester in the bone marrow or microvasculature with the final stage(s) 
being infectious. Our model assumes that gametocytes were produced from asexual parasites at a 
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  rate that varies with each wave of asexual parasitemia. Gametocytes then sequester for a variable 
length of time before becoming microscopically observable and infectious. 
As for the asexual model, the original gametocyte modeling work [22,23] fitted model 
parameters to each patient’s malaria therapy data. We have modified their model such that model 
parameters are now either constant or chosen from probability distributions such that the 
resulting outputs match the observed variability in the malaria therapy data (see goodness-of-fit 
below). Table 1 illustrates the changes in our model from the published parameters.  
4. Infectivity 
For our model we estimated the probability of human-to-mosquito transmission as a 
function of gametocyte levels at a given time. For our simulations, we utilized the nonlinear 
relationship between gametocytemia and infectivity described by Stepniewska et al., based on 
mosquito feeding studies on malaria therapy patients [36-38]. According to this function, 
infectivity rises sigmoidally on a long-linear scale. Thus infectivity rises rapidly at low levels of 
gametocytemia (1-100 gametocytes per µL) and then more gradually approaches a maximum of 
1.  
Model fitting 
Our modeling framework is designed to replicate both the means and the extremes of the 
dynamics of P. falciparum infections in adult humans with no preimmunity. For our asexual 
component, we utilized the medians, minima, and maxima of nine malariometric indices derived 
from the malaria therapy data as our simulation targets [21,39]. We used a bootstrap process to 
compare model outputs to the data. We first calculated the indices from the best-fit run from 50 
samples of 1000 runs (with replacement) as well as the minima and the maxima of the indices of 
these 50 samples. We then repeated this sampling and the means of 50 such experiments were 
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  recorded. Goodness-of-fit is according to the χ2 measure. Table 2 provides a comparison of 
model outputs to the indices from malaria therapy. 
We see that the model as parameterized does a good job of matching the median malaria 
therapy indices, though the model periods between appearances of PfEMP1 variants are shorter 
than observed in the data (Table 2, index 2-5). Further, the model slightly overpredicts the mean 
proportion of positive observations in both halves of patency, indicating that the model predicts 
that infections are more often observable during their duration of patency than observed (Table 2, 
indexes 2-7, 2-8). Given the high number of degrees of freedom in the model and in the data to 
be fitted, we could not use traditional fitting methods for these parameters, relying instead on a 
process of trial and error. A further complication encountered was that changing any one 
component may affect many indices simultaneously, and thus we were satisfied with the levels 
of fit here achieved.  
In addition to these nine indices, we also utilized a study which modeled the durations of 
infection observed in malaria therapy [32]. This study observed that the distribution of survival 
times of infections was Gompertz distributed, which informed our choice of distribution for the 
parameter Pm
*
km  (Table 1). 
For our gametocyte target data we relied upon the geometric means, minima, and maxima 
recorded from fits to malaria therapy as recorded by Eichner et al. [23]. This study recorded 
these data for three parameters describing gametocyte dynamics; see Table 3. We used 
bootstrapping to compare model outputs, as above, except that 113 samples were chosen from 
1000 runs with replacement and the means taken from 50 such experiments. In order to 
parameterize our model we utilized the reported quantiles for the gametocyte model parameters 
to help constrain our selection of distributions [22]. We also attempted to reduce the number of 
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  degrees of freedom in the model by setting β and µ0 to their mean values (after correcting for 
model differences). We note that our model fit the observed indices quite well, although the 
model predicted a shorter mean maximum duration of circulation for gametocytes (L) than was 
observed in the data. See Text S1 for a full mathematical description of all model components. 
As a further check of model outputs, our model predicts that the arithmetic mean duration 
of time between first fever and first gametocytemia detectable by smear is 12.0 days (with 
microscopic detection threshold of 10 gametocytes/mL), whereas the measured value from 
malaria therapy patients was 10 to 11 [40,41]. 
Model Illustration 
We illustrate how these dynamics play out in different simulated individuals in Figure 1. Figure 
1A shows the simulated asexual parasite densities over time for three individuals; densities are in 
log10 parasitized red blood cells (PRBC) per µL of blood. These individuals display the 
characteristic peaks and dips associated with PfEMP1 variation. The black line illustrated the 
lower limit of detectability by microscopy (10 PRBC/µL). The inset in Figure 1A shows the first 
50 days of infection along with the first fever day for each individual.  
In Figure 1B, the daily gametocytemias of the individuals from Figure 1A are shown. 
The gametocytemias are seen to stochastically track the asexual parasitemias after a slight lag. 
Figure 1C illustrates the daily probability that a mosquito bite will produce oocysts in the same 
individuals as in Figures 1A and 1B. Human to mosquito infectivity is seen to fluctuate rapidly 
in response to changing gametocyte density and infectivity. The large diversity in responses to 
infections within a population is illustrated in Figure 2A, which shows the asexual parasitemias 




We have developed a mechanistic model of the progression of malaria within a human host, 
parameterized such that the model reproduces the mean and extremes of the dynamics of 
infection observed in malaria therapy. Here we describe the mathematical formalisms that relate 
model outputs to R0 and compare the model outputs to those of three other models. 
Classical description of host contributions to R0  
The basic reproductive number 0R is one of the most important parameters in infectious disease 
modeling. This value describes the average number of hosts that would be infected following the 
full course of infection of a single host. If 0R  is greater than one, malaria will tend to be endemic, 
and if less than one then disease will progress toward elimination.  
The classical expression for the 0R of malaria was derived by Macdonald and can be 
formulated with four terms [16,42]. Potential transmission by a mosquito population is described 
by its vectorial capacity, V, which describes the number of infectious bites that would arise from 
all the mosquitoes that bite one fully infectious individual on a single day. Two parameters, b 
and c describe the proportion of blood meals that successfully cause an infection: b is the 
probability that an infected mosquito will infect an uninfected human upon biting; while c is the 
probability than an infected human will infect an uninfected mosquito upon biting. In the Ross-
Macdonald model, the infectious period of humans is exponentially distributed with a daily 
clearance rate of r and a mean duration of infection of 1−r  days. The basic reproductive number 
of malaria is then described by the classic formula:  
r
bcVR =0  
14
	  The Ross-Macdonald model [16,42] assumes that c is a constant over this period, so the ratio c/r 
describes the net infectiousness of a simple human infection. This net infectiousness fraction can 
be interpreted as the equivalent number of days that a person is fully infectious. 
Mean Human Infectivity Over Time  
In reality, neither V, b, c, nor r are constant among individuals over time and 0R  is only the first 
moment of a complicated multivariate distribution. Consider a population of N individuals, none 
of whom have been previously exposed to malaria. These individuals will differ in their 
responses to malarial infection, notably in terms of time of fever relative to the initiation of blood 
stage infection, parasitemias, and time to clearance of infection. We cannot use the ratio c/r in 
our calculations of 0R  to describe the infectiousness of these individuals because we do not 
assume constant rates of infectiousness and clearance. We let Di(t) denote the probability that 
individual i will infect a mosquito upon being bitten at time t; this function takes values between 
0 and 1. Our mechanistic model allows us to simulate the full variability of Di(t) for non-immune 
populations. 







then D(t) is a function of time only. We call this function as the mean human infectivity over 
time. The function D(t) for our mechanistic model is shown in Figure 2A along with the 25th and 
75th percentiles of daily infectiousness. The mean D(t) is skewed due to the presence of some 
individuals exhibiting long-lived infectious periods. Mean human infectivity is an important 
function for elimination in many contexts. Calculation of D(t) allows for a determination of how 
likely malaria will be able to persist through droughts or intensive antimalarial campaigns. Our 
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  mechanistic model predicts that individuals are, on average, infectious for a long period of time; 
see Discussion below. 
While D(t) and other functions of infectivity over time are important functions for elimination, 
there are still other ways of analyzing Di(t). Indeed, if we integrate over time, rather than over 
individuals, we are left with the expression 
Di = Di (t)0
∞
∫  dt , 
which describes the net infectivty of each individual. In a natural population there will be a 
distribution of Di over individuals. This distribution is shown in Figure 2B. 
If we integrate either the mean human infectivity over time with respect to t, or the 
distribution of net infectivity Di over a population, we arrive at the mean net human infectivity, 




∫ dt = DiNi=1
N
∑  
For our mechanistic model D ranges between approximately 31-34 for a population of 1000 
individuals (the mean of 5000 runs was 32.3). The units of D can be considered as fully 
infectious days, i.e., the number of days in which an individual has a probability of 1 of infecting 
a mosquito. This value represents the human contribution to R0, and we note here that D is 
invariant across time and space and ecological setting. Now that we have determined this 
parameter from our model, we compare this estimate to other models in the literature. 
Comparison of D(t) and D Among Malaria Models 
We will compare the calculation of D reported here to this value as imputed from three other 
models: the model of Lawpoolsri et al. [26], the model of Okell et al. [27], and the model of 
Dietz et al. (known as the ‘Garki model’) [15]. The former two models were designed to simulate 
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  the effectiveness of antimalarials at reducing malaria transmission. The model of Lawpoolsri et 
al. was fit to data from a low-transmission region of Thailand (PfPR ~ 0.0-1.5) [26] while the 
model of Okell et al. was fit to three regions of medium intensity transmission in Tanzania. Both 
are compartmental models (Lawpoolsri et al. has one infectious compartment and Okell et al. has 
four infectious compartments varying in infectivity and clearance rate), and both papers employ 
their models to predict the constant equilibrium prevalence in untreated and treated cases. We 
begin first by calculating the function D(t) for these two models. 
Lawpoolsri et al. assume that the mean duration of clearance in infectious individuals is 
1/188 day-1 with constant daily human to mosquito infectiousness (c) of .5. In the model of Okell 
et al. [27], each of the four infectious compartments in this model had different clearance rates 
(1/10.5, 1/10.5, 1/31.5, 1/157.5 day-1) and each compartment had a different proportional 
infectivity (1.90, 3.08, 1.53, 0.28) of the average daily infectivity c = 0.05. (We do not weight 
these durations of infectivity for age or body surface area, i.e., we calculate the unweighted D(t) 
here.) Figure 3 illustrates the cumulative distributions of the durations of 
infection/infectiousness for these two models as well that of the mechanistic model. We see that 
the mechanistic model matches the malaria therapy curve closely (not surprisingly), and that the 
other two models have significantly heaver tails, indicating that individuals are infected for a 
longer period of time in these models.  
Because we are here examining R0 from a novel perspective, neither of these studies 
reported D or D(t); however, we can derive D(t) for compartmental models using the curves from 
Figure 3 and the c values for each compartment. Figure 4A shows D(t) for both of these models 
as well as our mechanistic model; Figure 4B illustrates the first 200 days of this function for 
closer inspection. We see that the model of Lawpoolsri et al. predicts that mean infectivity is 
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  above 5% for 433 days, the output from Okell et al. is above this threshold for only 45 days, and 
our mechanistic model output is above this value for 151 days. The D values for these three 
models are 7.2 fully infectious days for the model of Okell et al., ~32 days using the current 
model, and 94 days in the model of Lawpoolsri et al. For the Garki model, we can calculate D 
from the formula D = gα1+δ  [15] such that D = 45.5 fully infectious days. 
Given our calculation of D for Lawpoolsri et al., Okell et al., and our mechanistic model, 
we can rescale the plots of D(t) by multiplying each curve by a scaling factor so that the three 
models share the same mean net infectivity as the mechanistic model; these results are shown in 
Figure 4C. Once the models are rescaled, we can see more clearly that the models of Okell et al. 
and the mechanistic model predict that infectiousness is cleared at very similar rates throughout 
the population, whereas Lawpoolsri et al. predict a much more gradual loss of infectiousness. 
However, the closeness of D(t) for the scaled stochastic representation of Okell et al. and the 
mechanistic model is surprising, although Okell et al. do parameterize some of their model 
parameters from malaria therapy data. 
Comparison of Di Among Malaria Models 
In the previous section we calculated the mean responses of individuals over time for the models 
of Lawpoolsri et al. and Okell et al. However, since these models are both compartmental, they 
can readily be formulated as stochastic, individual-based models by assuming that individuals 
are in each infectious compartment for exponentially distributed times. We can thus compute the 
distribution of net infectiousness within a population, Di, for both models. Figure 5A compares 
the distributions Di for these two models to the distribution generated by our mechanistic model 
(red cross indicates mean, green square the median). As implied by the D(t) curve, we see that 
the model of Lawpoolsri et al. has some individuals with very high D values, whereas the 
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  distribution generated by the model of Okell et al. is much more centered about its mean. If we 
scale the distributions Di to all have the same mean as the mechanistic model, we see that Di for 
Lawpoolsri et al. is still much more dispersed than the mechanistic model; however, Di for Okell 
et al. matches quite well to that of the mechanistic model (Figure 5B).  
 
Discussion 
We described the development of a novel, stochastic, within-host model of the progression of 
malaria in patients with no previous infections. This model utilized the difference equations 
developed by Molineaux and Dietz to simulate the progression of asexual and sexual 
parasitemias. By fixing some parameters and choosing others from stochastic distributions, we 
were able to fit the median and extremes of the dynamics of infections observed in malaria 
therapy, without the need to tune model parameters to individual case histories. We then 
validated this approach against three data sets from malaria therapy. 
There are three caveats to the modeling results described here. First, we are calculating D 
only among adults; there is no malaria therapy data for children. It is not known how children 
differ in their overall levels of infectivity from adults, and we do not speculate here. Further 
research will attempt to address this question. A second caveat is that our assumption that var 
genes switch in response to immune pressure is most likely incorrect. However, we have chosen 
to use previously published model structures that were validated against malaria therapy data, 
and these are the only models reproduce the range of observed responses in the data; we thus 
inherit their var assumptions.  
One existing mechanistic modeling framework, developed and described over three 
reports [39,43,44], does not allow for simulation of random individuals and thus does not allow 
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  for reproduction of the full range of host-parasite interaction. Given that var switching is 
extremely complex [45], we are content with a model that may not be correct mechanistically but 
may reproduce more complicated dynamics by a simpler mechanism. Finally, we note that in 
order to reproduce the dynamics observed in the data we reduced the degrees of freedom 
artificially in some cases by setting parameter values to their means. Given the difficulty 
involved in calculating parameter covariances from the malaria therapy data (they are not 
reported in Diebner et al. [22]), we chose to fix some parameters to facilitate analysis.  
Once our model was formulated, we revisited the Ross-McDonald framework to examine 
how human infectiousness enters into the formula for the basic reproductive number R0. We then 
analyzed human infectiousness in three novel ways, calculating D(t), the mean human infectivity 
over time, the distribution of net infectivity Di, and mean net human infectivity, D. We found 
that D in our mechanistic model is approximately 32 fully infectious days. This quantity is 
invariant in a population over time and plays a crucial role in determining R0. We have utilized 
this value in our recent malaria mapping work [1] although a full mathematical treatment of this 
quantity was left until the present.  
Given our interest in these functions, distributions, and integrals, we went back to the 
literature to determine if we could impute these quantities from other modeling work to examine 
the reasonableness of our conclusions. We examined the models of Lawpoolsri et al., Okell et al., 
and the Garki model, and found a wide variance among them. The reasons for the differences in 
compartmental models have something to do with model structure. Lawpoolsri et al. is 
constrained functionally by the assumption of only one infectious compartment. Okell et al. uses 
four infectious compartments and thus encompasses for a much larger class of distributions (the 
hypoexponential distributions) for the lifetimes of infection. Further, by weighting the infectivity 
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  of each of the duration of infectiousness compartments differently, Okell et al. increase the 
degrees of freedom of D(t), allowing them to better fit their target data.  
Finally, the differences in D(t) among the models may also have to do with the data being 
fitted: the endemicity of the regions being modeled at equilibrium Lawpoolsri et al. are much 
lower than those of Okell et al. It is possible that individuals in low endemicity areas are 
infectious at higher levels for longer periods than individuals in high endemicity areas, because 
preimmunity may limit the severity and density of repeated P. falciparum infections. This effect 
may provide a means of identifying the effects of immunity on transmission. However, we would 
need to fit a variety of endemic equilibria with hypoexponential models such as that of Okell et 
al. to test such a hypothesis; we cannot generate quantitative conclusions from comparing the 
models of Lawpoolsri et al and Okell et al directly, given their different model structures. The 
fact that the Garki estimate of D is so close to our own may be related to the fact that the 
estimate of D for the Garki model is derived from three parameters, two of which were assumed 
by the model structure and only one fitted to data from an endemic area [15].  
While these models may differ in their conclusions, our new estimate of D is the correct 
one for R0, because R0 is a quantity appropriate for a theory of elimination and assumes no 
preimmunity, and our model is parameterized solely from malaria therapy. The other models 
cannot easily disentangle the effects of preimmunity, multiplicity of infection, and control efforts 
from the effects of immunity acting on a single infection, though we have described how future 
efforts might begin to disentangle these quantities. In addition to our calculation of the invariant 
D and its importance for R0, we also found through calculation of D(t) that human infectiousness 
persists for a long period of time at levels sufficient to promote transmission in areas of high 
vectorial capacity. While these calculations are for naïve populations, they are relevant for 
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  malaria elimination efforts because antimalarial immunity wanes over time [6,11]. A recent 
study in Senegal found that persistent infectiousness prevented interruption of transmission even 
when incidence had been reduced to very low levels through insecticide treated bed nets and 
usage of ACTs [6]. Our model confirms the relevance of persistent low-level infectiousness for 
elimination efforts and we will analyze this function further in future work. We hope that the 
modeling platform and analytic framework we have described here will clarify the different 
assumptions among malaria models and improve elimination modeling going forward. 
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  Figure Legends 
Figure 1. Illustration of asexual, sexual, and infectivity outputs. Our mechanistic P. 
falciparum infection model was run six times to simulate three untreated individuals. (A) 
Individual log10 asexual parasitemias as a function of the number of days post emergence of 
parasites from the liver into the bloodstream. The inset depicts the first 50 days of infection; 
triangles above indicate the first day of fever. The black line is the level of detectability by 
microscopy (10 PRBC/µL). (B) Daily gametocytemias of the same three individuals. The 
gametocytemias are usually ~2 orders of magnitude less than the asexual parasitemias a few days 
prior. (C) Estimated probability of human to mosquito transmission. The x-axis maximum is 
changed from 700 to 200 as none of the 3 individuals were predicted to be infectious after day 
152. The areas under the infectivity curves are 19.3, 25.7, and 23.0 days. Areas under the 
infectivity curves are equivalent to the number of fully infectious days, D. Although the model 
predicts the persistence of long-lived low-level and sub-detectable infections (as observed in 
malaria therapy), (C) illustrates that these infections are usually not transmissible after the initial 
period of infection. 
Figure 2. Modeled Distribution of Human Infectiousness. Using our mechanistic model, we 
calculated the mean daily human infectiousness to mosquitoes as a function of time post 
emergence. To calculate this function we simulated the daily infectiousness of 1000 untreated 
individuals and calculated the arithmetic mean per day. (A) Mean daily infectiousness for the 
first 300 days in red; the area between the 25th and 75th daily infectivity percentiles is shown in 
blue. (B) We integrated out the temporal component of human infectiousness and calculated the 
net infectivity for each of 1000 individuals. The distribution of net human infectivity is 
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  represented as a violin plot. The plot extends to the maximum infectivity; the red cross illustrates 
the arithmetic mean infectiousness; the green box shows median infectiousness. 
Figure 3. Comparison of cumulative distributions of durations of infection. The cumulative 
distributions of the durations of infection for the malaria therapy data, as well as those of the 
mechanistic model and the models of Lawpoolsri et al. and Okell et al. are shown. The 
distribution from the malaria therapy data comes from fitting a Gompertz probability distribution 
to the durations of infection from 54 patients as reported by Sama et al. The cumulative 
distribution function of the best-fit Gompertz distribution is plotted in grey. The mechanistic 
model cumulative distribution was generated by calculating the duration of infections from 1000 
runs and plotting the empirical cumulative distribution function. The distributions from 
Lawpoolsri et al. and Okell et al. were generated running those models according to the 
mathematical assumptions of each model. The malaria therapy and mechanistic model 
distributions show relatively tight fits throughout the course of the distribution. The durations of 
infections for the malaria therapy data and the mechanistic model are defined as the last 
observable day by smear minus the first observable day; the durations for the compartmental 
models are defined as the durations of time in infectious compartments. 
Figure 4. Comparison of Mean Net Infectivity over Time, D(t). The mean net human 
infectiousness to mosquitoes is calculated as a function of time for three models: the mechanistic 
model as well as the stochastic representations of the models of Lawpoolsri et al. [26] and Okell 
et al. [27]. For each model, the mean daily infectiousness of 1000 untreated individuals was 
simulated. (A) Distributions for the first 800 days; (B) shows only the first 200 days for closer 
inspection. These functions were then scaled and plotted (C) so that all three models had the 
same mean net infectivity (33.5 days) as 1000 runs of the mechanistic model. 
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  Figure 5. Comparison of Net Human Infectivity Distributions, Di. The net human infectivity 
distributions were calculated for three models: the mechanistic model as well as the stochastic 
representations of the models of Lawpoolsri et al. [26] and Okell et al. [27]. (A) The infectivity 
for each of 1000 individuals was integrated over time for each model. These distributions are 
represented as violin plots; the plot extends to the maximum infectivity. (B) The distributions in 
(A) were rescaled by multiplying by a scaling factor such that all three distributions had the same 
mean as that of the mechanistic model. Red crosses illustrate arithmetic mean infectivity; green 
boxes, median infectivity. 
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Table 1. Best-fit Model Parameter Constants and Distributions
Model Parameter name Reference value Current value/distribution Description
kc 0.2 1 0.164
Affects levels of innate immune response to 
total parasitemia 
σ 0.02 1 0.15
Affects decay rate of acquired immune 
response to PfEMP1 variant
Pc* / kc Fitted to case history 1
truncated lnN(µ,σ2) | µ = ln(104.79), σ =1.148, 
truncation point = 5.5     
Asexual parasite density at the first peak of 
parasitemia 
Pm* / km Fitted to case history 1 Gompertz(α,θ) | α = .0311, θ = .0004
First day with observed asexual parasitemia 
minus last observed day
mi
truncated N(µ,σ2) | µ = 16, σ =10.4, 
truncation point = 1 1
truncated N(µ,σ2) | µ = 16, σ =10.4, truncation 
points = 1, 35     
Growth rates of different PfEMP1 variants
Ds Fitted to case history 2 round(truncated N(µ,σ
2)) | µ = 7, σ =1.5, 
truncation points = 4, 12     
Sequestration time for gametocyte 
maturation
γ Fitted to case history 2 truncated lnN(µ,σ
2) | µ = -6, σ = 4, truncation 
point = .189
Asexual to sexual conversion probability, 
peak specific
αG Fitted to case history 2 U(.06,1)
Rate at which age affects gametocyte 
mortality
β Fitted to case history 2 0.0013
Effects of previous asexual parasitemias on 
gametocyte death rates
µ0 Fitted to case history 2 0.03
Initial age-related component of total 
gametocyte mortality rate 
Asexual
Gamteocyte
1 Molineaux, L. et al. Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology 122, 379-391 (2001).
influencing the transmission of Plasmodium falciparum gametocytes to Anopheles gambiae s.s. mosquitoes. Trop Med Int Health 4, 131-138 (1999).
2 Diebner, H. et al., Modelling the Transition of Asexual Blood Stages of Plasmodium falciparum to Gametocytes. J. theor. Biol. (2000) 202, 113-127.
Table 1. Best-fit Model Parameter Constants and Distributions. The best-fit parameters for the asexual and gametocyte components of our mechanistic model 
are shown. These parameters are either constants or chosen from probability distributions. The original values for these parameters are also provided, along with a 
description of their usage. 'Fitted to case history' indicates that the model was run with this parameter as a free parameter and the best-fit value chosen after fitting 
outputs to the case history of an individual treated with malaria therapy.
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Table 2. Asexual Model Validation
Minimum observed from 
34 malaria therapy 
patients1
Median observed from 34 
malaria therapy patients1
Maximum observed from 
34 malaria therapy 
patients1
Mean minimum model 
values2
Mean median model 
values2
Mean maximum model 
values2
Model values for mean of 
best-fits2 to median 
malaria therapy values
2-1 Initial slope 0.188 0.487 0.872 0.238 0.520 0.752 0.514
2-2 Log density at first local maximum 3.37 4.79 5.66 3.69 4.78 5.67 4.64
2-3 Number of local maxima 2 10 17 2.4 9.4 17.1 10.5
2-4 Slope of local maxima -0.074 -0.013 -0.0007 -0.091 -0.015 -0.007 -0.012
2-5 Geometric mean (GM) of the intervals between consecutive local maxima 14.4 20 77.8 1.5 14.6 28.4 18.3
2-6 SD of the logs of the consecutive local maxima 0.03 0.2 0.47 0.039 0.313 0.565 0.278
2-7
Proportion of positive observations in 
the first half of the interval between first 
and last positive day
0.4 0.88 1 0.57 0.97 1.00 0.94
2-8
Proportion of positive observations in 
the second half of the interval between 
first and last positive day
0.08 0.46 0.94 0.12 0.58 1.00 0.50
2-9 Last positive day 37 215 405 38 193 404 215
1 Molineaux, L. et al. Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology 122, 379-391 (2001).
influencing the transmission of Plasmodium falciparum gametocytes to Anopheles gambiae s.s. mosquitoes. Trop Med Int Health 4, 131-138 (1999).
2 Model values are from the mean of 50 trials, each utilizing 50 draws from 1000 runs with replacement. Goodness-of-fit is according to the pseudo- 2 statistic.
Table 2. Asexual Model Validation.  The nine malariometric indices described by Molineaux et al. from analysis of malariatherapy data are listed at left. The next three columns provide the minimum, median, and maximum values observed for 
each of these indices from 34 malariatherapy patients. In order to examine the model fit, we bootstrapped our model outputs as follows. The mechanistic malaria model was run with default parameters 1000 times and samples of 50 runs each 
were selected.  The maximum and minimum values for the nine indices, as well as the best-fit run, were generated from these 50 runs.  This procedure was then repeated 50 times, and the mean of the minimum, best-fit, and maximum values 
were calculated.  These values are displayed at right. The end time for all runs was 801 days.
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Parameter
Source Table 1, N = 113 1 Simulated 2 Table 1, N = 113 1 Simulated 2 Table 1, N = 113 1 Simulated 2
Minimum 4.0 4.04 2.70E-04 6.52E-05 1.3 3.17
Geometric Mean 7.4 6.93 0.0064 0.0066 6.4 5.56
Maximum 12.0 10.78 0.135 0.111 22.2 13.90
Table 3. Gametocyte Model Validation. A comparison of three gametocytemic parameters is shown. The parameters are D, the gametocyte 
sequestration time in days; gbar, the gametocyte conversion rate as a proportion of asexuals; and L, the length of time gametocytes persist in 
circulation, are given. The first row for each parameter lists their values from fitting the model of Eichner et al. to the data from 113 
malariatherapy patients; the second row gives the values from the mechanistic malaria model using default assumptions. The end time for all 
runs was 801 days.
2 Model values are from the mean of 50 trials, each utilizing 113 draws from 1000 runs with replacement.
Table 3. Gametocyte Model Validation
D gbar L
1 Eichner, M. et al. Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to 
malariatherapy data. Trans R Soc Trop Med Hyg (2001) 95, 497-501.
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I) Alternative Mechanistic Model Frameworks 
When developing this model, our desiderata included four characteristics. Firstly, we wanted to 
develop a model that was parameterized from clinical and/or field data. Secondly, we wanted our 
model to be stochastic to allow for simulation of the full range of host-parasite responses 
observed in our target dataset. Thirdly (and fourthly) we wanted our model to simulate the daily 
levels of both asexual and sexual stage parasites. These features would allow us to simulate 
human infectiousness over time as well as calculating the effect sizes of various antimalarials. 
We are aware of three mechanistic modeling frameworks that have been built to simulate 
the within-host progression of malaria from infection through human-to-mosquito transmission. 
However, none of these frameworks satisfied all of our desiderata. One existing mechanistic 
modeling framework, developed and described over three reports [1-3] does not allow for 
simulation of random individuals and thus does not allow for reproduction of the full range of 
host-parasite interaction. In a second framework, developed and described in two reports [4,5], 
infectivity is a function of the asexual parasite density, and gametocyte densities are not 
modeled. While this approach is sensible for vaccine modeling, we need the capability of 
simulating gametocyte densities in order to determine the effects of drugs against both asexual 
and gametocyte densities. The third mechanistic framework [6] does not allow for stochastic 
simulation of parasite-host dynamics; the model is mean-fitting only and does not simulate of the 
range of diversity demonstrated in the malaria therapy data.  
Since our model includes these four features, our model allows for daily calculations of 
infectivity for treated and untreated individuals of varying resistance levels and types. We 
describe this model in detail below. 
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II) Model of Asexual Parasitemia 
a. Basic Asexual Parasite Dynamics 
The model used to calculate asexual parasitemia is a within-host model that simulates the course 
of an infection once merozoites have emerged from the liver (sporozoites are not modeled). This 
model was developed by Molineaux et al. and is described in more detail here [7]. The model 
was fit to malaria therapy patients, in which infections are monoclonal and there is no 
superinfection. Although the authors had data on 334 malaria therapy patients, they chose to fit 
their model to 35 P. falciparum infections, which were those classified as ‘spontaneous cures’ 
(although some received low-dose suppressive treatments). Thus, this asexuals model best 
reproduces the time course of asexual parasitemias in naïve adult male patients who exhibited 
strong native immune responses, and we note that some parameters are possibly biased by these 
low-dose treatments.  
The number of parasitized red blood cells (PRBCs) is calculated every two days. Red 
blood cells exhibit antigenic variation by displaying different PfEMP1 profiles. There are three 
immune functions, each of which responds to a different set of stimuli (described below). Each 
variant is assumed to grow at a different rate 𝑚!. This assumption has elicited some discussion 
and controversy [1,7,8]; however, there is experimental evidence that some PfEMP1 isotypes 
grow faster than others in vivo (specifically, those isotypes that are associated with severe 
disease have been shown to grow faster than those that are not) [9]. These net growth rates might 
be caused by differential sequestration, faster intrinsic growth, etc.; however, we do not model 
the specific processes causing variant-specific growth rates here. We also note that the 
assumption that infections are monoclonal may not be overly restrictive; a modeling study 
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showed that parasite dynamics in multiply infected individuals may behave similarly to 
monoclonal infections [10].  
i. Quantities Modeled 𝑃!(𝑡) is the number of red blood cells infected by Plasmodium falciparum parasites displaying 
PfEMP1 type i at time t.  𝑃!(𝑡) is the cumulative number of number of red blood cells infected at time t. 
ii. Constants and Parameters 𝑠: Probability isotype will switch var expression in the next period 𝑣: Number of isotypes (PfEMP1 variants) 𝜇!, 𝜎!! : Parameters for normal distribution describing isotype-specific growth rates 𝑚𝑖𝑛𝑝𝑎𝑟𝑎𝑠𝑖𝑡: Minimum parasitemia allowed by model 𝑚! : Growth rates of different PfEMP1 variants; stochastic with distribution 𝑁 𝜇!,𝜎!!   truncated so that  𝑚! ≥ 1 
iii. Equations Determining Asexual Parasitemia 
𝑃! 𝑡 + 2 ′ = 1− 𝑠 𝑃! 𝑡 + 𝑠𝑝! 𝑡 𝑃! 𝑡!!!! 𝑚!𝑆! 𝑡 𝑆! 𝑡 𝑆! 𝑡  
𝑃! 𝑡 + 2 = 𝑃! 𝑡 + 2 ′ if 𝑃! 𝑡 + 2 ′ ≥ 𝑚𝑖𝑛𝑝𝑎𝑟𝑎𝑠𝑖𝑡0 otherwise  
𝑃! 𝑡 = 𝑃! 𝑡!!!!  
b. Switching Rates Among PfEMP1 Variants 
As mentioned above, PfEMP1 isotype levels are explicitly modeled. The model assumes that all 
isotypes share a fixed probability (the parameter 𝑠) of switching to a different isotype in the next 
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period. However, the isotype that they switch to in the next period is assumed to be inversely 
related to the immune response against that type. 
This assumption that PfEMP1 switching is influenced by factors outside of the RBC has 
generated considerable discussion [1,7,11,12]. Though it is possible that var expression is 
mediated by external factors, we do not need to assume that immune responses affect var 
switching in vivo, even though our model implicitly uses immune responses to mediate 
switching. Complicated models of var switching utilizing branching pathways have recently 
been constructed that allow for var gene switching without signaling [13]. These models allow 
for parasites to avoid exhausting their var gene repertoire early in the course of infection. 
Parasites can thus persist for much longer than if they were switching among all var genes with 
an equal probability. 
This branching-process mediated var gene switching may result in var genes being 
expressed as if expression were directly mediated by antigenic response. The asexuals model 
employed here thus makes a simplification that may in practice mimic the much more 
complicated picture of var gene expression within the host. 
i. Quantities Modeled 𝑝!(𝑡): Probability that an infected red blood cell will display PfEMP1 on its surface at time 𝑡 +2.  
ii. Constants and Parameters 𝑞: Parameter for geometric distribution affecting isotype-dependent switching probability 𝑚𝑖𝑛𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒: Minimum immune response provoking var switching 
iii. Equations Determining Switching Probability 
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𝑝! 𝑡 = 0 if  𝑆! 𝑡 < 𝑚𝑖𝑛𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑞!𝑆!(𝑡)𝑞!𝑆!(𝑡)!!!! otherwise  
c. Host Immune Functions 
This within-host model includes levels of immune response. There are three types of immune 
response modeled here. 𝑆! 𝑡  represents the innate immune response to the total parasite load, 
irrespective of PfEMP1 type. The two other immune responses modeled here are acquired and 
are dependent on antibody production. 𝑆! 𝑡  represents the PfEMP1 variant-specific immune 
response. This response is mediated by IgM and IgG and develops in response to one specific 
PfEMP1 isotype. 𝑆! 𝑡  represents the acquired PfEMP1 variant-transcending immune response. 
This immune response is provoked by the conserved regions of PfEMP1 (since PfEMP1 variants 
have been shown to induce cross-reactivity) as well as conserved surface proteins (such as MSP-
1) and other antigenic variants. 
i. Quantities Modeled 𝑆! 𝑡  is the PfEMP1 variant-transcending innate immune response. 𝑆! 𝑡  is the PfEMP1 variant-
specific acquired function response. 𝑆! 𝑡  is the PfEMP1variant-transcending acquired immune 
function response. 
ii. Constants and Parameters 𝑘!: Affects levels of innate immune response to total parasitemia  𝑃!∗: Affects levels of innate immune response to total parasitemia 𝑘!: Affects levels of acquired immune response to PfEMP1 variant  𝑃!∗: Affects levels of acquired immune response to PfEMP1 variant 𝜎: Affects decay rate of acquired immune response to PfEMP1 variant 𝑘!: Parameter determining levels of acquired immune response to cross-reactive epitopes  
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𝛿!: Delay in onset of acquired immune response to PfEMP1 variant 𝛽: Affects levels of acquired variant-transcending immune response  𝑃!∗ : Affects levels of acquired variant-transcending immune response 𝛿!: Delay in onset of variant-transcending acquired immune response  𝜌: Affects decay rate of variant-transcending acquired immune response 𝐶: Level of parasitemia above which variant-transcending immunity does not increase 
!!∗!!: Asexual parasite density at the first peak of parasitemia (almost always also the maximum 
asexual parasitemia); stochastic following a truncated log-normal distribution with a mean of 
104.79 and a standard deviation of 1.148 [10] 
!!∗!!: First asexual parasitemia observation day minus the last asexual parasitemia observation day; 
stochastic following a Gompertz distribution with shape parameters (.0311, .0004) chosen to 
best match the data from Sama et al. [14] 
iii. : Equations Determining Host Immune Functions 
𝑆! 𝑡 = 1+ 1𝑃!∗ 𝑃! 𝑡 !!
!!
 
𝑆! 𝑡 = 1+ 1𝑃!∗ 𝑃!(𝜏)𝑒!!(!!!!!!)!!!!!!!
!! !!
 
𝑆! 𝑡 = (1− 𝛽) 1+ 1𝑃!∗ 𝑃!(𝜏)𝑒!!(!!!!!!)!!!!!!!
!! !! + 𝛽 
𝑃! 𝑡 = 𝑃! 𝑡 if 𝑃! 𝑡 < 𝐶𝐶 otherwise  
Case-specific parameters: 
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𝑃!∗ = 𝑘! ∙ first maximum local density  𝑃!∗ = 𝑘! ∙ last pos. day − 𝑓𝑖𝑟𝑠𝑡  𝑝𝑜𝑠.𝑑𝑎𝑦  
d. Model Fitting 
In order to ensure that the model accurately simulates the time-course of parasitemia in an 
immunologically naïve individual, we consulted the paper of Molineaux et al. to examine how 
their model was fit to data. In this paper, the authors define 9 quantities from a parasitemia time-
course as indices (such as initial slope of the parasitemia curve); we use these indices here as 
well [7]. Note that we define a local ‘peak’ in asexual parasitemia for the purpose of developing 
an index value as a parasitemia a) greater than the 6 values preceding it and b) greater or equal to 
the 6 values following. This is the definition of a peak found in Molineaux et al. [7]; however, 
Eichner et al. add a third criterion, that the parasitemia needs to be c) greater than or equal to 100 
PRBC/µL [15]. This latter criterion is added when using the asexual parasitemia to calculate 
gametocytemias. 
In the original paper, the authors attempted to fit their model to 35 actual case histories, 
according to how well their model fit these 9 indices. Because we are hoping to reproduce the 
range of phenomena seen in the malaria therapy trials, our simulation targets consist of the 
medians of the indices generated from the entire set of 35 malaria therapy trials. 
As a measure of fit, the authors construct a pseudo-χ 2 statistic, such that the distance 
between a model run and the experimental data is given by the formula 
𝐷 𝑥!,… , 𝑥! = 𝑥! − 𝐸! !𝐸!!!!!!!  
where 𝑥!,… , 𝑥!  are the 9 index values for the model run and 𝐸!,… ,𝐸!  are indices from the 
experiment (here, the median malaria therapy values) [7]. We call this statistic a ‘pseudo-χ2 
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statistic’ for the following reason. If we used the variance of each index in the denominator, and 
assumed that 𝑥! were distributed normally, then the value (𝐷) will have a χ 2 distribution. This 
sum 𝐷 would then be known as a χ 2 statistic. Also, if we knew that each of these indices is 
Poisson distributed, and that the means 𝐸!,… ,𝐸!  were large (>5, so that the Poisson was an 
acceptable approximate to the normal) then the above formula for 𝐷 would also be distributed as 
χ2 (approximately). However, since we have no reason to assume that all of these 9 indices are 
Poisson distributed, and even if they were their means are small in some cases, we cannot 
assume that the variance of each index is equal to its mean. Thus, the above sum may not 
converge to a χ2 distribution. We therefore call the above statistic a ‘pseudo-χ2 statistic,’ since it 
takes the general form of a χ2 statistic, but is not necessarily χ2 distributed, and we employ it as 
the measure of goodness of fit.  
A smaller distance between generated and observed values yields a smaller pseudo-χ 2 
value and indicates a better fit. If the statistic were a true χ2 statistic, i.e., 𝐷 𝑥!,… , 𝑥! ~𝜒! 𝑘 , 
then with 𝑘 = 9, the p-value for 𝛼 = .05  would be 16.92. This p-value gives a rough estimate of 
when model and empirical values differ significantly.  
To generate Table 2, we used this measure of goodness of fit to evaluate which runs best 
matched the medians of the malaria therapy data. In the original paper by Molineaux et al., after 
parameters were fit to each patient’s malaria therapy data, the authors ran their stochastic model 
and chose the best fit from 50 runs for each patient. These ‘best simulations’ were then compared 
to the malaria therapy data for statistical analysis. We utilize a similar methodology here but 
bootstrap our simulations in order to reduce random variation. The mechanistic malaria model 
was run with default parameters 1000 times and a sample of 50 runs was selected from this pool. 
The maximum and minimum values for the nine indices, as well as the best-fit run, were 
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selected. This procedure was then repeated 50 times, and the mean of the minimum, best-fit, and 
maximum values were calculated. These values are displayed in Table 2. The end time for all 
runs was 801 days. 
A further validation of the asexual component of the model is found in Figure 3. In this 
figure the cumulative distribution of the durations of infection for malaria therapy patients is 
generated in red. This distribution (Gompertz) resulted from a series of fitting exercises to the 
malaria therapy data; details are found in Sama et al. [14]. The mechanistic model cumulative 
distribution is shown in blue, generated using default assumptions; the model generates 
infections that last approximately 10 days less than observed in malaria therapy; however, the fit 
throughout most of the distribution is relatively tight.  
e. Malaria Mortality 
Mortality from malaria is highest among children in highly endemic areas, whereas in low 
endemicity regions the burden of mortality is spread more uniformly throughout the age 
distribution [16]. However, in some low endemicity regions, few individuals actually die from 
any particular malaria infection. An epidemiological study in a region of western Thailand with 
low and seasonal transmission (estimated incidence rate of 1.0 infections per person per year) 
yielded a case fatality rate of 1.9 deaths per 1000 infections, with the chance of death declining 
exponentially with age [17]. Further, mortality was low even though many adults were 
hyperparasitemic (defined as >4% parasitized red blood cells by smear). Indeed, of the 133 
adults hospitalized during the study period, 82 were hyperparasitemic [17]. This mortality level 
is probably an underestimate, as this area benefitted from effective health care; however, the 
magnitude of this value demonstrates that mortality is likely not a significant factor affecting 
malaria transmission by adults in low transmission settings with adequate health care. Because 
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our model reproduces the dynamics of malaria in low transmission areas such as western 
Thailand, we do not include mortality in our model. 
 
III) Model of Gametocytemia 
Gametocyte levels are modeled as a function of past asexual parasitemias. The gametocytemia 
model used here is that described by Diebner et al. and Eichner et al. (although the two models 
differ slightly; see below) [15,18].  
Each wave of asexual parasitemia produces gametocytes with a characteristic frequency. 
The fraction of gametocytes produced from each wave is determined by a function   𝛾() . 
Gametocytes are assumed to sequester for a variable number of days as they develop. Only fully 
mature gametocytes are counted toward the total number of gametocytes. Once the mature 
gametocytes emerge, they are cleared by the immune system or die on their own. The lifetimes 
of the gametocytes, in absence of immune response related to asexual parasitemia, follow a 
Gompertz distribution [18]. The level of immune response is assumed to be related to the 
cumulative levels of asexual parasitemia. 
i. Quantities Modeled 𝐺 𝑡  is the number of mature gametocytes circulating in the bloodstream. The gender of 
gametocytes is not specifically modeled (although mature gametocytes are often found in 
male:female ratio of 1:4, and so gender could be predicted if needed) [19]. 
ii. Constants and Parameters 𝐷!: Sequestration time for gametocyte maturation; stochastic with truncated normal distribution 
(lower limit, 1; upper limit, 33, mean, 7; standard deviation, 1.5) then truncated again to lie in 
interval (4, 12) 
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𝛾: Asexual to sexual conversion probability, peak specific; stochastic following log-normal 
distribution with location parameter of -6 and a scale parameter of 4 in natural log space 𝛼! : Rate at which age affects gametocyte mortality; stochastic with uniform distribution 
between .06 and 1 𝛽: Effects of previous levels of asexual parasitemias on gametocyte death rates 𝜇!: Initial age-related component of total gametocyte mortality rate  
iii. Equations Determining Gametocytemia 
𝐺 𝑡 =    𝛾 𝜏 − 𝐷! 𝑃!(𝜏 − 𝐷!)!!!!!!! ∙ 𝑒 !!!!! !!!(!!!)!! !! !"#(!! ! !!)!!!!  
Diebner et al. and Eichner et al. disagree on whether log!"(𝐴 s + 1) or log(𝐴 s + 1) should 
be used in the above equation [15,18]. The latter formulation is correct, as we now show. (We 
use the notation 𝐴 𝑡  for the asexual parasitemia at time 𝑡 for this proof, in line with the above 
references.)  
To prove this proposition, we shall assume that log(𝐴 s + 1) is correct and show that 
this assumption gives a result in line with their shared description of gametocyte-related death 
rates.  
To derive the asexual density-dependent component of the equation determining 
gametocytemia, we assume that the hazard (i.e. death) rate is 𝜆 𝑡 =   𝛽log 𝐴 𝑡 + 1  and so the 
cumulative hazard function is 𝛬 𝑡 = 𝛽log 𝐴 𝑡 + 1!! , where 𝜏 is the starting time.  
  However, we have by definition that 𝛬 𝑡 = − log 𝑆 𝑡 , so 𝛽log 𝐴 𝑡 + 1!! =− log 𝑆 𝑡 , and thus 𝑆 𝑡 = 𝑒!! !"#(! ! !!)!!!! , where 𝑆 𝑡  is the survival function (i.e. the 
probability that a gametocyte will survive to time 𝑡). Note that in this model we use the daily 
sum as an approximation for the integral.  
50
If we consider only one day’s contribution to the survival probability, i.e., the probability 
that a gametocyte will survive one more day given that it has already survived to that point, we 
have 𝑃 𝑆 𝑡 |𝑃 𝑆 𝑡 − 1 = 1 = 𝑒!! !"#(! ! !!) = (𝐴 𝑡 + 1)!!.  
Thus, the probability that a gametocyte will die in a one day interval is 1− 𝑆 𝑡 = 1−(𝐴 t + 1)!!, in agreement with Eichner et al. In order to account for this discrepancy, we 
adjusted the value of β given in Diebner et al. by multiplying a conversion factor !!" !" . 
a. Model Fitting 
Although the models described in Eichner et al. and Diebner et al. are similar, their parameter 
estimates differ. The gametocyte model utilizes five different parameters (described in Diebner 
et al.): 𝛾,𝐷!,𝛼! ,𝛽, 𝜇!. Both of the papers use malaria therapy data to parameterize their models, 
but the two differ in their choice of which patients to include in their analysis.  
In the paper by Diebner et al., the gametocytogenesis model was fit to a subset of the 
malaria therapy data, choosing patients who had P. falciparum inoculations and at least four 
positive gametocyte observations. Out of 334 malaria therapy patients with P. falciparum 
inoculations, 262 had at least four gametocyte positive observations. Diebner et al. reported the 
quantiles of the five parameters from fits to their selected subset of patients; however, the model 
was fit to the first 100 days of infection only [18].  
In the paper by Eichner et al., the model was fit to a smaller subset of the malaria therapy 
data [15]. The result of this selection was that out of the same 334 malaria therapy patients, only 
113 were chosen for the parameter fitting. Due to their exclusion criterion (iv), it is probable that 
the infections included in the Eichner analysis were less severe than those included in the 
Diebner study. (The study by Eichner et al. omitted all patients with gametocytemia densities > 
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100/µl). The end result of the different exclusion criteria is that a model using the parameters 
from Diebner et al. may need to be adjusted to fit the data as reported in Eichner et al. 
In order to assess how well the model outputs match the malaria therapy data, two indices 
were developed. These are the average asexual-sexual conversion probabilities, 𝑔, and average 
mature gametocyte circulation times, 𝐿  [15]. Eichner et al. reported minimum, mean, and 
maximum values for 𝐷! , 𝑔 , and 𝐿  as estimated from their subset of patients, along with 
information about the observed distributions of these parameters. We use 𝑔, and 𝐿 as our 
simulation targets. 
We decided to allow three of the parameters (𝐷!, 𝛾,𝛼!) to be stochastic. Our choice of 
these three parameters was driven partly by the data: Eichner et al. reported that the sequestration 
delay parameter 𝐷! roughly followed a normal distribution, and Diebner et al. reported that their 
model did not fit well with a constant value of 𝛾 for each infection. For 𝐷! we chose a truncated 
normal distribution for our model (with endpoints from the min and max observed by Diebner et 
al.). To fit the standard deviation, we created a loss function from the absolute value of the 
difference between the observed quantiles in Diebner et al. and generated quantiles from various 
normal distributions. When we included the last quantiles in Diebner et al. (33 days for 
sequestration), the normal fits were not satisfactory, so we omitted that point and used the 
remaining quantiles for our loss function (data not shown). It was found that a standard deviation 
of 1.5 best fit the quantiles from Diebner et al. However, because we regarded the tails of this 
distribution to be biologically implausible, after the above fitting we then truncated this 
distribution again to fit between the minimum (4 days) and maximum (12 days) as reported by 
Eichner et al. For the distributions for 𝛾 and 𝛼! , we noted that Eichner et al. reported that 𝑔 
roughly followed a lognormal distribution, and we chose parameters and distributions that gave 
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best fits to the gametocytemic targets 𝑔 and 𝐿. Because our system was overdetermined (more 
parameters than usable data), we set 𝛽 and 𝜇! to be fixed at their median values as reported by 
Diebner et al. (subject to the correction in section c above). Table 2 compares the results of 
running the model using these distributions against the target data.  
 
IV) Distribution of First Fever Onset 
Our model of the effects of antimalarials on transmission assumes that the day of first fever 
occurrence can be predicted. To determine when the fever occurs, we utilized a study by Dietz et 
al. [8]. In this analysis, the authors developed a model to describe the first wave of parasitemia 
from malaria therapy patient data.  
Dietz et al. built a mathematical model of the first wave of parasitemia and parameterized 
it from the first wave in the malaria therapy patients. The model-predicted asexual parasitemias 
were then correlated with the occurrence of fever. To predict when a fever would occur, the 
authors utilized a fever threshold, i.e., a level above which an individual would have a fever. The 
authors ran their model 2000 times to generate a set of asexual parasitemias, and fever thresholds 
were then randomly chosen for each individual according to a uniform probability distribution. 
The resulting distribution of fever times from the 2000 simulated cases was found to visually 
match the distribution of the fever times from the original 100 patients quite well [8]. 
We note that some of the malaria therapy patients for which data was available were 
excluded from their modeling: of the 334 malaria therapy patients, 100 were included in their 
analysis. It is unclear whether or how their selection criteria introduced selection bias into the 
fever model. However, all of the individuals included in their analysis had a fever in the first 
wave of parasitemia, and this was not necessarily the case for all of the patients in general. Thus, 
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it is possible that fevers might occur later in the course of parasitemia than the model would 
predict. The effect of this selection bias then may be to predict a fever day that is too early, 
which would have the effect of increasing the effectiveness of ACTs at interrupting transmission 
(because there would be a lower parasitemia at the predicted fever day than in actuality).  
i. Quantities Modeled 
feverday: The predicted first fever day of an individual  
Pfstar: Fever threshold; this value is stochastic and follows a uniform distribution 
ii. Constants and Parameters 
fevconst: Lower limit of uniform distribution determining fever threshold 
max(Ptot): Maximum level of asexual parasitemia 
iii. Equations Determining First Fever Onset 𝑃𝑓𝑠𝑡𝑎𝑟 = 𝑚𝑎𝑥(𝑃𝑡𝑜𝑡) ∙ 10!(!"#!" !"#$%&'( ,!), where 𝑈(𝑎, 𝑏) is a draw from a uniform random 
variable with lower bound a and upper bound b 
 
V) Host Infectivity to Mosquitoes 
In the Ross-MacDonald model, infectivity of humans to mosquitoes is parameterized by a 
constant, c [20]. Note that a successful human to mosquito infection can be defined by a variety 
of endpoints, whether the production of oocysts in the midgut or the development of (functional) 
sporozoites. For this paper we define a successful infection of a mosquito as the production of an 
oocyst, following Jeffery [21]. 
The relationship between gametocyte levels and host infectivity to mosquitoes has been 
quantified by a variety of mosquito feeding studies, in which mosquitoes are fed on infected 
individuals whose gametocyte levels have been assessed. Using these relationships, simulated 
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individuals’ infectiousness to mosquitoes can be calculated, given their predicted gametocyte 
levels. Stepniewska et al. report their results of curve-fitting the percentage of mosquitoes 
infected when fed on individuals with various gametocyte levels [22]. Stepniewska et al. report 
two infectivity curves: the relationship between gametocytemia and infectivity in malaria therapy 
patients and that found among Gambian children [21,23]. Because we have assumed 
immunologically naïve hosts for this modeling process, we utilize the relationship derived from 
the malaria therapy patients. These empirical gametocyte-infectivity relationships use the total 
number of peripheral gametocytes to predict infectivity; however, the relationships do not 
necessarily assume that all peripheral gametocytes are infectious. Rather, these relationships are 
highly non-linear, and that the causes of this non-linearity are still under analysis. We account 
for the fact that 2 gametocytes need to be present in a bite in order to allow for transmission by 
setting the minimum gametocytemia that permits transmission to be 2 gametocytes per 3 µl 
(where 3 µl is the approximate average volume of blood in a mosquito bite [24]). The malaria 
therapy infectivity curve predicts only a 1.7 percent chance of human to mosquito transmission 
at this level of gametocytemia. 
Many other factors besides gametocyte density have been postulated to affect infectivity 
to mosquitoes. For this paper, we assume that there are no other factors that affect transmission 
besides gametocyte levels. Three possible factors not modeled here that might also affect 
transmission are the presence of fever, the effects of drugs on gametocytes beyond simple 
killing, and host immune factors. Regarding the effects of fever, there is some evidence that 
fever reduces the effectiveness of gametocytes at successfully transmitting in P. vivax [25]. 
However, according to an analysis of the malaria therapy data using P. falciparum, there is no 
direct relationship between fever and host infectivity to mosquitoes [26]. Thus, we have not 
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included an effect of fever on transmission in our simulations. Further, we are not aware of any 
human feeding studies that have examined whether gametocytes surviving exposure to 
artemether-lumefantrine are able to transmit as efficiently as untreated gametocytes. However, 
field evidence seems to support the proposition that gametocytes that survive drug exposure are 
still capable of transmission, and we assume that these gametocytes capable of forming viable 
sporozoites later in their lifecycle [27]. Finally, it is very likely that host antibodies may interfere 
with transmission and thus affect the relationship between gametocytemia and infectivity [28]. 
Because we are simulating transmission among immunologically naïve patients, however, 
antibodies to gametocytes will not be present before infection. And for those antibodies that arise 
during the course of an infection, the malaria therapy feeding study data implicitly include their 
effects on transmission.  
A final note regarding infectivity is that of Jeffery and Eyles in their original 1955 study 
of mosquito feedings on malaria therapy patients [21]. First, the authors report that gametocytes 
generally become observable 10–15 days after parasite patency (recall that observability implies 
densities ≥ 10/µl for the purposes of this paper). When we ran the model as described above 100 
times, we found similar values (although the model also generated larger values).  
However, the authors also observe that, in the first two to four days after gametocytes are 
observable in the bloodstream of infected patients, individuals are not infectious to mosquitoes 
(what we call the “Jeffery-Eyles effect”). The authors attribute this phenomenon to the fact that, 
when gametocytes are first becoming patent, they are still immature and are thus unable to infect 
mosquitoes. To account for the observed non-infectivity of gametocytes appearing very early in 
the course of infection, we decided to adjust infectivity profiles slightly so that for individuals in 
which the difference between the first observable asexual and sexual parasitemias was 15 days or 
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less, these individuals would become infectious two days after gametocyte observability. For 
individuals with larger differences between asexual and gametocyte patency, or that never have 
an observable gametocytemia, we assume that individuals are not infectious until more than 17 
days after initial asexual patency have passed. This adjustment roughly corresponds to the 
feeding study data reported by Jeffery and Eyles. The effect of this adjustment on total 
transmission is minimal; however, we have included this effect in out model. 
i. Quantities Modeled 𝑐(𝑥) is the infectivity of humans to mosquitoes (i.e. the percent chance that a mosquito bite will 
produce oocytes in the mosquito midgut), where 𝑥 is the level of gametocytes 
ii. Constants and Parameters 
mintrans: minimum gametocyte level that allows for transmission 
iii. Equations Determining Host Infectivity 
𝑐 𝑥 =   1.08 ∙ 𝑒!!!.!" !"#!" ! !!.!" if  𝑥 ≥ 𝑚𝑖𝑛𝑡𝑟𝑎𝑛𝑠0 if  𝑥 > 𝑚𝑖𝑛𝑡𝑟𝑎𝑛𝑠 
 
VI) Fitting Untreated Model to Malaria Therapy Data 
With the model as specified above, we tested the outputs against a variety of malariometric 
databases. The first data we used as comparison was developed by Molineaux et al. from malaria 
therapy patient data [7]. Molineaux et al. describe the development of nine malariometric indices 
used to categorize and quantify the malaria therapy data. The authors then use this data to 
calibrate their asexuals model; these indices were also used by Gatton et al. [2] for model 
validation. In the model of Molineaux et al., the model parameters had to be set for to match the 
data for each patient; however, our model is stochastic and does not need to be calibrated on an 
individual basis. We designed the model so that our model would reproduce the median values of 
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the indices as seen in the malaria therapy data as well as exhibiting a similar range of variation. 
(Table S1) compares our model outputs using the default settings to the parameters from the 
model of Molineaux et al. as fit to the malaria therapy data; the model shows excellent 
agreement with both the median as well and the minimum and maximum values. This fit was 
achieved by careful choice of distributions for the stochastic parameters in the asexuals 
component of the model. 
In order to examine the degree of fit of model outputs to gametocytemic data, we utilized 
data from Eichner et al. [7]. In this study, the authors utilized their gametocytemic model to 
generate gametocyte profiles from the asexual parasitemias of malaria therapy patients. They fit 
their model to match each patient’s relationship between asexual and sexual parasitemias, and 
reported quantiles of the three variable parameters: D, the length of delay before gametocyte 
emergence; g , the asexual to sexual parasite production ratio; and L, the length of time 
gametocytes are observed in the circulation. (Table S2) shows the fits of the model to the 
maximum, minimum, and geometric means of these parameters; the model was run using default 
parameters. These results indicate that the model fits mean, minimum, and maximum asexual 
and sexual parasitemia levels for non-immune individuals quite well, using default assumptions. 
The length of time gametocytes are circulating matches not only the malaria therapy data but 
also model recent in vivo data from the field as well [29]. 
 
VII) Mathematical Description of Mean Transmissive Capacity Function 
Assume that there is a population of N individuals living in an area with j species of mosquito 
vector, each with vectorial capacity Vj(t). Let us further assume that individuals are infectious to 
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each species at a proportion cj of net their infectiousness; for simplicity, we assume cj = 1, for all 







We call T(i.t) the transmission capacity of an individual i at time t. The mean transmissive 





































Note that the commutativity of sums and integrals in this expression is a result of the well-
mixing assumption (i.e., humans and mosquitoes are well-mixed). 
 
VIII) Coding Specifications 
The model was built in MATLAB (Mathworks, Version R2011a). The model outputs include the 
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Background: Malaria elimination is a priority of increasing importance to the global public 
health community. However, a roadmap to achieve elimination is still unclear, especially in areas 
where the local ecology is favorable for high-level transmission of the most lethal human 
malarial parasite Plasmodium falciparum. Furthermore, evidence from Southeast Asia suggests 
that P. falciparum has begun to acquire resistance to artemisinin-based combination therapies 
(ACTs), a backbone of malaria control efforts. Mathematical modeling provides a tool to 
determine which interventions would have the greatest impact in driving towards malaria 
elimination. 
Methods and Findings: We have developed a mechanistic, within-host model that makes use of 
recent pharmacokinetic (PK) and pharmacodynamic (PD) data to simulate the effects of ACTs 
and other drug regimens on parasite transmission. Human infectivity was modeled over the 
course of infections with and without drug treatment initiated at variable times, and the effects 
were examined in relation to transmission and the basic reproductive number R0. These 
calculations were performed for both early and late treatment-seeking contexts in low 
transmission settings. Our model predicts that if all symptomatic individuals are treated early, 
then transmission is reduced 3.4-fold with drugs that target only the pathogenic asexual blood 
stage parasites, 5.5-fold with artesunate-mefloquine that targets asexuals and early stage sexual 
forms (immature gametocytes), and 7.0-fold with artesunate-mefloquine plus the transmission-
blocking drug primaquine that acts on mature gametocytes. In late treatment settings, the fold 
reductions are 1.5, 2.1, and 2.7, respectively.  
Conclusions: Malaria control efforts benefit substantially from the use of gametocytocidal drugs, 
including ACTs. Adding primaquine and other transmission-blocking agents to ACTs would 
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marginally enhance their transmission reduction effectiveness. In areas of low transmission (R0 
close to 1), antimalarials combining asexual and gametocytocidal action can be a highly effective 
tool for promoting elimination, if the majority of symptomatic individuals are treated promptly. 
However, the reductions in transmission are diminished if treatment is delayed or treatment 




Plasmodium falciparum, the most virulent of the Plasmodium species that cause malaria in 
humans, is responsible for hundreds of millions of cases and hundreds of thousands of deaths per 
year.  The exact number of malarial deaths is a matter of considerable debate, with estimates for 
2010 ranging from 655,000 to 1,238,000 [1,2]. Both of these studies agree that overall levels of 
morbidity and mortality have declined over the past decade, due at least in part to the worldwide 
scaling up of insecticide-treated bed nets and the use of artemisinin-based combination therapies 
(ACTs). ACTs are now the first-line antimalarial drugs in almost all of the malaria-endemic 
world and pair fast-acting yet short-lived artemisinin derivatives with a longer-lasting partner 
drug [3,4]. 
Given the substantial reductions in malaria morbidity and mortality achieved with these 
tools, public health and malarial infection experts are increasingly promoting elimination in areas 
of low transmission [5] while planning significant reductions in higher-transmission areas [6,7]. 
Major obstacles, however, stand in the way. These include insecticide and drug resistance [8,9], 
underdeveloped health systems, shifting public funding priorities, donor fatigue [5], malaria 
importation [10] and economic constraints. The complex life-cycle of P. falciparum also presents 
both challenges and opportunities for controlling malaria transmission [11]. The various life 
stages of P. falciparum differ in their levels of metabolic activity, their within-host locations, and 
their susceptibilities to antimalarials [12]. Mathematical modeling can help guide elimination 
efforts by providing quantitative predictions to assess the feasibility of achieving malaria 
elimination [13-16].  
Here we attempt to clarify the currently complicated literature regarding the effects of 
ACTs on malaria transmission. We also attempt to quantify the extent to which transmission can 
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be reduced by adding late-stage gametocytocides such as primaquine and methylene blue to 
current ACTs. These drugs and their analogues are currently receiving considerable interest 
within the malaria community as to how they might be deployed to help interrupt transmission in 
certain areas [17-19].  
To examine the role that antimalarials can play in reducing transmission, we report the 
development and utilization of a stochastic, mechanistic model that simulates the within-host 
progression of a malarial infection and its treatment. This model builds upon earlier work by 
Molineaux and Dietz, who developed much of the within-host malaria simulation and first 
evoked its possible extension to modeling antimalarials [20-24]. Our model also shares the same 
general design as other simulation models [25,26] though our model differs substantially in its 
specific within-host and PD assumptions. Our simulations begin approximately one cycle of 
replication after parasites have emerged from the liver and entered the blood as merozoites. 
These merozoites infect red blood cells, replicate, and develop before bursting from the infected 
cells to repeat the cycle of blood-stage infection. Some of these infected red blood cells sequester 
in the microvasculature to develop further and differentiate into sexual stages (‘gametocytes’); 
once mature, these gametocytes enter the bloodstream [27]. Mature male and female 
gametocytes are then primed to form gametes and mate in the Anopheles mosquito following 
blood meal ingestion. Our model simulates the total numbers of both asexual and gametocyte 
forms and allows us to estimate human infectivity over time [24,28-32].  
To this model we have also added the PK-PD properties of existing and hypothetical 
artemisinin-based combination therapies (ACTs) against both asexual and sexual forms. 
Treatment is individual-specific and is based upon treatment-seeking behavior. We utilized field 
data [33] in the model calibration and validation as well as a new set of in vitro stage-specific 
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antimalarial gametocytemic data [17]. Predictions were compared to outputs derived from other 
models [34,35].  
Using this combined model we have estimated the effectiveness of ACTs at reducing 
onward malaria transmission. Simulated combinations include artesunate-mefloquine (AM), AM 
plus primaquine, and AM plus methylene blue [3,36]. We find that highly gametocytocidal 
combination therapies are twice as effective at reducing human infectiousness than 
‘schizonticidal’ drugs that act only on the pathogenic asexual stages under conditions where all 
symptomatic individuals are treated early. Thus, we confirm that gametocytocidal drugs can play 
an important role in reducing onward transmission of malaria [34] but that these reductions 
depend heavily on the timing of treatment: late treatment diminishes most of the transmission 




To simulate the effects of drug treatment on transmission, we chose to utilize and extend a 
previously developed ,mechanistic within-host model developed by Molineaux, Dietz, and others 
[20-24] to reproduce the time courses of malaria therapy infections. For the malaria therapy data 
utilized in their model, immunologically naïve individuals with tertiary syphilis were infected 
with various strains of P. falciparum to induce a fever, and resulting asexual parasitemias and 
gametocytemias were tracked over time. Some individuals received non-curative drug treatments 
in instances where infections were judged to be dangerous [20-24]. The model incorporated three 
types of immune factors: innate immunity, and immunity that was PfEMP1 variant-specific or 
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variant-transcending. In their original publications, the authors modified parameters in order to 
fit each individual patient’s case history.  
We extended this model by drawing parameters from probability distributions such that 
the resulting model outputs matched the whole range of observed dynamics without the need to 
tailor the model to any particular patient. We also extended the Molineaux and Dietz model to 
allow predictions of first fever [37], and used data from mosquito feeding experiments to 
translate gametocyte densities into a probability of human-to-mosquito infection [38,39]. The 
process used to select and fit these distributions to malaria therapy data will be presented 
elsewhere (Johnston et al., manuscript in preparation). Here we describe the addition of drug PK 
and PD data to this model framework.  Figure 1 illustrates the progressions of asexual 
parasitemias, gametocytemias, and human-to-mosquito infectivity over time for three uninfected 
individuals (labeled). Figure 1A shows the log10 number of parasitized red blood cells (PRBC) 
per µL of blood, while Figures 1B and 1C depict the daily gametocytemias and human-to-
mosquito infectivity.  
In some areas asymptomatic infections are relatively common and these infections might 
serve as an important reservoir of parasitemia [40,41]. However, in a study conducted in a region 
of western Thailand with low and seasonal transmission, most infections (87%) were found to be 
symptomatic [42]. For our low-transmission analysis, we used this 87% value as an estimate of 
the proportion of individuals exhibiting symptoms (and potentially seeking treatment). Our 
model does not include the simulation of deaths from malaria and its complications because 
fatalities do not significantly affect malaria transmission at the population level [35].  
1. Antimalarial Drug Pharmacokinetics 
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We chose to simulate the PK properties of chloroquine (CQ) as well as two types of ACTs, 
artesunate-mefloquine (AM) and artemether-lumefantrine (AL). AM has been a frequently used 
first-line therapy in parts of Southeast Asia [43], while AL has recently become the most widely-
used ACT worldwide [3]. To model the PK properties of these drugs, we relied upon field 
studies that measured drug concentrations in plasma following a course of antimalarial treatment. 
These data were then fitted to one- or two-compartment models when the data were sufficient. 
For CQ we modeled the concentrations of both CQ and its active metabolite, monodesthyl-
chloroquine (mdCQ), using data from [44] in which Papua New Guinean children with 
uncomplicated malaria were treated with CQ and a single dose of sulphadoxine-pyrimethamine 
(we assumed no PK interactions between the two).  
The PK properties of both AM and AL have been well characterized in adults. For AL we 
utilized data from the treatment of uncomplicated individuals in western Thailand (Mae La) [45]. 
For AM we utilized two studies, one in Thailand [46] and one in Peru [47]. For AM we modeled 
both fixed (coformulated) and loose (non-coformulated) formulations. For the current study, we 
assumed treatment with only the loose formulation. Figure 2 illustrates the baseline PK-PD 
profiles of chloroquine, mefloquine (MFQ) and lumefantrine (LMF) as assumed in the model. In 
Figure 2A, the daily plasma concentrations of chloroquine are shown in blue, while the PD 
effects against asexuals are shown in green. The horizontal black line illustrates the 
gametocytocidal threshold. In Figures 2B and 2C show these data for mefloquine and 
lumefantrine respectively. Because of its longer half-life (12 vs. 5 days for mefloquine vs. 
lumefantrine respectively) these profiles predict that mefloquine is active against asexuals and 
gametocytes for a much longer duration than is lumefantrine, even though the maximum plasma 
concentrations of mefloquine are considerably lower. Our model also allows for the simulation 
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of PK variation among individuals. A complete description of the baseline PK modeling 
assumptions is included in Text S1. 
2. Pharmacodynamics 
In this paper, the effects of antimalarial drug concentrations on each life stage were modeled 
separately. For the PD properties of the artemisinins and their partners against asexual parasites, 
we assumed that the antimalarial dose-response curves against asexual parasites (excepting the 
artemisinins) follow the form: PRR ⋅K(x) = PRR ⋅ a− b( ) 1+ x c( )d( )+ b( ) , where a is fixed to be 
0, b is fixed to be 1, c is what we term the ‘EC50,’ d is the Hill slope, x is the plasma 
concentration of the drug, and PRR is the square root of the log10 of the 48 hour maximum 
parasite reduction ratio (PRR) for the drug. To determine asexual parasite densities during 
treatment, we subtract the quantity PRR ⋅K(x)  from the log10 asexual parasite densities during 
drug treatment. If multiple drugs are present at a given time point we assume that the effects are 
strictly additive (i.e. no synergism).  
 We set the PRRs of dihydroartemisinin, artesunate, and artemether to be 104, those of 
mefloquine and lumefantrine were set to 102, and for chloroquine we used a value of 103 [48]. 
Given the short half-lives of the artemisinins, we assumed that that they were either fully or not 
active. We used EC50 values of 90, 235, and 600 ng/ml for CQ, LMF, and MFQ, respectively; 
these values were derived from the ratios of in vitro 50% inhibitory concentrations (IC50) and the 
assumption that the EC50 MFQ was 600 ng/ml [49,50] (see Text S1). Note that a 600 ng/ml EC50 
for MFQ assumes a slightly MFQ-resistant background; this is the default value for simulations 
by Simpson et al. [45] and thus we used the same default value here. As a simplification, we also 
assumed all Hill slopes were the same as that of MFQ (2.5; value taken from [42]). 
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For drug activity against gametocytes, we assumed a binary activity model: antimalarials 
act against gametocytes only if plasma concentrations are above a given threshold. We chose 5× 
the in vitro IC50 against asexual parasites as our threshold; for CQ, LMF, and MFQ, these values 
are 40, 174, and 322 ng/ml, respectively (Text S1). This choice of threshold gives sufficiently 
long active periods against gametocytes (Figure 2); further, the 5× threshold was utilized in a 
recent in vitro gametocyte inhibition study [17]. 
Gametocytes mature over the course of approximately 15 days through stages I-V, with 
each stage differing in metabolic activity and drug susceptibility [17]. In our model, we allow for 
variable stage-specific effects of drugs against all stages (I-V) of gametocytes; this feature is 
novel to the literature so far as we know, although a recent article did allow for a differential 
effect on uncirculating vs. circulating gametocytes [51]. We are able to implement variable 
stage-specific killing in our model because we compute gametocytemias every day, allowing for 
differential effects of drugs against gametocytes of various ages. For the stage-specific activities 
of the drugs, we assumed two types of baseline gametocytocidal effects, which we call 
‘simplified’ and ‘in vitro’. In brief, the simplified assumptions assume a simplified stage-specific 
killing function for AM and AL: artemisinins are assumed to kill 100% percent of stage I-II 
gametocytes, 50% of stage III per day, and have no effect on stages IV-V [51,52]; mefloquine 
and lumefantrine were assumed to have no effect at any stage. For the in vitro parameterization, 
we utilized recent in vitro data that characterizes the responses of stages I-V to a variety of 
antimalarials [17].  
Figure 1 also shows the effect of drug treatment on three individuals infected with P. 
falciparum. As for the untreated cases, Figure 1A shows the log10 PRBC/µL, while Figures 1B 
and 1C depict the daily gametocytemias and human-to-mosquito infectivities. Treatment with 
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AL was assumed to start two days after the onset of fever; dosage was assumed to follow the 
Coartem dosing prescription (twice daily for three days). The effects of treatment are seen 
immediately on the asexual population, which shows a steep drop after dosing, as well as the 
gametocytemias that show a slightly more delayed effect. Net infectivity is 3.3, 5.7, and 3.9 days 
for treated and 19.3, 25.7, and 23.0 days for untreated individuals, respectively, demonstrating 
how reductions in gametocytemia translate into reductions in infectivity. Figure 1 utilizes the in 
vitro stage-specific gametocytocidal parameterization. 
We also modeled AM plus one dose of primaquine (PMQ; combination abbreviated 
AM+PQ) or one dose of methylene blue (MB). For our three-drug combinations (AM+PQ, 
AM+MB), we simulated the third drugs’ effects only against gametocytes (as ACTs are already 
potent schizonticides). We assumed that PQ was active for three days, including the day of 
dosing [34,53]; for methylene blue, we assumed activity for five days total [54]. 
3. Description of parameterization of modeled stage-specific gametocytemic effects 
Once the model was parameterized as above, we attempted to reproduce the patterns of 
gametocyte clearance observed after drug treatment in a variety of settings. The data sources 
used to parameterize the effects of drug treatment on gametocyte clearance are: 1,175 patients 
treated with an ACT (artesunate-mefloquine and artemisinin-piperaquine) in Thailand [33]; 397 
patients treated with ACTs + PQ (artesunate–amodiaquine, dihydroartemisinin–piperaquine, AL, 
and AM (fixed and loose formulations)) and 411 patients treated with ACTs alone in Myanmar 
[55]; 279 children treated with non-ACTs and 249 children treated with either sulphadoxine-
pyrimethamine + artesunate (SP+AS) or AL in Kenya [56]; and 53 children treated with SP + AS 
and 53 children treated with SP+AS+PQ in Tanzania [57]. All of these studies tracked the 
percentages of individuals gametocytemic by smear over time; the Kenya and Tanzania studies 
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also tracked gametocyte densities after treatment (using both smear and PCR). Percentages and 
proportions gametocyte positive over time for all data sets are shown in Figure S1. For our 
model calibration simulations we assumed treatment with either AM or AM+PQ as it was not 
possible to replicate such diversity of treatments here; further, the partner drug in an ACT has 
less of an effect on gametocyte densities than does the artemisinin and/or primaquine component 
[17]. 
The first step in utilizing the field data to parameterize our model was to match the 
starting gametocytemias in the model and the field data. We see from Figure S1 that the 
gametocytemias of patients upon admission range from .36 gametocytes per µL in Kenya to 7900 
gametocytes per µL in Myanmar; thus there are approximately 21,000 times more gametocytes 
per µL at admission among the treated Myanma population than the Kenyan population. In order 
to match these staring gametocytemias with our model, we adjusted the model day of treatment 
such that gametocytemias of simulated individuals at treatment matched the admission 
characteristics of the field population. For example, we found that individuals treated 15-16 days 
after emergence of parasites into the bloodstream yielded a good fit between model and Thai 
populations at admission. Treatment 15-16 days post emergence corresponded to treatment 
approximately 5 days after first fever; Table S1 provides the model and Thai field data fits at 
admission. To match the high gametocytemias observed in Myanmar, however, we had to delay 
treatment until 23 days after emergence; even then we could not replicate such high 
gametocytemias and we further assumed that only individuals with the highest gametocytemias 
were treated (top ~20%). The Myanmar study itself acknowledged that such treatment-seeking 
behaviors might have caused the high gametocytemias upon admission [55].  
74
Once we had configured the model such that the starting gametocytemias approximated 
admission gametocytemias from the field, we used an iterative fitting approach: we first fit the 
model clearance behavior to the Thai field data, examined how the model behaved relative to the 
other data sets, and then adjusted the model to give a reasonable fit to the Thai data while 
matching the other data sets as well. We used the Thai data as our primary data set because our 
model assumes no malarial preimmunity, and the Thai data is from low transmission areas; the 
Thai data tracks individuals for many days post treatment; and the Thai field study also provided 
a variety of data on asexual densities as well as treatment-seeking behavior prior to admission. 
(The Thai data could be used to calibrate only MFQ and DHA, as PMQ was not administered 
there.) Indeed, fitting underdetermined models is as much art as science (there are approximately 
15 stage-specific killing parameters for each drug); however, using the in vitro, Thai, and field 
data iteratively in this way we could reduce the degrees of freedom so that finding best-fit 
parameters was possible. We used the model-predicted Thai and Myanmar treatment-seeking 
behavior patterns for our ‘early’ and ‘late-treatment seeking’ results below as Thai treatment was 
quite prompt while the Myanmar treatment was significantly delayed.   
 
Results 
In this paper we report the development of the first mechanistic malaria model that incorporates 
the PK and PD properties of antimalarials against both asexual parasites and the five stages of 
gametocytes. In order to build this model, we expanded upon a model of the within-host 
progression of P. falciparum infections parameterized to malaria therapy. To this model we 
coupled the effects of antimalarials against asexual parasites as well as stage-specific 
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gametocytocidal effects, parameterizing the model with recently published in vitro data as well 
as a variety of field data. 
1. Modeled stage-specific gametocytemic effects  
In the Methods we described the data sets and methods used to fit the model to field data. After 
fitting, we found that neither the simplified nor the in vitro gametocytocidal models matched the 
Thai gametocyte clearance data well. Indeed, to match the field clearance data we needed to 
assume that the antimalarials were more efficient at removing gametocytes than the in vitro data 
indicated. Figure S2 illustrates the model-predicted clearance of gametocytes versus the field 
clearance data using the best-fit clearance parameters. For these best-fit parameters, we found 
that on average the model-predicted MFQ clearance parameter was .9 times the in vitro value [17] 
(we assumed that MFQ/LMF/CQ all shared the same gametocyte stage-specific clearances); the 
model-predicted DHA clearance was .67 times the in vitro value [17]; and the model-predicted 
PMQ was .15 times the in vitro value [17]; see Table S2 for a comparison of best-fit and in vitro 
clearance parameters. (For MB, we assumed the same improved efficacy in the field as for DHA.) 
We note here that a qualitative difference among the drugs comes from their effects against late 
stages; crudly, MFQ/LMF/CQ are not gametocytocidal against late stages, DHA is 
gametocytocidal against early stages but only slightly so against later stages, and PMQ is 
strongly gametocytocidal against all stages Table S2. 
A variety of factors could have caused the model-predicted clearance values to be lower 
than the in vitro values. Host immune responses to gametocytes could have been greater in the 
field than in vitro, although the model does include gametocyte-specific immune responses. 
Further, if the antimalarials damaged gametocytes without killing them, these would perhaps be 
more readily cleared in the body than in vitro. However, if immunity alone were the driving 
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factor, the model-predicted parameters for all drugs should have differed by approximately the 
same amount from the in vitro data; however, we see that PMQ is much more effective in the 
field than in vitro. This is likely due to the action of a metabolite of PMQ, and thus we find here 
that it is very likely that there is a much more active metabolite of PMQ that is responsible for 
much of its gametocytemic killing. 
Once the stage-specific gametocyte killing parameters were set, we then ran 1000 
individual simulations for each combination of drug and treatment timing. Figure 3A shows the 
time course of asexual parasitemias over time for untreated individuals, and Figure 3B shows 
the effects of treating 80% of symptomatic individuals with AM in the early-treatment scenario 
(15-16 days after emergence, or approximately 4 days after first fever). Visually, there are far 
fever parasitemias that progress over time in the treated and untreated cases; however, in order to 
establish a comparison, these differences needed to be quantified.  
In order to quantify the transmission reductions achieved, we used the daily 
gametocytemia counts, translated them to estimated daily human-to-mosquito infectivity 
probabilities, and summed these over time. The result is the net infectivity, which is equivalent to 
the number of days an individual would be fully infectious to mosquitoes (i.e. the number of 
days that a mosquito bite would be infectious and produce oocytes with a probability of 1). The 
net infectivity is the human-determined component of R0, the basic reproductive number, or the 
number of secondary infections that a typical index infection would cause, in the absence of 
preimmunity [58]. We then took the ratio of untreated to treated net infectivity,R0 RC , where RC 
is the number of secondary infections per index infection under control. This ratio is called the 
effect size of a treatment [34]; its utility for control is that this term is the fold change in 
transmission from a given baseline R0. Thus, if the R0 in an area is 10, and the effect size is 5, 
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then the R0 after control will be 2; a disease eventually become eliminated in an area if its R0 can 
be reduced below 1 for a sufficient period of time.  
Figure 3C illustrates the distribution of net infectivity in a population receiving early 
treatment with AM; simulations include treatment of all infected individuals, symptomatic 
individuals, and proportions thereof. The distribution of net infectivities of untreated individuals 
is shown for comparison. We find that there is a 18-fold decrease in mean net infectivity 
R0 RC =18( )  between untreated and treated populations if all simulated individuals are treated 
with AM. This effect size is larger than some other studies: Okell et al. [35] calculated 
individuals were 15.5% percent as infectious when treated with ACTs versus baseline treatment 
with failing antimalarials, whereas the ratio here is 5.5%. However, these results are not directly 
comparable, because our current modeling framework allows us to vary the treatment seeking 
behavior of the population and does not rely upon a baseline of semi-treatment, whereas earlier 
work cannot identify the effects of drugs alone. 
Figure 3D compares treatment of 80% of the symptomatic early-treatment population 
treated with either AM; AM+MB; AM+PQ; CQ; a non-gametocytocidal (NG) antimalarial; or a 
fully transmission-blocking drug. For the pure schizonticide NG, we removed the 
gametocytocidal effects of AM and simulated its action on asexuals; for TB we assume that all 
gametocytes are killed upon treatment, regardless of age. We find essentially no difference in 
effect size among the ACT treatments and TB; any transmission reductions are lost in model 
stochasticity due to including untreated individuals in the effect size calculations. However, the 
strongly gametocytocidal treatments are somewhat better at reducing transmission than CQ or 
NG. This is due to the fact that, in the early-treatment setting, there is little time for gametocytes 
to appear, and so there is little advantage to gametocytocidal drugs. 
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ACTs and other antimalarial drugs work on P. falciparum infections and reduce 
transmission in three ways: by killing the asexual stages of the infection and thus preventing 
continued production of gametocytes, by killing existing gametocytes and preventing infection of 
the mosquito, and by post-treatment drug prophylaxis wherein residual drug levels can prevent 
some new infections [11]. In Figure 4A we calculate the prophylactic effects of AM treatment. 
We assume that individuals were infected and successfully treated such that all parasites from the 
primary infection have cleared and only the residual partner drug remains. Then, during the 
period when only the partner drug is present, parasites emerge into the blood stream from a bite 
separate from the one that caused the primary infection; for simplicity we assume here that there 
is no cross-immunity between the primary and secondary bites. Emergence happens a variable 
number of days after treatment of the primary infection. We can see that by day 10 most of the 
prophylactic effects of AM have disappeared due to clearance of MFQ from the plasma; the 
prophylactic effect protective period is less than that observed in the literature [59], possibly 
because we assume a somewhat mefloquine-resistant baseline EC50 for MFQ and/or because we 
ignore cross-immunity between primary and secondary infections. 
Figure 4D demonstrates the prophylactic effect of various treatments with secondary 
infections emerging 10 days after treatment of primary infection. The prophylactic effects of all 
of the ACTs are similar, indicating that the prophylactic effect is due mainly to the action of the 
drug on asexuals. Indeed, the prophylactic effect of CQ is much greater, even though it is only 
weakly schizonticidal, since the remaining concentrations are sufficient to terminate some of the 
secondary infections, given its greater PRR (103 vs. 102). The gametocytocidal properties of the 
combinations only affect the gametocytes remaining during the unprotected half-lives, but so few 
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gametocytes are produced before the partners are cleared that the effects on transmission are 
small in comparison to the effect of interrupting the subsequent infection.  
The final figure (Figure 5) shows the treatment effect sizes of all combinations on 
primary infections in both early- and late- treatment seeking contexts. Given early-treatment 
seeking behavior, we find a very large effect size for gametocytocidal drugs; if all infected 
individuals were treated with AM+PQ, we find an 85-fold reduction in transmission (Figure 5A). 
Indeed, AM+PQ and AM+MB approach the maximum reductions in transmission theoretically 
possible at reasonable treatment coverage levels in early-treatment settings. However, given the 
reciprocal relationship between Rc and the effect size, very large reductions in transmission are 
achievable only at high levels of coverage. The shaded red region of Figure 5 illustrates the 
effect sizes that are achievable only through treatment of non-symptomatic individuals. The blue 
region highlights the effect sizes from treatment of 80% of the symptomatic cases, which range 
from 2.29-fold reductions for NG versus 3.18-fold reductions for AM+PQ (Figure 5A). 
The late-treatment seeking effect sizes tell a slightly different story than those from the 
early-treatment context. Here, the maximum effect sizes achievable by drugs are much smaller, 
since treatment is delayed approximately 10 days versus the early-treatment context and so some 
of the transmission happens before the treatment is received. However, because the gametocyte 
counts at admission are much higher, the differential effect of the gametocytocidal drugs 
becomes evident: the late-stage gametocytocidal combinations are more effective at reducing 
transmission. 
These results are consistent with those of Lawpoolsri et al. [34], who find that 
R0 RC ~ 50  if 99% of individuals are treated with AM+PQ (whereas we find R0 RC = 42.3  in 
the early-treatment setting). However, we find that the proportionate increase in effect size at 99% 
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coverage between no treatments versus AM (14.4-fold) is greater than the increase from AM+PQ 
versus AM (2.94-fold). Thus we find that the addition of a late-stage gametocytocidal drug is not 
as significant a benefit in the early-treatment setting as Lawpoolsri et al. Further, Lawpoolsri et 
al. assumes that individuals are treated with AM immediately after asexual parasite density 
reached 104 PRBC/mL (and treating with PMQ 8 days later) [33], whereas we extend these 
results to two treatment contexts with a variety of different treatments (some of which have not 
been used in the field). The results here concerning the late-treatment seeking setting have no 
parallel in the existing literature. Finally, the study by Gething et al. [60] reports an average 
effect size of 1.1-1.8 of ACTs versus failing pre-ACT treatment across contexts; here we 
disaggregate by treatment-seeking behavior and coverage level, and so our results are an 
extension of those estimates. 
 
Discussion 
We described the development of a within-host model of malaria infection in naïve patients 
coupled to an antimalarial drug model. Our model includes the PK-PD profiles of a variety of 
antimalarial treatments against both asexual and sexual stages, including CQ, AM, AM+PQ, 
AM+MB, a hypothetical non-gametocytocidal schizonticide, and a hypothetical fully 
transmission blocking drug. The effects of antimalarials against all of the five stages of 
gametocytes were derived from fitting model output to field data from four settings, using recent 
in vitro data as a starting point. The model described here differs from other recent work in that 
we are modeling the effects of drugs against all of the life-stages, rather than assuming that drug 
treatment kills 100% of parasites immediately [61].  
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One caveat to our model is that we assume that individuals have no preimmunity to 
malaria infections. This assumption confines the applicability of our results to low transmission 
settings, where preimmunity does not significantly affect the course of infection. However, as 
control efforts in high transmission areas reduce incidence, the levels of preimmunity will 
decrease because antimalarial immunity wanes over time [8,62]. Thus, as control efforts are 
more efficacious, malarial infections will behave more like those infections simulated by our 
mechanistic model and our model results will become applicable. Therefore we might describe 
the results here as describing a theory of elimination, rather than a theory of control, because 
these results are most relevant after endemicity has declined [63,64].  
A further caveat to these ACT effect size calculations is that the model developed in this 
paper does not consider the potential oocidal and sporonticidal actions of antimalarials in the 
mosquito. Tafenoquine [65], dihydroartemisinin, lumefantrine, and methylene blue [17] have 
been shown to be oocidal to varying degrees. Thus the effect sizes reported here could be 
underestimating the effectiveness of ACTs at controlling transmission. 
 Our first set of results concerned the determination of stage-specific gametocytocidal 
effects for MFQ, DHA, and PMQ; we found that the drugs acted more strongly in vivo than in 
vitro, even accounting for some level of gametocyte-directed immune response. In the case of 
PMQ, the discrepancy was so large that this result confirms our suspicion that much of the action 
of PMQ against gametocytes in vivo is caused by a metabolite of PMQ [19]. We also calculated 
the prophylactic efficacy of the modeled antimalarials assuming emergence of secondary 
infections 10 days after treatment for a primary infection and found that the more schizonticidal 
treatment was much more effective than the more gametocytocidal treatments.  
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For our third set of outputs we calculated the effect sizes of the various modeled 
treatments in both early and late treatment seeking settings. The modeling results described here 
provide a context for the various ACT effect size calculations reported previously [34,35,51,60] 
and paint a complex picture for the utility of antimalarials for malaria elimination. Our model 
predicts that, if all symptomatic individuals are treated early (approximately 5 days after first 
fever), non-gametocytocidal schizonticides reduce transmission 3.4-fold, artesunate-mefloquine 
reduces transmission 5.5-fold, while artesunate-mefloquine plus primaquine reduces 
transmission 7.0-fold. These results are in agreement with the 4-fold decrease in incidence 
observed with ACT usage in Senegal before the introduction of bed nets [8]. For comparison, 
Gething et al. estimate that the effect sizes of insecticide treated bed nets are approximately 5-15 
at coverage levels of 40-60% [60]. However, in late treatment settings, where treatment is 
delayed approximately 10 days past that in the early treatment setting, the reductions are 1.5, 2.1, 
and 2.7, respectively.  
Thus we find that in areas where infections are treated early and treatment coverage is 
high, ACTs may have a significant impact at reducing transmission, especially in areas of low R0, 
even approaching the lower range of the effect sizes of bed nets. These effect sizes are much 
higher than earlier estimates indicate [60]. However, much of these transmission reductions are 
lost if treatment is delayed approximately 10 days on average (Figure 5). We also find that late-
stage stage gametocytocides improve the effectiveness of ACTs, reducing transmission an 
additional 1.5-fold, and that these gains are intermediate relative to other types of interventions. 
For example, a 1.5-fold transmission reduction can also be achieved by increasing treatment 
coverage from 40% to 73% of infected individuals in the early treatment setting, or from 40% of 
individuals treated late to 69% of individuals treated early. Figure 5 visually illustrates the types 
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of tradeoffs that need to be made among treatment type, treatment coverage, and treatment 
seeking behavior in order to achieve a given level of transmission reduction. 
Given these conclusions, serious efforts to eradicate malaria will require intensive 
planning and sustained support [5]. We note the hopeful result that our model confirms previous 
field observations that moderately gametocytocidal combinations such as ACTs substantially 
reduce onward transmission [8,66] and given high levels of drug coverage antimalarials may be 
sufficient to interrupt transmission (especially if complimented by bed net distribution). We also 
note that the addition of gametocytocidal drugs to ACTs reduces onward transmission even 
further. Thus, in areas of drug sensitivity, there may be a benefit to introducing strongly 
gametocytocidal drugs to the ACT regimen, although such a determination would depend on a 
cost-benefit analysis of such deployment versus other means of achieving needed reductions, 
such as improved treatment coverage, shorter time to treat, or increased bed net coverage, to 
name a few. The results here can also be combined with recent mapping work in order to help 
plan and coordinate control efforts [67]. Efforts are also ongoing to utilize this model to predict 
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Supporting Information  
 
Text S1. Mathematical description of the model, along with parameter fitting.  
 
Text S2. User guide for use of the graphical user interface of the model. 
 
Table S1. Validation of the simulated Thai population outputs. The severity of malaria 
among a set of Thai individuals treated with ACTs is provided. The model was then run 
assuming similar treatment-seeking behavior. Model outputs are compared to the Thai data in 
order to validate the ACT-treated asexual and gametocyte models’ performance against field data. 
 
Figure S1. Gametocyte field data. A variety of data sets tracking the clearance of gametocytes 
from treated individuals are shown [33,55-57] (see Methods for description). (A) The percent of 
individuals who tested gametocyte positive by smear. (B) The proportion of individuals who 
tested gametocyte positive by smear, normalized to day 0 (day of admission). (C) The percentage 
of individuals testing gametocyte positive, by smear in Thailand and Myanmar, by polymerase 
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chain reaction (PCR) in Kenya and Tanzania. (D) The proportion of individuals gametocyte 
positive, normalized to day 0, by smear or PCR. The average numbers of gametocytes per 
microliter at admission are also shown. (E) The effects of primaquine in the Myanma setting on 
gametocyte clearance. The arrow indicates that the clearance curve is shifted due to the 
gametocytocidal action of primaquine. (F) Clearance of gametocytes. The Myanma data (E) 
shows the distinct effect that primaquine treatment has on gametocyte clearance, all other 
covariates being equal. However, a variety of factors influence measured rates of clearance, 
including the gametocytemia at admission, the type of drugs used, the method of detection, and 
the levels of immunity.  
 
Figure S2. Comparison of percent of individuals gametocyte positive. (A) The percentages of 
individuals smear positive for gametocytes in both modeled and field settings. Simulated 
individuals are treated with no treatment, non-gametocytocidal treatment, or three different 
parameterizations for artemether-mefloquine (AM). The model assumes treatment began days 
15-16 after parasites emerged from the liver; this treatment-seeking behavior best fit the 
observed field data. The model parameterizations for AM (simplified, in vitro, scaled in vitro) 
assume different levels of stage-specific gametocyte killing (see Methods). Simulated treatments 
are compared to the clearance of gametocytes from Thai field data [33]. (B) The data from panel 
(A) are plotted after dividing by the percentage of pretreatment individuals who are 
gametocytemic (model day 0). (C) Model predicted data for the proportion of individuals 
gametocytemic by smear is compared to field data from Myanmar [55]; the proportions were 
derived by simulating the percent of individuals gametocytemic pre- and post-treatment and 
dividing by the day 0 percentages. Model treatment was assumed to begin on day 23; some 
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individuals with lower gametocytemias were omitted in order to match the admission 
gametocytemias in Myanmar. The model was run assuming a variety of different treatment types 
(NG, non-gametocytocidal antimalarial; CQ, chloroquine, MB, methylene blue; PQ, primaquine); 
the Myanmar individuals were all treated with either AM or AM+PQ. (D) The the percentages of 
individuals treated with either AM or AM+PQ who were gametocytemic over time was 
normalized to day 0 for both the model and field data. The difference of these proportions was 
then calculated and graphed to isolate the effect of PQ treatment on gametocytemia.  
 
Figure S3. Comparison of modeled gametocyte densities in treated individuals to two field 
data sets. (A) The natural log of the geometric mean gametocytemia among individuals PCR 
positive for gametocytes is shown for modeled and field treated individuals. Simulated 
individuals were treated 15-16 days after emergence of parasites from the liver, according to the 
behavior best matching Thai individuals (classified as ‘early treatment’). The threshold for PCR 
detection is assumed to be .02 gametocytes per µL, versus 10 per µL for smear. Modeled 
individuals were treated with either AM, artemether-mefloquine; a non-gametocytocidal 
antimalarial; CQ, chloroquine, MB, methylene blue; PQ, primaquine, or a combination thereof. 
The field data come from gametocyte clearance among treated Kenyan or Tanzanian children [56] 
[57]. (B) Modeled and field data from (A) were subtracted by the log gametocyte densities at 
admission to yield normalized densities among gametocytemic over time. (C) The daily 
normalized densities from (B) were normalized again in a data dependent manner: for the model 
data, the densities in (B) were subtracted by the normalized densities among CQ treated 
individuals; for both sets of field data, the densities were subtracted by the normalized densities 
among non-ACT treated children in Kenya. The resulting data illustrates the effects of strongly 
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gametocytemic treatments on gametocyte densities, controlling for the combined effects of 
schizonticidal treatment and immunity on gametocytemia. Gametocytemias among modeled 
untreated gametocyte positive individuals continue to rise versus the normalized data. (D-F) The 
same analyses as in (A-C) were run assuming highly gametocytemic modeled individuals treated 
23 days after emergence of parasites from the liver, according to the behavior best matching 
Myanmar individuals (classified as ‘late treatment’). These data were then compared to the field 
data from Kenya and Myanmar; all normalizations in (D-F) are identical to those in (A-C).  
 
Figure S4. Graphical user interface for model standalone software. Screen capture of the 
mechanistic malaria model user interface. The interface allows users to adjust a variety of 
parameters affecting the relationship between treatment and transmission, including the parasite 
reduction rate of dihydroartemisinin and its partner drug, the PD properties of dihydroartemisinin 
and its partner against asexuals and gametocytes, treatment-seeking behavior such as the delay in 
treatment and the probability of treatment. The software is designed for standalone operation on 
both Windows and Mac operating systems and allows for saving of outputs including asexual 
and gametocyte densities as well as daily and net infectiousness.  
 
Dataset S1. Standalone model designed for Windows operating systems. 
 
Dataset S2. Standalone model designed for Macintosh operating systems. 
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Figure Legends 
Figure 1. Illustration of asexual, gametocyte, and human-to-mosquito infectivity model 
outputs. The P. falciparum infection model was run six times to simulate three untreated 
individuals and another three treated with artemether-lumefantrine two days after the onset of 
fever. Treated individual data are colored red/magenta/orange; untreated are blue/violet/green. 
(A) Individual log10 asexual parasitemias as a function of the number of days post emergence of 
parasites from the liver into the bloodstream. The inset depicts the first 50 days of infection; 
triangles above indicate the first day of fever. The black line is the level of detectability by 
microscopy (10 PRBC/µL). (B) Daily gametocytemias of the same six individuals. The 
gametocytemias are usually ~2 orders of magnitude less than the asexual parasitemias a few days 
prior. In the treated individuals, the asexual parasitemias and gametocytemias dropped rapidly 
after treatment. (C) Estimated probability of human-to-mosquito transmission given the 
gametocytemias illustrated in (B). The x-axis maximum is changed from 800 to 300, as none of 
the six individuals were predicted to remain infectious after day 152. The areas under the 
infectivity curves are 3.3, 5.7, and 3.9 days for treated and 19.3, 25.7, and 23.0 days for untreated 
individuals, respectively. Areas under the infectivity curves are equivalent to the number of fully 
infectious days. Drug treatment with an ACT rapidly reduces the probability of onward infection. 
Although the model predicts the persistence of long-lived low-level and sub-detectable infections 
(as observed in malaria therapy), (C) illustrates that these infections are usually not transmissible 
after the initial period of infection. 
Figure 2. Modeled pharmacokinetics and pharmacodynamics of chloroquine, mefloquine 
and lumefantrine. (A) Modeled plasma concentrations of chloroquine (CQ) and mono-
desethylchloroquine (mdCQ) (both in ng/ml) are given in blue. The green curve illustrates the 
95
proportion of complete killing against asexual blood stage parasites as a function of plasma 
concentration. We estimated an in vivo EC50 of 90 ng/ml and a Hill slope of 2.5. The horizontal 
dashed black line indicates the assumed threshold for gametocyte killing, calculated from 5× the 
in vitro EC50 against drug-sensitive asexual parasites (40 ng/ml). (B) Modeled plasma 
concentrations of mefloquine (MFQ; ng/ml) are shown in blue. The green curve illustrates the 
proportion of complete killing against asexual parasites as a function of plasma concentration. 
We used the published in vivo EC50 is 600 ng/ml and the Hill slope is 2.5 [49]. The 
gametocytemic threshold for MFQ is 322 ng/ml. (C) Modeled plasma concentrations for 
lumefantrine (LMF; in ng/ml); the blue line is the output of a two-compartmental model 
parameterized from field data. We calculated the in vivo IC50 as 235 ng/ml and the Hill slope as 
2.5. The 5× in vitro EC50 is 174 ng/ml.  
Figure 3. Effect sizes of various antimalarial therapies assuming early treatment. The mean 
effect sizes of various simulated treatment scenarios were calculated. (A) Distribution of net 
infectiousness of untreated individuals, as well as the infectiousness of treated (artesunate-
mefloquine) individuals with admission characteristics roughly matching Thai patients. Effect 
sizes were calculated from simulated treatment of 100%, 80%, 60%, and 40% of symptomatic (S) 
individuals. (B) Treatment of 80% of the symptomatic simulated Thai population with different 
regimens: chloroquine (CQ); artesunate-mefloquine (AM); artesunate-mefloquine plus 
primaquine (AM+PQ); artesunate-mefloquine plus methylene blue (AM+MB); a non-
gametocytocidal antimalarial (NG); and a transmission-blocking antimalarial (TB). All 
distributions are from 1000 runs. 
Figure 4. Effect sizes from antimalarial prophylaxis. (A) Prophylactic effects of artesunate-
melfoquine (AM) treatment. Individuals were assumed to have been infected and successfully 
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treated with AM. A secondary infection was simulated emerging into the bloodstream a variable 
number of days after treatment of the primary infection. (C) Comparison of the prophylactic 
effects of CQ, AM, AM+PQ, AM+MB, NG, or TB. Primary infections were assumed to have 
been successfully treated 10 days previously. Abbreviations: chloroquine (CQ); artesunate-
mefloquine (AM); artesunate-mefloquine plus primaquine (AM+PQ); artesunate-mefloquine 
plus methylene blue (AM+MB); a non-gametocytocidal antimalarial (NG); and a transmission-
blocking antimalarial (TB). All distributions are from 1000 runs. 
Figure 5. Effect sizes of antimalarials as a function of treatment coverage and time of 
treatment. (A) Modeled effect sizes of various antimalarial treatments assuming early treatment. 
For early treatment, simulated individuals were matched to patients with admission 
characteristics of a Thai field study. Treatment occurred 15-16 days after emergence of parasites 
from liver (4-5 days after first fever). The shaded red region illustrates effect sizes that are 
achievable assuming treatment of nonsymptmatic individuals, assuming 87% of individuals are 
symptomatic. The blue region illustrates treatment of 80% of symptomatic individuals. (B) 
Modeled effect sizes of various antimalarial treatments assuming late treatment. For early 
treatment, simulated individuals were matched to patients with admission characteristics of a 
Myanmar field study. Treatment occurred 23 days after emergence of parasites from liver 
assuming that some individuals with low gametocytemias were not treated. Abbreviations: 
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Effect Sizes as Function of Treatment Coverage, early treatment
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Table 1. Antimalarial Effect Sizes in Two Treatment-Seeking Contexts
Simulated 



























Infectivity Curve 40.14 14.73 18.92 12.39 8.31 10.57 4.68
Myanmar (late 
treatment) Effect Size N/A 2.72 2.12 3.24 4.83 3.80 8.58
Table 1. Antimalarial Effect Sizes in Two Treatment-Seeking Contexts. The effect sizes of various artemisinin-based treatment regimens were simulated using 
the mechanistic within-host malaria model. Treatment-seeking behavior was assumed to match field pattens observed in either Southwestern Thailand (early 
treatment) or Myanmar (late treatment).  The areas under the infectivity curves were computed for the various treatments listed in each of the two regions; reported 
values are the arithemtic means of 1000 simulated individuals.  Effect sizes were calculated by taking the ratio of the mean infectiousness of untreated treatment-
seeking individals vs. the mean infectiousness of treatment-seeking individuals who received treatment. 
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Supplemental Text S1: Model equations and distributions  
I) Pharmacokinetics 
a. Pharmacokinetics of artemisinins 
b. Pharmacokinetics of lumefantrine  
c. Pharmacokinetics of mefloquine  
d. Pharmacokinetics of methylene blue 
II) Pharmacodynamics 
a. Pharmacodynamics of artemisinins, lumefantrine, mefloquine, and chloroquine 
against asexual parasites 
b. Pharmacodynamics of artemether and lumefantrine, and mefloquine against 
gametocytes 
III) Fitting Thailand Gametocyte Carriage Data 
IV) Fitting Treated Model to Field Data from Myanmar, Kenya, and Tanzania 




a. Pharmacokinetics of artemisinins 
For all ACTs we assume that artemisinin and/or artesunate and dihydroartemisinin are present at 
relevant concentrations for only the days on which they are consumed. This is due to the fact that 
artemether, artesunate, and dihydroartemisinin (the active metabolite of both), are rapidly 
absorbed [1] and very quickly eliminated (t1/2: .5-3 hrs) [2,3]. We thus do not explicitly model 
the plasma concentrations of this component, as clearance of pharmacodynamically relevant 
concentrations occurs within the smallest time step of the model (1 day). 
b. Pharmacokinetics of lumefantrine  
The pharmacokinetics of lumefantrine differ from those of artemisinins. Clinical studies have 
found that lumefantrine pharmacokinetics follow a two compartment model with first-order 
absorption and a lag time of approximately two hours between ingestion and onset of absorption 
[2]. Lumefantrine is cleared much more slowly than the artemisinins (the mean terminal half-life 
ranges from 30 – 87 hours) [2]. Due to its much-longer half-life, we explicitly model 
lumefantrine plasma concentrations.  
The standard adult prescription regimen of AL is four doses of a fixed dose tablet 
containing 20 mg artemether and 120 mg of lumefantrine twice daily for three days; it is this 
regimen that we are interested in modeling. For the pharmacokinetics of lumefantrine, we rely 
upon a group of studies that were conducted in Thailand among patients with P falciparum 
infections who were treated with AL [1,2,4]. In these studies, plasma concentrations of 
lumefantrine were tracked over time and a two-compartment model was fit to the population 
data. To simulate plasma concentrations for our model, we used the equations describing a two-
compartment model and parameterized them with the parameters from Ezzet, van Vugt et al. [5]; 
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the current dosage recommendations correspond to what they called ‘regimen B.’ For this 
regimen, 18 Thai patients hospitalized in Bankok were paired with 72 community-based patients 
from Mae La, and pharmacological modeling was performed to fit the plasma lumefantrine 
measurements. The Cmax achieved was approximately 7,000 ng/ml for the patients from Bankok 
and approximately 8,000 ng/ml for the patients from Mae La. Since the pharmacokinetic 
parameters differed slightly between the two populations, we utilized the values from Mae La. 
This combination of parameters was found to fit day 7 plasma lumefantrine 
concentrations from a later study [6] quite well. At day 7, the PK model parameterized as 
described above yielded a prediction of 759.5 ng/ml for lumefantrine, compared to an observed 
mean value of 528 ng/ml (range 49-5175 ng/ml) in a study among Karen women in Thailand (the 
model predicts that 528 is reached between days 8 and 9) [6]. The two other Thai studies 
yielding plasma lumefantrine concentrations near these values are Ezzet et al. [1] (although this 
study examined a two day regimen rather than three) and van Vugt et al. [4] (with 
pharmacokinetic parameters as reported in White et al. [2]). 
While these studies have similar pharmacokinetic profiles, some other studies report 
much higher levels of lumefantrine plasma concentrations. In one study, 219 patients with acute, 
uncomplicated P falciparum malaria in Thailand were treated with AL and lumefantrine 
concentrations were monitored during treatment [7]. In a second study, lumefantrine 
concentrations were monitored among 14 Western Europeans without malaria but treated with 
AL [8]. In both studies, the mean Cmax was much higher than in the set of trials above: ≥ 25,700 
and 28,300 ng/ml, respectively. Further, the terminal half-life of the latter study was quite long 
(11.5 days vs 3.1 and 4.5 for two Thai studies) [2]. The higher values for the latter study were 
expected: lumefantrine levels are lower among individuals who are infected with P falciparum, 
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and in this study the medications were taken with a standard diet (ensuring adequate lipid 
consumption). However, the former study provides a slight outlier, as these were infected Thai 
individuals; moreover, since their plasma concentrations were not followed after treatment, few 
pharmacodynamic implications can be drawn. Thus, for lumefantrine modeling we utilize the 
two compartment model parameterized from the Ezzet, van Vugt et al. [5] study. 
To model pharmacokinetic variation, we multiply the bioavailability parameters 𝐹! − 𝐹!  by a randomly chosen constant, simulating the effects of increased or decreased 
absorption. We do not simulate the effects of parasite load on bioavailability, though high loads 
generally yield lower bioavailability [5]. 
c. Pharmacokinetics of mefloquine 
For the pharmacokinetic profile of mefloquine, we utilized a recent study in which adults 
presenting with P. falciparum at the Hospital for Tropical Diseases, Bangkok, Thailand were 
treated with either a fixed dose (n = 25) or loose dose (n = 25) formulation of AM [9]. The fixed 
dose formulation consists of two fixed dose tablets containing 100 mg artesunate and 200 mg of 
mefloquine daily for 3 days. The loose dose formulation is dosed by weight and consists of non-
fixed artesunate at 4 mg/kg of body weight/day for 3 days plus mefloquine at 15 mg/kg on day 1 
and 10 mg/kg on day 2. These individuals’ mefloquine plasma concentrations were followed for 
28 days.  
We used a different study for estimation of the terminal half-life of mefloquine. In this 
study, 39 Peruvian adults infected with P falciparum were treated with a loose dose formulation 
of AM and their mefloquine plasma concentrations monitored for 56 days [10]. The terminal 
half-life was calculated (utilizing concentrations at days 21, 28, 35, 42, and 56) as 347 hours, 
compared to 286 and 322 for the fixed and nonfixed regimens in Thailand. Mefloquine 
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pharmacodynamics are often described by a two component model, [11] and because the Thai 
half-life estimates come from earlier measurements, they might not represent the true terminal 
half-life but rather a combination of initial and terminal half-lives. In neither study was a 
compartmental model fit to the concentrations.  
To model the plasma concentrations of both loose and fixed concentrations, we extracted 
the recorded mefloquine plasma concentrations data for days 0-28 from Krudsood et al. [9] using 
the DataThiefIII software [12]. To extrapolate plasma mefloquine concentrations past day 28, we 
utilized the terminal half-life from the Peruvian study [10]. This model allows for simulation of 
mefloquine concentrations at any day during and after treatment for both loose and fixed 
formulations and utilizes the most reliable data from both studies. 
To model pharmacokinetic variation for mefloquine, because we do not have an analytic 
pharmacokinetic model, we simply multiply plasma concentrations by a random constant (taking 
the first 29 days of treatment) and then use the terminal half-life to extrapolate the remainder; we 
choose a value between !! and 3 (the upper and lower bounds are proportionally equal as 
mefloquine absorption is not as negatively affected by diet as lumefantrine). 
d. Methylene Blue 
Regarding the pharmacokinetic profile of methylene blue, all of its pharmacokinetic data are 
from uninfected individuals. In these individuals its oral and intravenous half-lives are short (5–
6.5 hours) [13,14]. Further, its bioavailability via oral or intravenous administration is poor [15]. 
However, the bioavailability and half-life of methylene blue depend significantly on the mode of 
administration and are increased by aqueous delivery (faction absorbed = 72.3±23.9%; terminal 
half-life = 18.4 hours) [15]. Efforts are ongoing to adjust its pharmacokinetic profile [15]. 
 
108
i. Equations Determining Pharmacokinetics 
The plasma concentrations of lumefantrine in the central compartment are given by the equation 𝐶 𝑡
=    𝐷! 𝐴𝑒!! !!!! !!"#$ + 𝐵𝑒!! !!!!!!!"#$ − 𝐴 + 𝐵 𝑒!!! !!!!!!!"#$  if
!!!
!!! 𝑡 − 𝑡!! ≤ 𝑇𝑙𝑎𝑔𝐷! 𝐴𝑒!! !!!!!!!"#$ + 𝐵𝑒!! !!!!!!!"#$ − 𝐴 + 𝐵 𝑒!!! !!!!!! !"#!!!! if not
 
The parameters for this model are given in [2,16]. For mefloquine and chloroquine, we did not 
use an explicit compartmental model, rather we use the measured plasma concentrations from 
published studies and interpolate among them. For time points where we could not interpolate 
plasma concentrations, we use the terminal plasma concentration half-lives to extrapolate. 
 
II) Pharmacodynamics 
a. Pharmacodynamics of artemisinins, lumefantrine, mefloquine, and chloroquine 
against asexual parasites 
A variety of models have examined the pharmacodynamics of the artemisinins within the asexual 
blood stage cycle [17,18]. These models simulate the effects of artemisinins against the various 
developmental stages of the asexual stage (rings, mature trophozoites, schizonts). However, 
since the time step of this model is 2 days (1 complete asexual cycle), we can simulate the 
asexual effects of the artemisinins and their partner drugs as a bulk effect by decreasing the 
overall parasite densities by a given factor without regard to asexual stage-specificity.  
The effectiveness of antimalarials on asexual parasitemias is quantified using a parasite 
reduction ratio (PRR), which is the ratio of the initial parasite concentration to the concentration 
of parasites remaining 48 hours after drug administration. For the artemisinins, the maximum 
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PRR in vivo is 103 - 105; for lumefantrine the maximum PRR in vivo is 10 - 103 [19]. For our 
model we have made the assumption that the maximum PRR of artemether is 10! and that of 
lumefantrine is 102. While the expected net maximum PRR would then be 10! ∙ 10! = 10!, 
because new parasites are being generated while the drugs are active, the net PRR is lower. In 
order to measure the net PRR for our model, we ran it 1000 times assuming treatment with AL 
according to the early treatment (Thailand) treatment seeking behavior (see below) and took the 
average daily interpolated asexual parasitemia.  
The modeled net maximum PRR for this average parasitemia was 7.48   ∙ 10! (the fold-
change between days 2 and 4 after treatment). This value is biased however, as approximately 
30% of individuals cleared their infections during this portion of treatment and their parasitemias 
were counted as having reached the model lower bound of 10-5 after clearance. When those 
individuals who cleared their infections during this portion of treatment are dropped, the 
modeled PRR falls to 2.01   ∙ 10!. The latter estimate of net maximum PRR for AL agrees with 
an estimate of 7.0 ∙ 10!  for the PRR of AL in treated Nigerian children [20]. Regarding 
mefloquine, because this drug is an arylamino alcohol along with lumefantrine, White et al. [2] 
speculated that the two drugs share similar modes of action (at least against asexual parasites) 
and so we set the maximum PRR of mefloquine to be 102 as well. 
While the above calculations determine the maximum asexual killing effect of the drugs, 
once the plasma concentrations begin to fall, this killing effect will decrease, and thus dose-
response curves for these drugs must be calculated. Because the artemisinins are so rapidly 
cleared, we simulate the pharmacodynamics of the artemisinins as a binary model, such that the 
PRR is 104 when the drug is present and 1 when absent. However, for the partner drugs 
lumefantrine and mefloquine, because the duration of partial activity is on the order of weeks and 
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spans many asexual cycles, we cannot assume that the PRR for these drugs is either maximal or 
unitary. We thus need to determine the in vivo dose-response relationships for the partner drugs. 
While in vitro studies of drug effectiveness can be readily conducted so that dose-
response relationships might be derived, determining in vivo dose-response relationships is more 
complicated. Indeed, the in vivo relationship between observed plasma concentrations and 
parasite response is dependent on the proportion of free (more active) to bound (less active) drug, 
a proportion that is difficult to determine as high performance liquid chromatography measures 
only total plasma concentrations and this proportion varies according to drug. Other sources of 
variation are the concomitant effects of the immune system, which varies from individual to 
individual, and the diversity of genotypes found in the field. 
However, there have been field studies and mathematical modeling efforts at determining 
the dose-response relationships for mefloquine and lumefantrine. For mefloquine, two 
mathematical studies attempted to quantify the in vivo EC50, here defined as the concentration at 
which the drug kills parasites at a rate of .5 times the PRR; this value was computed from the 
minimal inhibitory concentration (MIC), the concentration at which the within-host growth of 
parasites is exactly equal to the parasitical effect of the drug (approximately equal to the in vivo 
EC90) [21,22]. Both studies utilized a MIC of approximately 500 ng/ml, a value that was 
determined from field studies among mildly resistant strains [23,24]. The study by Simpson et al. 
[21] calculated the EC50 as 665.4 ng/ml for mildly resistant strains, whereas the study by Hoshen 
et al. [22] yielded two EC50 values: 350 ng/ml for sensitive parasites and 1150 ng/ml for resistant 
strains.  
After experimenting with the model developed by Simpson et al. [21] with their original 
data, we decided to use an EC50 value of 600 ng/ml for mefloquine, a value that assumes mild-
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moderate mefloquine resistance. For the entire dose-response curve for mefloquine, we utilized a 
4-parameter sigmoidal curve with a Hill slope of 2.5, a minimum of 0, and a maximum of 1, as 
in Simpson et al. [21] (see equations below). For lumefantrine, less modeling work has been 
published; however, field studies have attempted to determine an in vivo MIC. These studies 
generally attempted to determine the day 7 lumefantrine plasma concentration that served as the 
best (greatest Youden index) predictor of treatment failure. The values from these studies ranged 
from 175-500 ng/ml, with 280 ng/ml often mentioned [2,6].  
Given the relative paucity of published research regarding the in vivo pharmacodynamics 
for lumefantrine and chloroquine, and the extensive modeling work done for mefloquine, for our 
study here we relied upon the mefloquine modeling work as our baseline and assumed that the 
EC50 for mefloquine was 600 ng/ml; for lumefantrine and chloroquine we multiplied this 
quantity by the ratio of their in vitro IC50 values to that of mefloquine. We assumed that the IC50 
of chloroquine was 25 nM (8 ng/ml) [25], that the IC50 of lumefantrine was 66 nM (34.9 ng/ml) 
[26], and that the IC50 of mefloquine was 170.4 nM (64.5 ng/ml) [27]. Thus, the ratio of in vitro 
IC50 values for chloroquine and mefloquine is 25:170 = .147, and the ratio for lumefantrine and 
mefloquine is 66:170 = .387.  
If we multiply these conversion factors to the assumed EC50 value for mefloquine (600 
ng/ml), we get that the corresponding values for chloroquine and lumefantrine are 88 ng/ml and 
232 ng/ml, which we round to 90 ng/ml and 235 ng/ml, respectively. These latter values are the 
EC50 values that we use for chloroquine and lumefantrine herein.  
i. Equations Determining Pharmacodynamics Against Asexual Parasites 
We assume that the antimalarial pharmacodynamic dose-response curves against asexual 
parasites (excepting the artemisinins) follow the form:  
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𝑃𝑅𝑅 ∙ 𝐾 𝑥 = 𝑃𝑅𝑅 ∙ 𝑎 − 𝑏1+ 𝑥𝑐 ! + 𝑏  
where a is fixed to be 0, b is fixed to be 1, c is what we term the ‘EC50,’ d is the Hill slope which 
we set to be 2.5, x is the plasma concentration of the drug, and PRR is the square root of the log10 
of the 48 hour maximum parasite reduction ratio for the drug. To determine asexual parasite 
densities during treatment, we subtract the quantity 𝑃𝑅𝑅 ∙ 𝐾 𝑥  from the log10 asexual parasite 
densities during drug treatment. If multiple drugs are present at a given time point we assume 
that the effects are strictly additive (i.e. no synergism).  
b. Pharmacodynamics of artemisinins, lumefantrine, and mefloquine against 
gametocytes 
One beneficial aspect of modeling gametocytes with a 1-day time step is that this granularity 
allows for simulation of the effects of antimalarial drugs over small time scales. Indeed, we can 
model the stage-specific effects of drugs on gametocytes, since we can track gametocytes as they 
age. These effects are very important to determining infectivity, as the duration of gametocytes 
within the host after drug treatment and clearance of asexuals determines how effective a drug is 
at blocking transmission. However, until recently, there was little data with which to 
parameterize such an effect. With the recent release of data reporting the stage-specific in vitro 
effect of various antimalarials on gametocytes [26], we can now parameterize the stage-specific 
gametocytocidal effects for many drugs.  
For this paper, we begin with two sets of assumptions. The first set, which we call the 
‘simplified’ assumptions, assumes that the artemisinins killed gametocytes that were up to 7 days 
old at the time of treatment, reduced gametocytes by 50% per day for days 8-10, and had no 
effect on late-stages. This assumption is consistent with prior evidence that the artemisinins are 
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effective at killing immature gametocytes, but that they do not affect mature gametocytes very 
strongly; see discussion in Bousema et al. [28] as well as the in vitro study by Kumar and Zheng 
[29]. For the partner drugs, before Adjalley et al. [26] lumefantrine alone was not known to have 
a gametocidal effect on P. falciparum, thought it has been shown to kill/disable gametocytes in 
both P. yoelii and P. berghei [30,31]. Regarding mefloquine, a recent study indicates that 
mefloquine is at best a very weak gametocytocidal drug against later stages (III-IV) [32]. Thus 
for our simplified assumptions, we assume that lumefantrine and mefloquine are not 
gametocytocidal. 
The second set of assumptions is that antimalarials decrease gametocyte populations 
proportionally by stage-specific constants. From the in vitro data [26], we assume that the 
artemisinins kill 45.3%, 17.4%, 18.8%, and 16.9% of stage I-II, III, IV, and V gametocytes per 
day, respectively. In the case of lumefantrine, the effects were more ambiguous; if we do not 
assume a delayed action phenotype, then these proportions are 22.4%, 0%, 0%, and 0%; if we 
assume delayed action, then we have reductions of 22.4%, 20.9%, 16.2%, and 11.1%, 
respectively [26]. We assume that lumefantrine acts without delayed action. Mefloquine was not 
included in [26]; however, data indicates that mefloquine is at best a very weak gametocytocidal 
drug against later stages (III-IV) [32]. Because mefloquine and lumefantrine share chemical 
similarities [2] and agree in their gametocytocidal effects in the limited data available, our 
default model assumption is that mefloquine and lumefantrine have identical gametocytocidal 
properties.  
The gender of gametocytes is not specifically modeled (although mature gametocytes are 
often found in male:female ratio of 1:4, and so gender could be predicted if needed) [33].  
 
114
III) Fitting Thailand Gametocyte Carriage Data 
In order to test the treated model, we needed to select a dataset against which to validate the 
model. For our first analysis we utilized a dataset generated from patients treated in western 
Thailand [34]. Malaria transmission in this region is low and seasonal [35]. In this study, data 
from 1,175 patients treated with an ACT (artesunate-mefloquine and artemisinin-piperaquine) 
were pooled and analyzed [34]. No significant differences in gametocyte clearance were 
observed between the various ACTs used [34]. The proportion of individuals who were 
gametocytemic was tracked and monitored over time. Gametocytemic patients differed wildly in 
their admission characteristics in terms of age (2-62 years), duration of fever before seeking 
treatment (0-60 days), and intensity of infection at presentation; a variety of these individuals’ 
malariometric indices are reported in (Table S1). The daily percentage of Thai individuals who 
were gametocytemic at treatment and post treatment is shown in Figure S1 [34].  
The Thai study provides significant amounts of detail about the infections of individuals 
before and during treatment. In order to validate that the treated model infections cleared 
similarly to those from the field, we first needed to match the treatment seeking behavior of 
modeled individuals to those observed in Thailand. This would provide a simulated population 
resembling the Thai population at admission so that we could compare the two populations’ 
responses to treatment. The most important parameter to vary was the delay in treatment 
(assumed to be AM): a shorter delay meant a higher pre-treatment parasitemia, and a longer 
delay meant a lower parasitemia.  
After experimentation, we found a good fit assuming that individuals were treated on 
days 15-16 after emergence of parasites from the liver (Table S1). This assumption yielded a 
median number of fever days before treatment of 3.8 days, assuming fever every other day [36], 
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in line with the field-reported value of a median of 5 days of fever before treatment [34] (it is 
unknown how this value was calculated in the field). Further, the model-generated pre-admission 
geometric mean and median asexual parasitemias are roughly the same (though lightly lower) as 
those observed in the field (Table S1). Once the treatment seeking behavior and admission 
characteristics were matched, we then compared the geometric mean of the maximum 
gametocytemia observed before and during treatment as well as the rates of gametocyte 
clearance. 
We simulated treatment of the synthetic Thai population with AM. We varied the 
gametocytemic properties of AM in three ways in order to compare model response to field data. 
For the first set of simulations we utilized the ‘simplified’ assumptions. The second set of 
assumptions utilized the observed in vitro stage-specific killing proportions determined in 
Adjalley et al. [26]. For the third set of assumptions, we adjusted the various in vitro stage-
specific killing proportions for the artemisinins and their partner until a reasonable fit was 
achieved. 
The model using the simplified assumptions as well as the in vitro adjusted assumptions 
underpredicted maximum gametocyte levels, indicating greater than observed gametocyte 
killing, while the in vitro assumptions overpredicted the gametocyte levels (Table S1). This 
metric did not provide much useful information to discriminate among models other than to 
confirm that the maximum simulate gametocytemias were relatively close to those observed in 
the field.  
However, the daily percentage of individuals who were gametocytemic proved much 
more useful. In (Figure S2A), the model was run with untreated individuals and the daily 
percentage gametocytemic was plotted. The percentage gametocytemic is seen rise rapidly to 
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approximately 75% and then decay slowly over time due to killing of asexuals and gametocyte 
clearance by the immune system. We then treated this synthetic population with AM using the 
‘simplified’ and in vitro gametocytocidal assumptions and copared the results to the untreated 
model output as well as the Thai field data and output assuming that the antimalarials were not 
gametocytocidal. Figure S2B shows the gametocyte clearance data for these treatment types 
normalized to day 0. 
The simplified assumptions matched the observed data quite well; however, gametocytes 
were cleared faster in the model than observed in the field, possibly indicating that ACTs do not 
completely kill early stage gametocytes. The in vitro assumptions do not fit as well: the 
gametocytemia levels are too high, indicating that the in vivo gametocytocidal effects of AM are 
significantly greater than those observed in vitro. After some experimentation, an approximate 
best fit of model output to field data was found using the parameters in Table S2. In fact, our 
fitting process was more complicated than this, because we also used other data sets to fit the 
stage-specific gametocytocidal factors (see below). Indeed, the parameters of Table S2 are those 
parameters that best fitted the Thai clearance data as well as the clearance data from Myanmar, 
Kenya, and Tanzania (see below); in this section we only describe the Thailand target data and 
model fits to this set. From Table S2 we see that more gametocytes died per day after exposure 
in vivo than would have been expected from the in vitro data. Because the Thai data came from 
quite varied individuals, a semi-quantitative fit is all that can realistically be achieved. 
The discrepancy between the field data and model outputs with the in vitro assumptions may 
have multiple causes; we examine two of them here. First, the difference may be due to the fact 
that the drugs in vitro were impairing the functionality of gametocytes without entirely killing 
them; these gametocytes might have been able to produce luciferin, but were otherwise impaired. 
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These gametocytes might possibly have been more easily cleared by the immune system and so 
the effects of drugs in vivo would be greater than those observed in vitro. Second, the effects of 
immunity on the proportion of individuals who were gametocytemic might be greater than 
assumed in the model. Although the majority (57.9%) of gametocytemic individuals in the Thai 
study were experiencing their first episode, and P. falciparum infections occurred only once 
every two years on average [34], some individuals might have developed anti-parasitic immunity 
beyond that observed in the malaria therapy data. It is difficult to identify how much of the 
difference is due to either cause because we cannot easily monitor the natural progression of 
gametocytemia in field settings (due to the ethical imperative to treat individuals on 
presentation), and our conversion factors necessarily incorporate both of these effects.  
 
IV) Fitting Treated Model to Field Data from Myanmar, Kenya, and Tanzania 
We used three other data sets as target data to match model outputs. The first data that we 
consider comes from Myanma children and adults treated with ACTs whose gametocytemias 
were monitored over time [37]. As for the Thai data, we first matched the gametocyte levels of 
patients at admission (7900 gametocytes per µL). We adjusted the modeled treatement seeking 
behavior so that individuals did not receive treatement until 23 days after emergence of parasites 
from the liver. However, even with this delay we were not able to replicate such high 
pretreatment gametocytemias, and we had to assume that only individuals with gametocyte 
densities in the top 20% were treated. Why these gametocytemias were so high even accepting 
for the delay in treatment is a matter of speculation, and we cannot decide the question here other 
than to note its importance.   
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Once the model treatment seeking behavior was set and individuals with high 
gametocytemias were selected, the model was run assuming various treatment types (Figure 
S2C). Since the Myanmar data included treatment with AM+PQ, we were also able to calibrate 
the modeled effects of primaquine; our best-fit parameters are provided in Table S2. We 
disaggregated the effects of PQ from those of AM by taking the normalized fraction of 
individuals gametocyte positive over time after treatment with AM and AM+PQ treatment and 
subtracting; these data for both model and field settings are shown in Figure S2 D. 
In addition to the percentage of individuals who were gametocyte positive over time, we 
also utilized the gametocyte densities of treated children from two sites as target data. In these 
studies, Kenyan and Tanzanian children treated with antimalarials had gametocytemia levels 
monitored over time using microscopy and polymerase chain reaction (PCR) [28]. Figure S3A 
shows the natural log of the gametocyte densities per microliter in the study sites, as well as the 
gametocytemias in individuals treated according to the Thai treatment seeking behavior (15-16 
days after emergence of parasites from the liver). These trends are taken from the daily 
geometric means of individuals registering gametocyte positive by PCR (the threshold for 
detection by PCR is assumed to be .02 gametocytes per µL).  
Gametocytemia levels in modeled individuals continue to rise after treatment as more 
gametocytes emerge into the bloodstream because individuals were assumed to have been treated 
early and there is a large bolus of sequestered gametocytes that emerge during treatement. All 
fits shown in Figure 3 assume the stage-specific killing parameters from Table S2. In Figure 
S3B these same data are plotted after normalizing by dividing each trend by its value at day 0. 
Normalization helps to illustrate differences in clearance that are unrelated to the pretreatment 
gametocyte densities. Modeled clearance rates are slower than those observed in the field; 
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however, this is true even for the Kenya non-ACT treatment set versus the modeled chloroquine 
data. Neither of these treatments should have significant impacts on gametocytemia over time 
other than to arrest their production from asexual parasites and thus both trends should overlap. 
The differences between the two trends may be related to the effects of immunity, both to the 
single infection and preimmunity from earlier infections, as well as to other complications. In 
order to identify the gametocytocidal effects of treatments from these other confounding factors, 
we normalized model trends by subtracting the modeled chloroquine trend from the other trends. 
Likewise, we subtracted the Kenyan non-ACT treatment trend from the observed field clearance 
trends; these data are plotted in Figure S3C.  
This figure illustrates that, after these two normalizations, the ACT+PQ treatment trend 
matches the Tanzania ACT+PQ trend quite well, even reproducing an upward slope in the last 
few timepoints observed in the field. This upward slope may be due to the fact that the 
distribution of gametocytemias among individuals is nonlinear (this is due to the fact that the 
distribution of maximum asexual parasitemias among individuals is log-linear). As individuals 
with fewer gametocytes have their infections clear, the remaining individuals have 
disproportionately higher gametocyte densities, and so the censored geometric means rise over 
time due. Figure S3C also illustrates that the modeled AM treatment trend approximately splits 
the difference between the Kenya ACT treatment trend and the Tanzania ACT treatment trend 
without PQ, as would be expected. 
Figure S3 (D-F) illustrates the same data as Figure S3 (A-C) with the exception that 
modeled treatment is assumed to occur according to the treatment seeking behavior observed in 
Myanmar (23 days after emergence from liver including only individuals with gametocytemia 
densities in the top ~20%). The starting gametocytemia densities are much higher than those 
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observed in the Thai scenario among modeled individuals (field trends are identical); however, 
after normalization the same qualitative trends are observed as above, with the exception of the 
peak in gametocytemia midway through the doubly normalized trends (Figure S3F). This peak 
is due to the fact that chloroquine clears parasites much faster in the model than observed in the 
Kenyan non-ACT treated data set (Figure S3E). The reason for this is that treatment in the 
Myanmar setting occurs at the absolute peak of observable gametocytemia, whereas in the field 
settings gametocytes are still presumably emerging from the liver in increasing numbers at the 
onset of treatment, and thus gametocyte levels post-treatment in the chloroquine-treated model 
scenario fall faster than those in the field (the reverse of the effect noted in the Thai model 
treatment). Because we do not know how far into their infections these children were treated, we 
cannot know which of the two treatment-seeking behaviors best match the field data. 
 
V) Coding Specifications 
The model was built in MATLAB (Mathworks, Version R2011a). The model outputs include the 
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Figure S2
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Mechanistic Malaria Model 1.0
Number of runs
Probability infection is treated [0-1]
Treatment delay in days (if treated)
Choice of partner drug
Residual partner drug from earlier infection
Number of days ago previous
treatment was received
(if previous infection occurred)
Gametocyte pharmacodynamics (Adjalley et al.)
For MEF as partner, ‘LMF’ is recommended 
Percent survival per 48 hours, DHA
(1/Parasite Reduction Ratio)
For Pailin-type DHA resistance, use 0.415%
Percent survival per 48 hours, partner drug
(1/Parasite Reduction Ratio)
Stochastic pharmacokinetics
Partner drug in vivo IC50 (ng/ml)
Default is 900 ng/ml for MEF
Default is 241ng/ml for LMF
Assume that the partner drug
completely blocks transmission
Save data





Note: Each run takes
approximately 10 seconds
Parasitological Indices Host Responses
log10 Asexual Parasitemia (PRBC/microL) Partner Drug Pharmacokinetics (ng/ml)
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log10 Gametocytemia (GAM/microL) Partner Drug Asexual Pharmacokinetics






















































0 200 400 600 800
0 200 400 600 800





0 50 100 150 200
0 50 100 150 200
2 4 6 8 10 12 2 4 6 8 10 12
128
Table S1. Treated Model Validation
Parameter (Units) Measure Thai Patient Data




Assumptions (N = 
1,000)
Model, in vitro 
Assumptions (N = 
1,000)
Model, Modified in vitro 
Assumptions (N = 
1,000)
Duration of Fever Prior to 
Admission (Days) Median 5.0 3.5
† 4† 3.5†
Geometric mean 5363 4240 4845 4311
Median 8720 7023 7820 6815
Minimum 1.0 10.0‡ 10.1‡ 10.0‡
Geometric mean 209.7 125.8 236.8 115.0
Maximum 20370 25628 62305 14715
1Piyaphanee, W. et al. Emergence and clearance of gametocytes in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 74, 432-435, 
doi:74/3/432 [pii] (2006).
Table S1 | Treated Model Validation. In order to determine how well model behavior matches field data post treatment, the model was calibrated to 
reproduce the characteristics of the Thai study population. The malariometric indices of infected, ACT-treated individuals are shown in the first data column. 
The model fitting was performed to give the optimal match to the malariometric indices in the field. Once the model parameters were set, the model was run 
assuming treatment with one of three sets of assumptions: the 'simplified' assumptions, the in vitro gametocytocytemic data from Adjalley et al., or the 
modified stage-specific gametocytocidal drug effects (described in text).
Asexual Parasitemia At 
Presentation (PRBC/µL)
Gametocytemia At 
Presentation and During 
treatment (GAM/µL)
†Fever duration calculated assuming fever once every two days.
‡Minimum gametocytemia in model is 10 gametocytes per µL, given the assumpition of detection by smear.
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Table S2. Daily Proportion of Gametocytes Killed by Drug Treatment
!"#$%&$"'(#)%*+)# , - . / 0 1 2 3 4 ,5 ,, ,- ,. ,/ ,06
7)'"#$%&$"'(#)%*+)# 7)'"#$8 7)'"#$8 7)'"#$8 7)'"#$8 7)'"#$88 7)'"#$88 7)'"#$88 7)'"#$88 7)'"#$888 7)'"#$888 7)'"#$888 7)'"#$89 7)'"#$89 7)'"#$89 7)'"#$9
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Table S2. Daily Proportion of Gametocytes Killed by Drug Treatment. The proportion of gametocytes killed per day as a function of gametocyte age. The model killing fractions were determined using the in vitro data (Adjalley et al., 2011) as a starting point and then curve fitting treated 
model gametocyte clearance to field data. All in vitro data is from (Adjalley et al., 2011). The ratio model:in vitro provides the scaling factors needed to translate in vitro killing to observed decreases in gametocytemia after treatment in the field. Mean scaling factors for each drug are provided at 
right. MFQ = mefloquine; LMF = lumefantrine; CQ = chloroquine; DHA = dihydroartemisinin; MB = methylene blue; PMQ = primaquine.
/01)
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Supplemental Text S2 
User manual for the graphical user interface to the mechanistic malaria model (M3), Version 1.0 
I) Getting Started 
0. Terms of use 
a. Redistribution, modification, and/or utilization for commercial purposes 
b.  Citations 
1. Installation 
a.  On a Windows computer 
b.  On a Macintosh computer 
II) Running the Model 
III) Saving the Outputs 




 I) Getting Started 
0. Terms of use 
You agree to all of the following terms of use when redistributing/modifying/using this software 
in any way, including use of its output and/or any part of its computer code. 
a.  Redistribution, modification, and/or utilization for commercial purposes 
The Mechanistic Malaria Model (M3) Simulator. Copyright © 2011 Geoffrey Johnston. 
This program is free software: you can redistribute it and/or modify it under the terms of 
the GNU General Public License as published by the Free Software Foundation, version 3. 
This program is distributed in the hope that it will be useful, but without any warranty; 
without even the implied warranty of merchantability or fitness for a particular purpose. See the 
GNU General Public License for more details. 
For a copy of the GNU General Public License see http://www.gnu.org/licenses/. 
b.  Citations  
Please cite this software in any publications that benefit from its use, including (but not limited 
to) its output or any of its computer code. 
1. Installation 
a. On a Windows computer 
In order to install and run the software, you will need to download two files. 
The first file, called a runtime library, allows the model software to run on any computer, 
whether or not MATLAB is installed.  To download this file, go to the Fidock Lab website and 
download the Windows MATLAB runtime installer.  
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Once downloaded, double click on the file MCRInstaller.exe; this file installs the 
MATLAB runtime compiler which allows MATLAB programs to be run on any computer even 
if MATLAB is not installed. Follow all of the installation directions; the ‘Typical’ installation is 
recommended.  
The second file that you will need is the model file itself (model.exe); this file is found in 
the supporting information. Place this file in the same directory as the MCRInstaller.  
To run the M3 software, simply double click on model.exe; this should open the graphical 
user interface to the model. 
b. On a Macintosh computer 
In order to install and run the software, you will need to download two files. 
The first file, called a runtime library, allows the model software to run on any computer, 
whether or not MATLAB is installed.  To download this file, go to the Fidock Lab website and 
download the Macintosh MATLAB runtime installer.  
Once downloaded, double click on the file MCRInstaller.dmg; this file installs the 
MATLAB runtime compiler which allows MATLAB programs to be run on any computer even 
if MATLAB is not installed. Follow all of the installation directions; the ‘Typical’ installation is 
recommended.  
The second file that you will need is the model file itself (model.exe); this file is found in 
the supporting information. Place this file in the same directory as the MCRInstaller.  
To run the M3 software, simply double click on model.exe; this should open the graphical 
user interface to the model. 
 
II) Running the Model 
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In the User Manual we will assume that the model is being run from the graphical user interface 
(GUI).The GUI appears as shown in Figure 1. The GUI allows users to change model parameters, 
examine output in real time, and save their results. 
 
Figure 1: The Graphical User Interface 
There are seven windows that are displayed on the GUI. The three windows on the left 
display the daily log10 asexual parasitemia per µL, the log10 gametocytemia per µL, the daily 
probability of human to mosquito transmission. These are termed the ‘Parasitological 
Responses.’ The top two windows in the middle of the GUI depict the modeled daily plasma 
concentrations of the partner drug used in treatment as well as the pharmacodynamics of the 
partner against asexual parasites (these windows remain blank if untreated).  
The bottom two windows depict the pharmacodynamics of the partner drug against 
gametocytes. The daily percentage of gametocytes surviving after drug exposures are shown (at 
left is the effects of dihydroartemisinin, at right is the partner of choice). The x-axis is the age of 
the gametocyte: in general, antimalarials have greater effects on young gametocytes than old 
ones. The higher the daily value for a given gametocyte age, the greater the proportion of 
gametocytes of that age that survive exposure. These windows display the pharmacodynamic 
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profiles against gametocytes regardless of treatment (but have no effect if untreated). These four 
windows are termed the ‘Host Responses.’ 
The parameters that can be adjusted in the model are found in the upper right hand 
section of the GUI. (Not all model parameters are user-adjustable in Version 1.0.) We describe 
these parameters here: 
Parameter Name Default 
Value 
Description 
Number of Runs 1 The number of runs the model will perform. Each 
run takes approximately 10 seconds on a Windows 
laptop with an Intel Core 2 Duo processor; faster 
computers will take significantly less time per run. 
Range: [1 – ∞). 
Probability infection is 
treated 
0 The probability that an infection will be treated with 
an ACT; the parameters determining the efficacy of 
this treatment are defined below. Set this value to 1 
to insure individuals are treated. Range: [0 – 1]. 
Treatment delay in days 2 The number of days after the first fever that an 
individual will receive treatment. Set this value to 0 
to have an individual treated on their first fever day. 
Range: [0 – ∞). 
Choice of partner drug LMF The partner drug that will be utilized in the 
treatment. This parameter determines the 
pharmacokietics of the partner, as well as setting the 
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in vivo IC50. The IC50 and other parameters can be 
adjusted separately. There are currently three 
possible selections: ‘LMF’ - Lumefantrine; ‘MEF 
fixed’ - Mefloquine, fixed dose; ‘MEF loose’ - 
Mefloquine, loose dose. 
Residual partner from earlier 
infection 
No Determines whether an earlier infection was treated. 
If ‘Yes,’ then the model simulates residual partner 
drug being present. The number of days previous the 
treatment was assumed to occur is set by a 
parameter below; the default value is 20 days. 
Number of days ago previous 
treatment was received (if 
infection occurred) 
N/A This paramter determines the number of days 
previous that an infection was treated. The model 
assumes that only the partner drug is present in the 
system (and that the dihydroartemisinin component 
is no longer present). The default value is 20 days. 
This parameter has an effect only if the ‘Residual 
partner from an earlier in fection’ parameter is set to 




LMF This parameter determines the stage-specific effects 
of the partner drug on gametocytes. The x-axis 
indicates the age of the gametocyte and the y-axis 
indicates the proportion of gametocytes that survive 
one day of drug treatment. These curves were taken 
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from the Adjalley et al. paper. The ‘simplified’ 
assumptions are described in Text S1 and affect the 
pharmacokinetics of both dihydroartemisinin and its 
partner. 
Percent survival per 48 
hours, DHA 
.01 This is the percentage of parasites surviving 
treatment with dihydroartemisinin after 48 hours. 
This parameter can be adjusted in order to simulate 
the resistance observed in Pailin, Western 
Cambodia, by changing the value to 0.415. This 
parameter does not determine the net parasite 
reduction ration per 48 hours; that is determined by 
a variety of factors (including this parameter). 
Range: [0 – 100]. 
Percent survival per 48 
hours, partner drug 
1 This is the minimum percentage of parasites 
surviving treatment with the partner drug after 48 
hours. The effectiveness of the partner is modified 
by its plasma concentration; this parameter 
determines its maximum effectiveness. This 
parameter does not determine the net parasite 
reduction ration per 48 hours; that is determined by 
a variety of factors (including this parameter). 
Range: [0 – 100]. 
Stochastic pharmacokinetics No This parameter determines whether the 
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pharmacokinetics of the chosen partner drug are 
stochastic or not. If set to ‘Yes,’ the standard 
pharmacokinetic properties of the partner are 
modified as described in Text S1. 
Partner drug in vivo IC50 241 This parameter determines the plasma concentration 
at which the parter drug exerts half of the killing 
effects of its maximum parasite reduction ratio 
against asexual parasites. In other words, when the 
plasma concentration of the partner drug reaches this 
value, the 48 hour percent survival is half of its 
maximum value. The default value for mefloquine is 
900 ng/ml; for lumefantrine, it is 241 ng/ml.  
Assume that the partner drug 
completely blocks 
transmission 
No This parameter determines whether the partner drug 
is perfectly transmission blocking. If set to ‘Yes,’ 
upon treatment the partner drug immediately kills all 
gametocytes that were produced and does not allow 
any gametocytes to be produced in the future.  
Save data No This parameter determines whether some of the 
output data is saved. If set to ‘Yes,’ the daily asexual 
parasitemias, gametocytemias, infectivitys, and net 
infectivities aresaved. See Section III) ‘Saving the 
Outputs’ below for more information. 
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III) Saving the Outputs 
When saving the model outputs, first, set all of the parameters to their desired values. The ‘Save 
data’ parameter needs to be set to ‘Yes’ before the model is run; you cannot save data by 
adjusting this parameter once the model has started. Assuming that ‘Save data’ is correctly set, 
the model will save the following outputs: the daily asexual parasitemias, the daily 
gametocytemias, the daily infectivities, and net infectivities for each run. Each of these four sets 
of data is saved to a separate ASCII text file. The file names are ‘Asexuals.txt,’ 
‘Gametocytemias.txt,’ ‘Daily_Infectivities.txt,’ and ‘Net_Infectivities.txt.’ On Windows 
computers, these files should appear in the directory in which the model is run.  
 
IV) For Researchers 
Although the model GUI provides significant functionality to the end-user, researchers may 
desire additional capabilities. For example, researchers may desire to modify parameters beyond 
those included in the GUI or run very large numbers of simulations.  
There are two options to accommodate these needs. The first option is that researchers 
could modify the source code as they see fit and run multiple instances of the model from the 
command line or a modified GUI. The second option is to utilize the computing structure already 
developed by the authors to run massively parallel computations. To perform the simulations in 
the paper, as well as ongoing work, the authors use a high-performance computing cluster known 
as Hotfoot, based at Columbia University. This cluster runs Linux and utilizes the Maui/Torque 
job scheduler to allocate computing resources. To access this cluster, the authors wrote a script 
for Maui/Torque that allows for parallel execution of the model and modified the MATLAB 
code so that the code can be called by this script. This cluster allows for hundreds of 
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simultaneous runs, such that the time needed to run simulations is reduced approximately 50-fold 
versus single-instance simulation. If researchers are interested in accessing this resource to run 
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Malaria is a leading cause of childhood morbidity and mortality throughout the developing 
world, particularly in Africa. Artemisinin-based combination therapies (ACTs) are currently the 
recommended first-line therapy for treating malaria and are in use worldwide. However, given 
their relatively high cost, these therapies are currently heavily subsidized in both the public and 
private sectors in many parts of Africa and Southeast Asia. The private sector subsidy 
mechanism, known as the Affordable Medicines Facility for malaria, is now under review. To 
help evaluate the benefits of antimalarial subsidization, we fitted semi-mechanistic models to 
malaria mortality data from 1980-2010. We simulated the impacts of first-line antimalarial 
therapy and drug resistance as well as insecticide treated bednets, ACTs, and rapid diagnostic 
tests (RDTs) on mortality during this period. We also projected future trends in mortality and 
assessed the benefits of treatment by the metrics of lives saved and dollars per disability life year 
(DALY) averted. First, we find that ACTs are cost-effective at reducing mortality over time: our 
model predicts that ACTs average approximately $13 per DALY averted, well below the $50 
threshold for an intervention to be considered ‘very cost-effective’ [1]. Second, we find that the 
risk-averse decision planner will only employ RDTs in a limited number of settings. Third, our 
model predicts an 8-10 year window after emergence of resistance in Africa before resistance 
necessitates a change in therapy for Africa as a whole. ACT subsidization is a highly cost-
effective tool even if resistance is not averted for a significant period of time. However, if 
resistance can be averted for even three years, we predict that ~1.3 million lives will be saved by 








Malaria is a significant cause of morbidity and mortality throughout the developing world. 
Though estimates of the death toll during the past three decades vary substantially because of 
real underlying uncertainty, the general trends are well documented. During 1980-2000 a tide of 
mortality swept through Africa after chloroquine (CQ) and sulphadoxine-pyrimethamine (SP), 
the two previous first-line treatments, failed due to drug resistance [2,3]. The situation has 
improved recently due to improved treatments and large-scale deployment of long-lasting 
insecticide treated bednets (LLINs) in Africa [4].  
The recommended first-line therapy for malaria is now artemisinin-combination therapy 
(ACT) [5]. Artemisinin is a fast-acting, potent antimalarial with exceptional biological 
properties. Artemisinin-based combination therapies combine an artemisinin with a partner 
antimalarial in order to improve the clinical efficacy of artemisinin and delay the evolution of 
resistance [6-8].  
Given the importance of artemisinin to global malaria control, it is imperative to protect it 
from resistance to the extent possible while ensuring access to all who are in need. In 2002, an 
Institute of Medicine committee was convened to address concerns that resistance to artemisinins 
would evolve. The committee’s report, issued in 2005, advocated “a sustained global subsidy of 
artemisinin co-formulated with other antimalarial drugs in order to reduce malaria mortality 
(‘saving lives’) and delay resistance (‘buying time’) until new categories of antimalarials could 
be developed [6]. This subsidy would save lives by lowering the costs of ACTs and thereby 
increasing access; it would also buy time by ensuring that ACTs were more affordable than 
artemisinin monotherapies, thus crowding out the monotherapies from the market [6].  
Large-scale uptake of ACTs began in 2005, and the Affordable Medicines Facility for 
malaria (AMFm) was launched in the fall of 2009 in nine countries to subsidize the private-
sector purchase of ACTs and has been successful at lowering the retail price of ACTs [9-12]. In 
2011 the commitments toward AMFm amounted to $316 million from various partners [13]. A 
distinct advantage of the policy was pooled procurement, which allowed the AMFm to purchase 
ACTs at the cost of $1 per curative dose.  
The pilot AMFm program is now being evaluated for renewal [13]. In this paper we 
develop a semi-mechanistic model to evaluate the benefits of ACT subsidization. We examine 
trends in imputed malaria mortality over time from multiple sources and develop an 
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intermediate, ‘consensus’ set of mortality data. To this mortality data we fit a model of the 
effects of drug resistance, deployment of ACTs, and scaling-up of LLIN usage. We also include 
a model of the effects of rapid diagnostic testing (RDT) on ACT efficacy, given that RDTs are 
another mechanism by which resistance might be averted. 
We then use this model to project what the effects of future ACT resistance might be, 
assuming similarity to the spread of resistance in 1980-2000. We evaluate subsidization from the 
perspective of numbers of lives saved as well as dollars per disability-adjusted life year, a 
common measure of program cost-effectiveness [14]. Given the difficulties involved in 
predicting to what extent subsidization will delay resistance, we conduct a sensitivity analysis of 
the effects of ‘buying time’ on these metrics. 
These studies lead to three main conclusions. First, we find that ACTs are cost-effective 
at reducing mortality over time: our model predicts that ACTs average approximately $13 per 
DALY averted. Second, we find that rapid diagnostic testing (RDT) can reduce ACT overuse by 
as much as 15-33% at high coverage levels, though costs are increased by 25-30% if RDT prices 
remain constant. Third, we predict that if ACT resistance patterns follow those of CQ, then the 
10% clinical treatment failure threshold is not likely to be reached in Africa until 8-10 years after 
the emergence there of resistance, providing a short window for the development and 
deployment of new pharmaceutical compounds.  
 
Methods 
Most mathematical models for the evolution of anti-malarial resistance, whether population 
genetic or population dynamic models, have several common properties [15,16]. Models must 
make some assumption about the initial frequency of resistance. These initial conditions can 
include a lag, called a “honeymoon period,” between the introduction of the drug and the 
emergence of resistance somewhere. Then, after resistance has emerged or been imported from 
elsewhere, some other model for the spread of resistance considers the initial condition and 
determines increases in the frequency of resistance in some set of populations. Models for spread 
predict that, if there is net positive selection for resistance because of drug use, the frequency of 
resistance will increase over time and that these changes in a single population will have a 
sigmoidal shape. Selection is related to factors that may vary from place to place, including the 
intensity of malaria transmission, the rates of use of antimalarial drugs, and the mathematical 
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assumptions of the model. There is also some uncertainty about the asymptotic frequency of 
resistance, which may be related to superinfection, the cost of resistance, and the effects of 
chemoprophylaxis [17,18]. In the end, though, key uncertainties can be reduced to four 
parameters: 1) the length of the honeymoon period; 2) the rate of increase of drug resistance over 
time; 3) the asymptotic frequency of resistance; and 4) the clinical consequences of resistance. 
Here, we have adopted a semi-mechanistic approach in which we take the sigmoidal shape 
without making any explicit underlying assumptions about the underlying biological (e.g. 
parasitological, pharmacological, epidemiological, clinical, behavioral, immunological) causes. 
Values of these three parameters are chosen to make the model consistent with existing data.  
 
Model Specification 
We used estimates of worldwide malaria mortality to parameterize a model of the spread of first-
line antimalarial resistance and subsequent reductions in mortality using LLINs, ACTs, and 
RDTs. The malaria mortality data came from three sources, which served as the basis upon 
which our semi-mechanistic model was built. The first data are the estimated worldwide malaria 
deaths from the Global Burden of Disease (GBD) Project [4]; these data estimate mortality from 
1980-2010. The second data are from the 2011 World Malaria Report, which provides the WHO 
estimates of malaria mortality from 2000-2010 [2]. These two data sets differ considerably in 
their estimates of mortality over time; as an intermediate scenario we took the arithmetic mean of 
the two datasets. This approach results in deaths for 2000-2010; the mean estimate for 2000 
matches the estimate for 2000 reported in [19] adapted from the WHO World Health Report, 
2002. For those years in which only one data set was available (1980-1999), we took the data 
from the GBD and scaled it linearly.  
The shape of the sigmoidal curves were scaled so that deaths in 1980 were 20% higher 
than what would have resulted if we had taken the GBD 1980-2000 mortality data and simply 
shifted it down to meet the mean estimate of 2000. The reason for this scaling is two-fold. First, 
since the trends are so prominent in the GBD data, if we had used the un-scaled trends then there 
would have been an unrealistically low number of deaths in 1980. Second, the effect of this 
scaling is that the increase in deaths during 1980-2000 is shallower than if the non-scaled data 
had been used; we wanted to produce a more conservative estimate of the spread of CQ 
resistance than would have resulted from a translation of the GBD data. The results of this 
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estimate are shown in Figure 1, where the red line indicates the intermediate scenario of deaths 
used in the modeling and the shaded area provides the difference between GBD and WHO 
estimates where both exist. 
Once the mortality data had been generated, we then fitted a semi-mechanistic model to 
these data based on the following assumptions. First, we assumed that in the absence of any 
treatment, malaria mortality would be increasing linearly over time. This assumption was 
justified on the basis that the rural African population has been increasing linearly over the past 
30 years (linear fit R2 = .998; data from World Bank DataBank; http://databank.worldbank.org) 
and that approximately ~90% of all malaria deaths are from Africa [2]. The second assumption 
was that first-line malaria therapy was relatively constant over the period 1980-2000 and that the 
increase in deaths was due to increasing resistance and declining efficacy of these antimalarials. 
Specifically, we assumed that resistance over time 𝑅 𝑡  was described by the function 𝑅 𝑡 = 1− 1 1+ 𝑡 𝑎 ! . This model assumes that resistance had no significant effect on 
mortality until 1980; up to that point, resistance had been most prevalent in Southeast Asia, 
where the global share of deaths is low. The virtue of this model is simplicity: although the 
spread of first-line antimalarial resistance is a complicated process involving appearance, 
emergence, and spread in multiple locations [16], the trend of resistance worldwide will appear 
sigmoidal because the different rates of spread in various areas will be averaged over time. 
To account for the contributions of LLINs and ACTs to malaria reductions, we included 
the uptake of these control measures over time [2] in our model. We did not include any effects 
of spraying on reductions in mortality, as LLINs and ACTs were the likely first-order drivers of 
mortality over the past decade, given that spraying coverage in Africa is still low even after 
recent growth (~11% in 2010 [2]), and that spraying may not be as effective in areas of very high 
LLIN coverage [20]. For LLINs, we assumed a linear relationship between African household 
coverage (for 2000-2010 [2]) and deaths averted. For ACTs we also assumed a linear 
relationship between worldwide public and subsidized private sector purchases (2005-2010 [2]; 
we ignore unsubsidized purchases given their small share of total supply) and decreases in 
mortality. However, the effects of ACTs are also augmented by the use of RDTs, which increase 
the efficacy of antimalarial treatment by increasing the proportion of malarious individuals 
treated as a proportion of all treatment-seeking individuals. 
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To parameterize the effects of RDTs on improving ACT efficiency, we developed a 
model to predict how much RDTs increase the efficacy of ACTs and reduce overtreatment; we 
then applied this model assuming the RDT uptake trends from [2]. Consider the case of ACT 
usage in the absence of RDTs. Individuals with fever visit either public or private health care 
providers to purchase/receive treatment. Most of these individuals will have a febrile illness 
other than malaria but will receive malaria treatment nevertheless. The proportion of febrile 
individuals who have malaria (prop_mal) will vary with the levels of malaria endemicity in an 
area. However, WHO model estimates predict that prop_mal will be 38% on average under 
current LLIN coverage levels in 2015; this is the value that we use here [2]. In absence of 
diagnosis, prop_mal is the proportion of individuals who will be cured by treatment. A much 
smaller fraction of prop_mal will avert death, and the remaining proportion (1− 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙) of 
individuals will be treated improperly. 
In the presence of RDTs, however, the probability that an individual will be properly 
treated for malaria increases. Thus, the probability that a given ACT will cure an individual or 
save a life will increase, and a given pool of drug will save more lives than in the absence of 
RDT usage. The probability that a febrile treatment-seeking individual will receive treatment for 
malaria (the true positivity rate or the sensitivity of treatment) is a function of six variables in the 
presence of RDTs: prop_mal; the proportion of individuals receiving RDTs (RDT_p); the 
probability that an individual will receive treatment given a positive RDT (c_pos); the 
probability that an individual will not receive treatment given a negative result (c_neg); the false 
negative rate of the RDT (false_neg); and the false positive rate of the RDT (false_pos). 
Given the function for the specificity of ACTs in the presence of RDTs, we can calculate 
by what factor specificity is increased versus the case with no RDT usage; we call this function 
sensitivity_mult and is defined as 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙. These parameters vary significantly 
depending on the treatment-seeking behavior of the population; for example, non-compliance 
with a negative RDT (1-c_neg) varies from <16% to 85% depending on age, season, training, 
etc. [21-23]. We assume very good compliance with RDTs: specifically, we assume compliance 
with a positive result is 95%, compliance with a negative result is 60%, the false negative rate of 
the RDT is 5% and the false positive rate is 20%. 
Given these assumptions, the specification for our model is (where mortality is the 
dependent variable, 𝛽 is the vector of parameters to be estimated, 𝜌 is the vector of assumed 
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parameters for the RDT specificity function, RDT(t) is RDT usage over time, ACT(t) is ACT 
usage over time, and LLIN(t) is LLIN usage over time): 
 𝑌 𝒕 = 𝛽! + 𝛽!𝒕 − 𝛽! 1− 1 1+ 𝒕 𝛽! !! − 𝛽! ∙ 𝑠𝑝𝑒𝑐𝑖𝑓𝑐𝑖𝑡𝑦_𝑚𝑢𝑙𝑡 𝜌,𝑅𝐷𝑇 𝒕 ∙ 𝐴𝐶𝑇(𝒕)− 𝛽! ∙ 𝐿𝐿𝐼𝑁(𝒕) 
 
To estimate 𝛽 we used the lsqnonlin function (MATLAB 2012a; MathWorks), which 
finds the best-fit estimates using least-squares (to minimize the sum of squares cost function) 
among a set of constrained parameters. We found that meaningful parameter identification with 
the full set of parameters was not possible, even though we specified functional forms for the 
effect of each of the contributors to mortality over time and we had differential patterns of uptake 
among the various contributors. We thus manually set the probability of an ACT saving a life in 
such a way as to be consistent with the data (see below); the rest of the parameters were then 
fitted to the data. We can also use this statistical model to explore parameter sensitivity apart 
from any mortality estimation. Table 1 provides the parameter estimates with this specification 
from the mortality data.  
Our assumption of linear returns to control measures is most applicable in areas of 
medium endemicity. In areas of high endemicity, interventions might have lower returns to 
control measures given the high levels of incidence. In low endemicity areas, interventions may 
be sufficient to interrupt transmission. We thus assume that malaria transmission is not reduced 
sufficiently on a worldwide scale such that elimination is achieved in many areas. In such a case 
the returns to ACTs will be higher than modeled here. We also do not consider any synergies 
among treatments (ACTs being more effective in the presence of LLINs, for example). 
We also assume that LLIN usage after 2011 is constant at 2011 levels with approximately 
50% coverage of African households with at least one bednet [2]. For RDT uptake, we used 
African data and assumed that if individuals seek treatment in a public health facility that 
provides RDTs, then the case is first tested by an RDT. In the public sector RDT coverage has 
risen rapidly over the past few years; in 2010 level, 45.7% of suspected malaria cases attending 
public facilities were in a facility that used RDTs [2]. However, only 29% of individuals are 
estimated to seek care in a public facility in Africa [2], and we assumed that there is no uptake 
outside the public sector; thus our coverage level was estimated at 13.25% of cases for 2010 and 
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afterwards. We also scaled RDT efficacy over 2007-2010 according to the panel detection scores 
reported in [2]. It is very likely that this proportion will rise over time1; however, our baseline 
estimates are for the effect of ACTs only, not in concert with other interventions. 
For our costing analysis and calculation of DALYs averted, we assumed that the price of 
ACTs fell from $3 per dose to $1 per dose over the period of 2005-2012 and then stayed constant 
at this level going forward [13]; the price of $1 per dose is the approximate price cap negotiated 
by the Clinton Health Access Initiative (CHAI) and reported by the Global Fund.2 We assumed 
that RDTs cost $0.67 per test and that this price is also constant.3 Our baseline assumptions thus 
consider the benefits of ACT subsidization certeris partibus. For the cost of the first-line 
therapies we assumed a cost of $0.085 per dose, which is the mean cost per treatment episode for 
an adult in 1990 [24]. Note that the cost of SP in 1990 was not much higher, at $0.13 per dose, 
and that the cost of CQ dosing for children would be lower (the relative proportions of each are 
described below). 
The DALYs averted for each treatment are derived from two sources: mortality and 
morbidity. For mortality, we use the age distribution of clinical malaria cases from [4] and the 
life tables for estimated African life expectancy in each age class from WHO estimates.4 For 
morbidity, we assume that the proportions of fevers that are malarious are cured for each 
treatment, accounting for resistance, and that these avert 3/52 of a DALY (i.e. each infection 
causes 3 weeks of morbidity). We do not consider prophylactic effects of treatment. 
One caveat to our analysis of resistance is that increasing ACT treatment levels past a 
certain point might increase the spread of resistance. Because there may be more selection for 
resistance when the number of treatments increases, resistance might spread faster. We do not 
consider such thresholds or functional responses here but do note that further research is needed 
to help understand the relationship between treatment, overtreatment, and spread of resistance. 
Also, we do not consider cases where ACT subsidization slows the spread of resistance versus 
the CQ case, which is also possible given the crowding out effect. Rather, because little is known 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  See	  www.theglobalfund.org/documents/amfm/AMFm_AffordableMedicinesFacilityMalaria_FAQ_en.	  2	  The	  CHAI	  price	  caps	  (2009,	  French)	  are	  here:	  http://www.clintonhealthaccess.org/news-­‐and-­‐information/chai-­‐act-­‐price-­‐list-­‐french-­‐2009;	  and	  the	  Global	  Fund	  price	  tracking	  estimates	  (monthly)	  are	  here:	  http://www.theglobalfund.org/en/amfm/pricetracking/.	  3	  This	  estimate	  was	  taken	  from	  the	  RDT	  cost-­‐effectiveness	  estimator	  provided	  by	  the	  WHO:	  http://www2.wpro.who.int/sites/rdt/using_rdts/assessing_cost_effectiveness.htm.	  	  4	  See	  Annex	  Table	  2,	  http://www.who.int/healthinfo/paper09.pdf;	  average	  of	  males	  and	  females	  in	  AFR	  D	  and	  AFR	  E	  regions.	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about such processes on a global level we simply assume that ACT resistance and CQ resistance 
spread at the same rates, and examine what happens to the sensitivity of our results if the waiting 
time to resistance is varied. 
 
Consistency of Model Outputs with Prior Studies 
Once our statistical model was specified and fitted to data, we examined the quality of the fit; 
Figure 2 shows the model-predicted mortality as well as the estimated mortality over time, along 
with the estimated fractions of lives saved from first-line therapies, LLINs, and ACTs aided by 
RDT usage. The first point to note is that the model predicts that first-line therapies prevented 
~793,000 deaths or 55% 𝛽! 𝛽!  of total malaria mortality in 1980. By 1999, however, the 
model predicts that resistance to these therapies had reduced efficacy by approximately one-half. 
We consulted the literature to examine whether we could derive some estimates of these 
parameters as a basis for comparison with our estimates. We found few estimates of the total 
levels of first-line antimalarial usage during 1980-2000; however, one study estimated that in 
1989 national malaria control programs distributed the equivalent of 134 million adult doses of 
chloroquine (CQ); 17.7 million adult doses of sulphadoxine-pyrimethamine (SP); and 2.0 million 
doses of adult quinine (QN) [25]. Thus, the vast majority of first-line therapies (87%) provided 
through the public sector were CQ. Further, the paper reports that approximately 20% of 
treatments were through national malaria control programs, implying a total number of 769 
million adult doses of antimalarials consumed worldwide in 1989. We assume that private sector 
drug shares were similar to those of the public sector. 
We can use our numbers of lives saved from first-line antimalarial use to generate a very 
rough estimate of the number of doses received. We can assume that, at a first pass, the number 
of lives saved (β3) by first-line therapies in absence of resistance equals the number of doses (x) 
times the proportion of fevers that are malarious (prop_mal) times the probability that an ACT 
averts a death (β6) in absence of an RDT. Thus 𝑥 ≈ 𝛽! ∙ 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙!! ∙ 𝛽!!!; if we use our 
estimates from above, we predict a total of 1.40 billion treatments, or 1.8 times more treatments 
that estimated in [25]. One reason that our estimates differ is that our estimate is of total doses, 
whereas [25] estimates adult dose equivalents. The total recommended adult dose of CQ for 
acute malaria is 2.5 g; for children it is 25 mg/kg. If a child weighs an average of 25 kg (55 lb), 
this would represent 0.625 kg of CQ (1/4 of the adult dose). Thus, if two-thirds of the doses 
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estimated in [25] were for adults and the rest for children (at a 4:1 ratio of dosage), the two total 
dosage estimates would be approximately equal. This calculation assumes that the probability of 
saving a life given CQ or an ACT is equal (in the absence of resistance). 
Regarding the spread of first-line therapy resistance, the vast bulk of treatments during 
1980-2000 and onward were CQ. According to [26], “most African countries only abandoned 
chloroquine between 2004 and 2008.” Thus malaria drug resistance and mortality kinetics should 
roughly follow those of CQ. According to a contemporaneous study in three rural populations in 
Senegal [27], “from 1984 to 1995 … the emergence of chloroquine resistance has been 
associated with a dramatic increase in malaria mortality … (mortality in 0-9 year olds) was 
multiplied by 2.1, 2.5, and 5.5 times, respectively.” A recent retrospective analysis confirms that 
CQ resistance was causing substantial increases in mortality in Uganda through 1997-1998 [28]. 
There can be no doubt that mortality was increasing during 1980-2000 due to CQ resistance.  
Chapter 21 of [29] provides WHO estimates of chloroquine treatment failure rates 
throughout Africa, from 1997-2002. Failure rates range from approximately 70% in Ethiopia to 
as low as 0-15% in Nigeria (where a considerable number of deaths are concentrated). Thus there 
was substantial room for increases in mortality due to CQ resistance as late as 2002. The spread 
of resistance was slow throughout Africa during 1980-2005, likely due in part to the fitness cost 
of CQ resistance [30] in an environment of high multiplicity of infection. Indeed, CQ resistance 
was first discovered in Cambodia in 1957 [31] but was not documented in Africa until 1978. 
 We chose the parameter 𝛽! so that relative effects of LLINs and ACTs on mortality are 
approximately equal (Figure 2). (The proportion of lives saved by ACTs from 2006-2010 varies 
from  48-54%.) This is in some conflict with the study by Murray et al. [4], which attributes the 
bulk of changes in mortality over 1980-2010 to drug uptake and resistance. However, we have 
seen that our estimate of β6 is roughly consistent with available data. Further, LLINs and ACTs 
have both been found to be contributors to reduced morbidity and mortality in field settings 
[5,26,32]. 
 
Analytic Description of the Effects of RDTs for Malarial and non-Malarial Diseases 
There are many benefits to using RDTs to diagnose febrile treatment-seeking individuals [33]. 
First, RDTs reduce the level of ACT overtreatment, i.e., the treatment of individuals without 
malaria. By reducing ACT usage, RDTs will reduce the appearance, emergence, and spread of 
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ACT partner drug resistance and thus increase the waiting time to appearance of ACT resistance. 
Although the precise functional relationship between overtreatment and resistance is not known, 
there is evidence for the existence of such a relationship [34]. We do not consider the benefits of 
multiple first-line therapies here, although control strategies incorporating these might be able to 
preserve the effective lifetime of artemisinin [18]. Another benefit of RDTs is that individuals 
who are shown to be RDT negative can seek treatment for a disease other than malaria. If 
malaria-negative individuals are presumptively treated for malaria, either by themselves or a 
health-care provider, these individuals may delay seeking treatment for the true cause of 
morbidity because of the mistaken antimalarial use. 
 The extent to which malaria overtreatment interferes with rational treatment of other 
causes of morbidity is difficult to determine; however, we try to provide an estimate here. Figure 
S1A provides our estimate of the distribution of febrile illnesses in Africa; the proportions of 
each cause of fever are shown, including the fraction of comorbidity with malaria. The 
proportion solely attributed to malaria (purple) has fractions of comorbidities with other diseases, 
but these cannot be determined from the data. Text S1 I provides an explanation of our 
estimation. To breakdown how those causes might benefit from treatment, we apportioned the 
various causes of fever into categories. Text S1 II provides an explanation of the treatment 
options for each type of febrile illness. Figure S1B illustrates the assumed proportion of malaria 
mortality as a function of prop_mal; the remaining fraction of mortality is assigned 
proportionally according to the proportions in Figure S1A.  
 In order to sort out the complex effects of RDTs on treatment outcomes for malaria and 
non-malarial diseases, we can quantify the effects of RDTs as follows. We focus on the benefits 
of RDT information for improved antibiotic targeting in our analyses here. Let a be the increase 
in the extensive margin of treatment, i.e., the encouragement or discouragement of individuals to 
treatment in the presence of an RDT subsidy. Let b be the change in intensive margin in 
targeting, i.e., the increased proportion of individuals receiving proper antimalarial treatment. Let 
c be the change in extensive margin of RDTs for non-malarial disease, and let d be the change in 
intensive margin for non-malarial disease, considering only diseases that benefit from antibiotic 
usage. Thus, with RDTs, 𝑎 ∙ 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙  is the percentage of individuals receiving treatment for 
malaria that actually have malaria, and 𝑎 ∙ 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙 ∙ 𝑏 is the percentage receiving proper 
treatment, i.e., ACTs. Let 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜 be the proportion of individuals receiving antibiotics in 
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the absence of RDTs who have a disease that is cured by antibiotics, then 𝑐 ∙ 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜 ∙ 𝑑 is 
the percentage in the presence of RDT subsidies. 
 These percentages will differ depending on whether individuals seek treatment in the 
public sector or the private sector. Thus we have that the effect of RDTs can be broken down as 
follows: 𝑎!"# ∙ 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙!"# ∙ 𝑏!"# is the percentage of individuals with malaria seeking treatment 
in private sector; 𝑐!"# ∙ 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜!"# ∙ 𝑑!"# is the percentage in the presence of RDT subsidies 
in the private sector; the quantities 𝑎!"# ∙ 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙!"# ∙ 𝑏!"# and 𝑐!"# ∙ 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜!"# ∙ 𝑑!"# 
are the same percentages seeking treatment in the public sector. 
 Using this framework, we can analyze the complex data resulting from field studies. 
First, 𝑎!"#/𝑎!"#  and 𝑐!"#/𝑐!"#  represents ‘crowding out’; we assume that there is some 
crowding out and set 
!!"#!!"# = !!"#!!"# = 1.5, i.e., more people seek treatment in the private versus the 
public sector and that RDTs increase this proportion [35]. In the absence of RDTs we assume 
29% public 71% private so this ratio is 2.44; under RDTs we assume the proportions are 40% 
and 60%. We assume that RDTs do not affect the total extensive margins (𝑎!"# + 𝑎!"# = 1 and 𝑐!"#   +  𝑐!"# = 1.  
 
1. Effects on Malarial Diseases 
For the effects on the intensive margin, we assume that RDTs actually slightly decrease the 
proportion of treatment-seeking individuals with malaria receiving of ACT treatment (𝑏!"# =𝑏!"# < 1), which we generate using our RDT model. In the case of presumptive treatment, the 
number of DALYs averted is proportional to prop_mal. Once test-and-treat protocols are 
implemented, however, some individuals with malaria do not receive treatment because of 
failures of compliance and/or testing. Thus, as RDT coverage increases, the average number of 
DALYs averted per treatment-seeking individual decreases. This is one of the costs of RDTs; we 
call this ‘treatment discouragement.’  
 Corresponding to the quantities above, we can also consider the effects of RDTs on 
overtreatment outcomes. Let 𝛼 ∙ (1− 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙)  be the percentage of individuals receiving 
treatment for malaria that do not have malaria under RDT subsidies and let 𝛼 ∙ (1− 𝑝𝑟𝑜𝑝_𝑚𝑎𝑙) ∙β be the percentage of individuals without malaria seeking treatment and receiving ACTs under 
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RDT subsidization (‘overtreatment’). The proportion of individuals being overtreated is shown in 
Figure S2 which we generate using our RDT model; we assume that β!"# = β!"#.  
 Using our model of the effectiveness of RDTs, we find that antimalarial overtreatment 
can be reduced by 17.1% at 80% RDT coverage, assuming ‘very good’ compliance and by 33% 
at 93% treatment coverage, assuming ‘excellent’ compliance. (For ‘very good compliance’ we 
assumed 95% compliance with a positive RDT and 60% compliance with a negative RDT; for 
‘excellent compliance,’ 95% and 80%, respectively.) A recent report finds that overtreatment can 
be reduced by 58%; however, in this case the ACT subsidy was also reduced to discourage over 
consumption in addition to RDT subsidies [35]. Once the effects of the lowered ACT subsidies 
are controlled for, the authors find that, “(s)omewhat surprisingly, (our analysis) does not reveal 
many significant impacts of RDTs on ACT targeting” [35]. They attribute this lack of effect of 
RDTs on reducing overtreatment to the fact that “noncompliance in	  our	  population	  was high,” 
thus illustrating the importance of encouraging compliance among RDT negative individuals. 
However, other studies report a nearly complete reduction in overtreatment [36], illustrating the 
sensitivity of antimalarial overtreatment outcomes to compliance, test sensitivity and specificity, 
RDT coverage, the proportion malarious among treatment-seekers, etc. 
 
2. Effects on non-Malarial Diseases 
Let 𝜅 ∙ (1− 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜) ∙ δ be the percentage of individuals who have diseases that do not 
respond to antibiotics but receive antibiotics. Both of these quantities may be differentiated by 
public and private sectors as above. We assume that 
𝛂!"#𝛂!"# = 𝛋!"#𝛋!"# = 1.5 and α!"# + α!"# = 1 and κ!"#   +  κ!"# = 1, i.e., RDTs crowd out antibiotics at the same level as antimalarials and do not 
alter the extensive margins. For the change in the percentage receiving antibiotics, we assume 
that in the absence of RDTs, 25% of individuals with febrile illnesses receive them.  
 The effect of RDTs on antibiotics, 𝑑, depends on how individuals and health care 
practitioners use both RDT positive and RDT negative results. Let us assume that in the public 
sector, if antibiotics are prescribed to x% of individuals that are RDT positive that they are 
prescribed to (x + 24)% of RDT negative individuals (in line with field estimates [22,37]); this is 
the benefit of RDT targeting for non-malarial diseases. In order for the antibiotic prescription to 
be revenue neutral, that is, for there to be the same quantities of antibiotics prescribed before and 
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after RDT subsidization, antibiotics need to be prescribed to 1+ .24 ∗ 𝑅𝐷𝑇_𝑝𝑜𝑠  percent of 
RDT positive individuals, where 𝑅𝐷𝑇_𝑝𝑜𝑠 is the percentage of RDT positive individuals.  
 Using our RDT model, we predicted what proportion of RDT positive and RDT negative 
individuals had illnesses that were curable with antibiotics (Text SI III). Further, given our 
assumption of revenue neutrality and the 24% benefit of RDTs to targeting of antibiotics, we can 
calculate what percentage of individuals is cured of disease with antibiotics as a function of RDT 
coverage. The quantity 𝑑 as a function of RDT coverage and prop_mal in the presence of RDT 
subsidies is shown in Figure 3A, assuming RDTs have a false positive rate of 20% and a false 
negative rate of 5%.  
 As illustrated in Figure 3A there is a threshold region such that antibiotic targeting using 
RDTs saves more lives than no antibiotic targeting, because if most individuals do not have 
malaria, RDT negatives predominate and using RDT information improves treatment outcomes. 
However, outside of this region there are few RDT negatives and so RDT information should be 
discarded and presumptive antibiotics given. For simplicity we assume that 𝑐!"# ∙ 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜!"# ∙ 𝑑!"# = 𝑐!"# ∙ 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜!"# ∙ 𝑑!"# , i.e., that individuals target 
antibiotics in the private sector at the same proportion as the public sector. Note that we have 
assumed a fixed targeting scheme with a ~24% difference. If antibiotic supplies are limited then 
preference should always be given to RDT negative individuals, i.e., there should be a 100% 
difference. Indeed, the greater the targeting, the larger the region of RDT coverage and prop_mal 
in which it is optimal to use RDT information.  
 Regarding the levels of antibiotic overuse, in the presence of RDTs overtreatment with 
antibiotics is reduced. However, in the absence of an RDT for bacterial febrile illnesses, these 
individuals cannot be said to be overtreated in a practical sense, since it is likely difficult to 
distinguish among individuals who will benefit from antibiotics among febrile treatment-seekers. 
We do not simulate the effects of antibiotic overtreatment on antibiotic resistance here, although 
this could become a significant factor as RDT usage increases; in this paper, we assume that 
RDTs do not affect the extensive margins for antibiotic usage. 
 
3. Combining Effects of RDTs on Malarial and non-Malarial Diseases 
Once we calculated the benefits of RDTs in terms of non-malarial deaths averted, we 
incorporated the effects of decreasing intensive margins for ACT treatment among treatment 
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seeking individuals (𝑏!"# = 𝑏!"# < 1; Fig S1) to get a fuller picture at the costs and benefits of 
RDTs. The resulting change in mortality averted per RDT used is shown in Figure 3B; the z-axis 
illustrates the change in probability of averting mortality with antibiotics and antimalarials 
among individuals who would have died. Once the treatment discouragement effect was 
incorporated, RDTs caused a net increase in mortality over the a large range of RDT coverage 
and prop_mal values, because the loss of malaria positive individuals being treated with ACTs 
outweighed the effect of improved antibiotic targeting. 
 However, three points must be noted. First, we have implicitly assumed that ACT usage 
is not supply constrained. That is, we have assumed that at baseline every treatment-seeking 
individual can purchase ACTs at subsidized prices. If this is not the case, i.e., if ACTs are 
rationed, then the benefits of RDTs increase (see example in Text SI IV). Figure 3C illustrates 
the net effect of using RDTs to target antibiotics and antimalarials. This figure illustrates that 
RDTs result in improved outcomes for a larger region of RDT coverage levels and prop_mal 
values. Second, we have assumed that RDTs do not affect the external margins of antibiotic and 
antimalarial treatment. Thus, the subsidized price of RDTs must be so low as to not affect the 
purchasing decisions of these other therapies, or individuals have a high willingness-to-pay for 
RDTs. If RDTs reduce external margins, then their benefits will be reduced. 
 Third, we have only considered the direct effects on mortality of RDT usage. We have 
not considered the positive and negative externalities that result from RDT targeting, namely, the 
benefits of decreased antimalarial usage on increasing the waiting time to ACT resistance. In the 
Results section below we determine how ACT resistance will result in a significant increase in 
malaria-related morbidity and mortality, and so our estimates here represent the lower bound for 
the benefits of RDTs.   
 
Effects of ACT Subsidization for non-Malarial Diseases 
Regarding the effects of ACT subsidization alone on treatment choice, there is some evidence 
that ACT subsidization alone (independent of RDTs) discourages antibiotic use even among 
individuals treating in the private sector [35], because individuals treat malaria with antibiotics if 
those are cheaper than antimalarials (‘lowest cost first’ purchasing behavior) [35]. Thus, ACT 
subsidization will affect the extensive and intensive margins of both antimalarial and antibiotic 
usage. Second, subsidization of private sector ACTs may crowd out public sector use; we 
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discussed the effects of crowding out in the context of RDTs above. We do not examine these 
complex externalities on non-malarial diseases other than to note that further research is needed. 
 
Results 
Once the model had been fitted and compared with other estimates, we used the model to 
forecast malaria mortality under various scenarios. Figure 4 shows the four scenarios considered 
here: (I) expansion of AMFm over time to reach approximately 384 million doses of ACTs 
delivered per year; (II) maintenance of AMFm at the current level of approximately 291 million 
doses per year; (III) discontinuance of AMFm to approximately 193 million doses per year; (IV) 
and the counterfactual scenario of AMFm having never occurred. These scenarios do not model 
where the expansion of AMFm occurs, i.e. whether in high or low endemicity settings, or the age 
structure of the expansion. Rather, we predict the effects of worldwide increases/decreases in 
uptake assuming that the probability of averting mortality and morbidity in the future is governed 
by the same probabilities as was fitted to the 1980-2010. It is possible that by targeting the 
subsidy to certain groups the subsidy would be more effective going forward, though such 
benefits might be reduced by leakage. We thus might consider the present estimates conservative 
in this sense.  
A sample model projection is provided in Figure 5; this figure assumes that AMFm 
usage going forward is maintained at a constant level (Scenario III). We see that the increase in 
ACTs provided through AMFm causes a large decrease in mortality in 2011 and beyond (green 
line). After reaching a post-resistance minimum of ~639,000 in 2011, deaths rise over time due 
to increases in the rural African population size. However, ACTs provide a substantial reduction 
in mortality; in 2011 onward, at current levels of public and private subsidization ACTs are 
predicted to save ~450,000 lives per year. 
While the green line assumes constant ACT efficacy, we might also consider the effects 
of ACT resistance on deaths. Currently there have been no documented cases of clinical 
treatment failures with ACTs, which is what we refer to as ‘ACT resistance’ [38]. However, it is 
likely only a matter of when, rather than if, treatment failures to ACTs will appear. ACT 
resistance will eventually occur due to the therapeutic failure of artemisinin; we refer to 
artemisinin resistance and ACT resistance interchangeably since much of the therapeutic efficacy 
of ACTs relies upon the action of artemisinin.  
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We can simulate the effects of failing artemisinin and ACTs on mortality using our 
model. From the 1980-2010 mortality data we were able to estimate the shape of the curve 
describing the spread and effects of CQ resistance. This curve provides a baseline by which we 
might project mortality going forward if ACT resistance spreads as CQ resistance earlier did. It 
is not possible to know whether ACT resistance will spread faster or slower than CQ resistance 
at this point. However, using CQ resistance as a model for ART resistance might provide an 
illuminating reference point for further analysis. Further, the patterns of resistance between CQ 
and artemisinin might be similar for biological reasons as well. In the case of CQ resistance, at 
least four point mutations were required for CQ-resistant parasites, and mutants with 4-8 point 
mutations also occurred [39,40]. Given the nonspecific mode of action of artemisinin, it is likely 
that multiple mutations will also be necessary for the development of artemisinin resistance [41], 
possibly incurring fitness costs in the same way that CQ mutations engendered a fitness costs 
against wild-type strains. 
To simulate the spread of ACT resistance we used the same sigmoidal function as fitted 
for CQ and applied it to the efficacy of ACTs over time. It is not known how resistance for a 
combination might spread versus for a single drug; however, a degree of resistance to most of the 
ACT partner drugs has been documented (with the notable exceptions of piperaquine, where 
there is insufficient evidence, and lumefantrine, where there is limited evidence of high-level 
resistance), and so the spread of ACT resistance is likely to be governed by artemisinin failures 
[42]. For the purposes of modeling we assume here that ACT resistance will emerge in Africa in 
2015. Recall that there was a period of 21 years before appearance of CQ resistance in SE Asia 
and appearance in Africa. Our assumption of emergence happening early in Africa is thus a 
worst-case scenario. 
Given the assumption of a similar temporal progress of resistance for CQ and artemisinin 
and a date of 2015 for emergence in Africa, the projected mortality curve is shown in Figure 5A 
in red. The shaded red area illustrates the difference between the sensitive and resistant cases. 
The 10% treatment failure rate threshold (at which the WHO recommends that a therapy be 
replaced) would be reached at 2023 with 50% treatment failures worldwide by 2033. There 
would thus be a period of approximately eight years after emergence of resistance in Africa 
before the resistance would reach levels at which the WHO recommends switching therapies.  
One caveat to our analysis of resistance is that we do not consider the possibility of 
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reversion, i.e. that the proportion of resistant to sensitive alleles decreases, rather than increases 
over time. Certainly this phenomenon has been observed over time, for example the increase in 
CQ sensitivity in Malawi over time after cessation of treatment [43]. However, as noted in [17], 
“the complexity of malaria infections (in Malawi) suggests that drug-resistant parasites may still 
be present at low frequencies and that the reintroduction of CQ may be followed by a rapid 
resurgence in resistant infections.” Thus, we consider the general shape of the logistic resistance 
curve as areas where drug resistant alleles are present and where reintroduction would be met 
with rapid clinical failures.  
Figure 5B illustrates the number of lives saved using ACTs per year under each of the 
four scenarios. We can see that if the subsidy is expanded, then ~600,000 lives would be saved 
per year at maximum; 450,000 lives saved if AMFm were maintained, and 300,000 lives saved 
per year if subsidies go only to public providers. In each of the four scenarios we modeled the 
effects of resistance, which reduces the number of lives saved per dose with increased mortality 
coming rapidly around year 2025.  
As discussed previously, part of the justification for AMFm is that by crowding out 
monotherapies, resistance may be averted for a time. We simulated this effect by increasing the 
waiting time to appearance of resistance in Africa by 3 years until 2018 for the expanded subsidy 
levels. We see from Figure 5B that the result is to shift rightward the mortality curve such that 
more lives are saved per year in the ‘buying time’ case; the total difference over the depicted 
period is ~1,324,000 lives saved due to the three year shift. Thus, there are substantial returns to 
preserving the artemisinins in terms of lives saved, even by as short a time as a few years. 
  We also examined the cost-effectiveness of presumptive treatment (also called 
‘presumptive’ or ‘empirical’ treatment of febrile individuals) with CQ and ACTs over time, 
including the effects of resistance. Figure 6 shows the estimated number of dollars spent on each 
symptomatic therapy to avert one DALY. The dashed line illustrates the $50 threshold for an 
intervention to be considered ‘very cost-effective’ [1]. Due to the very low cost of CQ, dollars 
per DALY averted is low for presumptive treatment during the 1980s through the mid 1990s, 
though there is some cost of treatment of febrile patients who do not have malaria. However, 
resistance slowly increases the costs of treatment because of increased numbers of treatment 
failures, and by ~2022 the costs of treating individuals is no longer very cost effective. This 
might seem counter-intuitive, as resistance has rendered CQ almost useless at this point (96% 
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treatment failure rate). However, given the extremely low cost of CQ, even at this low 
probability of cure, it would still make financial sense to use CQ up to this point had no other 
therapies been available. In terms of the human costs in morbidity and mortality, however, as we 
have seen the therapy should have been supplanted many years ago (~1991). Our costing 
analysis for CQ resistance does not take into account the very considerable drug development 
costs to find replacement therapies, and so the costs of resistance are even higher than reported 
here. 
As regards ACTs, these are cost-effective even at the $3 per dose level, but much more so 
at the CHAI-negotiated price of $1 per dose. Our modeled treatment scenario for ACTs also 
includes the effects of RDTs; we call treatment with ACTs conditional upon a positive RDT a 
‘test-and-treat’ protocol. At current RDT coverage levels the vast majority of treatment is 
presumptive. From Figure 6 we see that ACTs became more cost-effective than presumptive 
treatment with CQ around 2010 as the prices for ACTs dropped. However, if we include the 
effects of resistance on ACT treatment outcomes, ACTs rapidly become less and less cost-
effective; whereas it took 42 years for presumptive treatment with CQ to fail from a cost-
effectiveness perspective, it only takes 25 years for the ACTs to fail.  
 
Discussion 
The costs of malaria over the past few decades have been great in terms of lives lost and 
morbidity incurred. In this paper we used a simple statistical model to examine the effects of CQ 
usage and resistance on overall malaria mortality over time. We also incorporated the effects of 
LLINs and ACTs on mortality, including the benefits of RDTs.  
 We found that our model could replicate the mortality trends averaged over three studies 
for the period of 1980-2010 using a set of parsimonious assumptions. We also corroborated our 
estimates from a variety of other published sources. The effects of CQ resistance during the 
period of 1980-2004 were dire: our model estimates that 5.7 million deaths are attributable to CQ 
resistance over this period. We also found that the 10% threshold of treatment failures worldwide 
was reached ~8-10 years after emergence of CQ resistance in Africa. If we compare this period 
to the time it takes to bring a new malaria drug or drug combination to market, it took 
approximately twenty years before ACTs were widely deployed after they were first reviewed in 
the literature [44]. Thus, our findings imply that the spread of resistance is faster than the spread 
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of drug development even if that resistance incurs a substantial fitness cost, unless urgency is 
brought toward development and clinical trials.  
 Our results have important implications for the preservation of ACTs. Regarding the 
extension of AMFm, we find that ACT subsidization saves lives relatively cheaply. Presumptive 
treatment with ACTs costs well below the level of ‘very cost-effective’ interventions in terms of 
dollars per DALY. Thus, even if ACT subsidization does not buy a substantial amount of time 
against resistance, there are very strong arguments in favor of subsidization from the perspective 
of both lives saved and dollars per DALY. Second, we found that delaying resistance can avert 
many deaths in the medium-term. If we assume ACT and CQ resistance spread similarly, 
pushing pack resistance for only three years would save approximately 1,324,000 lives by 2040, 
in the absence of new antimalarials.  
The main mechanism by which ACT subsidization would ‘buy time’ would be by 
crowding out monotherapies. Given that the pilot phase of AMFm began only in 2010, there are 
few studies of the effectiveness of subsidization at reducing monotherapy use. In Tanzania, 
artemisinin monotherapy use was quite low at baseline (< 1%) and so ACTs did not crowd out 
monotherapy so much as replace older treatments and increase treatment coverage [45]. In rural 
Cambodia, in the absence of any ACT subsidy, ACT coverage was low (11%) and artemisinin 
monotherapy coverage rates were quite high (~40% in 2002) [46]. The artemisinin monotherapy 
coverage rates at baseline in Cambodia were so much higher than in Tanzania likely because of 
proximity to producers in China, higher incomes, and familiarity with artemisinin. In areas where 
ACTs were provided at low or no charge, coverage rates increased (23-52%) and artemisinin 
monotherapy rates declined (5-13%).  
The extent to which the subsidy might buy time by crowding out monotherapies is 
unknown, but it surely depends upon context and there is some evidence for a benefit. Further, a 
perverse outcome is also possible if AMFm is discontinued. Because CHAI and the Global Fund 
have encouraged widespread artemisinin cultivation, if the subsidy is reduced it is possible that 
those producers will sell the artemisinins as monotherapies, thus increasing the supply of 
monotherapy above levels that would have prevailed had the subsidies never existed. It is also 
possible that increasing levels of antimalarial subsidization will actually decrease the time until 
onset of antimalarial resistance and/or increase the rate of spread of resistance because of the 
increase in selection pressure. Given these uncertainties, it is not immediately clear whether or 
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not antimalarial subsidization will delay or speed the onset of resistance, and thus we simply 
point out these conflicting factors and note that further research is needed. 
Another mechanism by which resistance might be averted is through decreasing the 
overtreatment of ACTs by increasing the proportion of malarious individuals among treatment-
seekers. Overtreatment can be reduced using RDTs, and here we have analyzed the relationships 
between overtreatment, cost-effectiveness, and RDT usage. Our first result regarding RDTs was 
that RDTs have a net benefit on mortality outcomes for only a small range of RDT coverage and 
prop_mal values.  
However, our analysis did not include the benefits of reduced overtreatment. If 
compliance is very good to excellent and coverage is increased to a high level (~70-90%), then 
overtreatment can be reduced by as much as 15-33% versus the purely presumptive treatment 
case (Figure S2). Thus, RDT usage is faced with a tradeoff of a decreased proportion of 
malarious individuals treated versus decreased overtreatment levels.  
In terms of a tradeoff, we predicted above that increasing the lifetime of ACTs by three 
years would save ~1,324,000 lives by 2040, or 9.23% of the total number of lives saved at 
baseline. Thus, each year of preserved ACTs results in 441,000 lives saved (3.1% of total until 
2040). We can use this result to quantify the positive externalities of reduced overtreatment. 
Let us assume that a 17.1% reduction in overtreatment (80% RDT coverage) at the 
expanded AMFm level preserves 1.5 years of effective ACT lifetime over five years of RDT 
coverage. Then 384,000,000 ∙ 5 ∙ .8 = 1,536,000,000 RDTs would save 663,000 lives, i.e., 
each RDT increases the probability that an individual treated with an ACT would survive by 
0.043%. To consider the magnitude of this effect in context, in Text S1 we calculate that every 
treatment-seeking individual has a 0.66% chance of dying. The magnitude of change from the 
effects of RDTs on targeting is on the order of ~1-5% (Figure 3); the effects are small because 
the improvements in targeting of antibiotics and the effects of ‘treatment discouragement’ are 
small.  
Thus, the changes shown in Figure 3 will affect on the order of 0.01% of treatment 
seeking individuals in the optimal case, which is smaller than the scale of changes due to delayed 
resistance. From this perspective, RDTs are a net benefit, as the benefits of increased lifetimes of 
ACTs outweigh the individual costs. However, RDTs are a net benefit from the perspective of 
the social planner. Individuals who are profit-maximizing would not internalize the benefits due 
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increased waiting time to resistance. Such individuals and would use the results from Figs 3B for 
their decision process, and thus RDT usage would be low because there is a narrow range of 
RDT coverage and prop_mal values for which RDTs provide a direct individual benefit.   
Further, the analysis considering the benefits of delayed resistance has a considerable 
level of uncertainty associated with it. It is possible that RDTs will delay the onset of resistance, 
but it is also possible that they will not (or will delay the spread, rather than the onset). Because 
the levels of uncertainty around delaying resistance are not quantifiable at present, this may 
reduce our confidence in using such analyses in determining RDT policy. In this case, the results 
from Figure 3C should be used to determine the optimal levels of RDT coverage, as these 
effects pertain to individuals directly (or if ACT supplies are not limited, to Figure 3B). Thus, 
for the risk-averse social planner, RDTs should only be employed in limited circumstances with 
the assumption above, though as the risk-aversion decreases, they might be employed more 
widely.  
We have laid out a framework for analyzing the effects of fever etiology, antibiotic and 
antimalarial targeting, RDT compliance, and RDT quality, as well as ACT resistance on the 
decision whether or not to adopt RDTs. Further research will probe those parameter sets that 
yield positive or negative contributions from RDTs. However, regardless of the costs and 
benefits of diagnostic testing, we have shown that subsidization of ACTs is very cost-effective in 
terms of the metrics of dollars per DALY, even in the absence of buying time, as well as total 
lives saved. Further, we have shown that the costs of malaria drug resistance are very high. Thus, 
subsidization programs like AMFm provide a strong return on public health investment dollars, 
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Figure 1. Malaria-attributable mortality estimates, 1980-2010. Malaria mortality data were 
collected from two sources and averaged to form an intermediate estimate. The dashed blue line 
on top is the estimated malaria-attributable mortality from the Global Burden of Disease (GBD) 
estimates [4]; the dashed orange line on bottom is the estimate from the 2011 World Malaria 
Report [2]. For the estimate used here, we took the mean of the two data series for 2000-2010. 
For the period 1980-2000, we applied a linear scaling to the GBD trend such that our estimated 
mortality differed at baseline from the GBD trend by 80% of the mean difference in 2000, 
scaling to 100% of the difference by 2000. The effects of the scaling are shown by the difference 
of the red trend line from the two vertical black lines at 1980 and 2000. The green cross provides 
the estimated year 2000 worldwide malaria-attributable mortality from the 2002 WHO World 
Health Report for comparison [19]. 
 
Figure 2. Relative shares of failing first-line therapies, bed nets, and ACTs on modeled 
mortality. We fitted a simple statistical model to the estimated worldwide malaria mortality data 
from 1980-2010. The relative contributions of artemisinin-based combination therapies (ACTs) 
and bednets were set to have approximately equal shares of mortality reductions. The model then 
assigned the total levels of reductions from failing first-line therapies (mostly chloroquine, CQ) 
as well as the trend of mortality over time using a least-squares fitting procedure. The dotted 
black line at top gives the predicted trend in mortality in absence of interventions, whereas the 
dotted orange line gives the estimated mortality assuming only first-line therapies. The orange 
line converges to meet the top line due to the spread of resistance. The modeled effects of 
bednets and ACTs are shown in blue and green, respectively. The red line provides the estimated 
mortality over time. 
 
Figure 3. Effects of RDT targeting of antibiotics and antimalarials on mortality. The RDT 
model was run to determine the effects of RDT usage on mortality. (A) The fold-change in 
mortality from antibiotics usage. The baseline treatment scenario assumes 25% coverage with 
antibiotics and no RDT targeting; the fold-change using RDTs results from targeting antibiotics 
to RDT negative individuals. The green region indicates the region of net improvement in 
outcomes; prop_mal is the proportion malarious among treatment-seeking individuals. (B) The 
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net change in probability of saving a treatment-seeking individual that would otherwise have 
died using RDT targeting for antibiotics and antimalarials. The benefits of RDTs for targeting 
antibiotics are diminished by including the effects of ‘treatment discouragement’ on antimalarial 
treatment outcomes. (C) The net change in probability of saving a treatment-seeking individual 
that would otherwise have died using RDT targeting, assuming that ACTs are supply-
constrained. The optimal region for RDT usage increases relative to (B) given the direct benefits 
of averted overtreatment.  
 
Figure 4. Four scenarios for private sector ACT subsidization. We modeled the effects of 
four different subsidization levels on future ACT uptake; these four Scenarios served as the bases 
of our prospective analyses. In all four Scenarios we assume that public sector subsidization 
levels remain constant; the change in artemisinin-based combination therapy uptake levels are 
the result of changes in private sector subsidization (through the Affordable Medicines Facility 
for malaria; AMFm). Scenario I represents an expansion of the AMFm such that ~384 million 
doses are provided on average through both private and public sectors (dotted purple line). 
Scenario II represents maintenance of AMFm at current levels (291 million doses). Scenario III 
represents discontinuance of AMFm in 2012 (193 million doses through various public sector 
donors from 2013 onwards). Scenario IV represents the counterfactual of never having had 
AMFm. The blue crosses provide the total public sector subsidization of ACTs over time; the red 
cross gives the total number of ACT doses provided in 2011, including AMFm; the black cross 
gives the number of subsidized doses in the public sector only in 2011. We do not include private 
sector purchases of ACTs at unsubsidized market prices in our analysis, as these represent a 
small fraction of total doses. 
 
Figure 5. Malaria mortality averted by ACTs per year, including resistance. The statistical 
model was used to simulate the effects of artemisinin-based combination therapy (ACT) on 
mortality over time. (A) ACT subsidization levels remain constant at 2011 levels (Scenario II). 
The dotted black line gives the trend in malaria-attributable mortality in absence of intervention; 
the orange line is mortality using first-line therapies (chloroquine, CQ) only; the blue line is 
mortality with CQ and bed nets; the green line is mortality with CQ, bed nets, and artemisinin-
based combination therapies (ACTs). To simulate the effects of ACT resistance on mortality, we 
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assumed that resistance will emerge in Africa in 2015 (triangle) and that ACT resistance follows 
the same kinetics of temporal and spatial progression as those observed for CQ. The red line 
gives mortality with ACT treatment and resistance. The shaded red region is the difference 
between ACT resistance and fully sensitive scenarios. (B) Estimates of malaria-attributable 
mortality averted through ACTs over time. The model was run under the four ACT uptake 
scenarios to simulate mortality averted over time. For Scenario I, the expansion of the Affordable 
Medicines Facility, malaria (AMFm), two different resistance patterns were simulated: resistance 
emerged either in 2015 (blue) or 2018 (red). The effects of ‘buying time’ by prolonging the 
effective clinical life of artemisinin is observed by examining the difference between the red and 
blue lines; the difference in area between the curves is ~1,324,000 lives by 2040. Maintenance, 
discontinuance, and the counterfactual scenario of no AMFm are shown in magenta, orange, and 
green, respectively; AMFm is already predicted to have saved ~305,000 lives from 2011-2012 
(difference between orange and green lines). 
 
Figure 6: Cost-effectiveness of antimalarials and effectiveness of RDTs. The semi-
mechanistic model describing malaria mortality was run to simulate the effects of antimalarial 
treatment over time and the number of disability-adjusted life years (DALYs) averted was 
calculated from life tables and the age-structure of mortality. Effects of treatment on morbidity 
were inferred from the overall levels of drug usage and the proportion of febrile illnesses 
attributable to malaria worldwide. The cost-effectiveness of presumptive treatment using first-
line therapies (modeled as chloroquine, CQ) was then calculated over time including the effects 
of resistance (purple). The cost-effectiveness with ACTs in terms of dollars per DALY averted 
was also calculated (green; no resistance), including usage of rapid diagnostic tests (RDTs). ACT 
resistance was modeled to emerge in Africa either in 2015 (blue) or 2018 (red), and follow the 
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Table 1: Semi-Mechanistic Model Parameter Estimates from Malaria Mortality Data
Parameter Description Estimate
β1 Number	  of	  malaria-­‐caused	  deaths,	  1980 1.43E+06
β2 Increase	  in	  number	  of	  deaths,	  per	  year,	  no	  intervention 6.06E+04
β3 Number	  of	  deaths	  averted	  by	  first-­‐line	  therapies,	  per	  year,	  no	  resistance 7.93E+05
β4 Time	  of	  50%	  first-­‐line	  treatment	  failues	  (years	  post	  1980) 18.36
β5 Hill-­‐slope	  of	  increase	  in	  treatment	  failures 3.90
β6 Probability	  that	  an	  ACT	  will	  avert	  a	  malaria-­‐caused	  death,	  no	  RDT 1.50E-­‐03
β7 Probability	  that	  an	  LLIN	  in	  a	  household	  will	  prevent	  a	  malaria-­‐caused	  death 5.31E-­‐03
Table 1: Semi-mechanistic Model Parameter Estimates from Malaria Mortality Data. The semi-
mechanistic model predicting malaria mortality from first-line therapy use, long-lasting insecticide-
treated nets, artemisinin-based combination therapy use, and rapid diagnostic test uptake was fitted to 










1980 1990 2000 2010
Year
1985 1995 2005
Malaria Deaths, GBD Estimate, 1980-2010
Malaria Deaths, WHO World Malaria Report 2011 Estimate, 2000-2010
Malaria Deaths, WHO World Health Report 2002 Estimate, 2000



































1980 1990 2000 2010
Year
1985 1995 2005




























Malaria mortality including failing first-line therapy
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Scenario I: Long-term expansion of AMFm
Scenario II: Maintenance of AMFm at current level
Scenario III: Discontinuance of AMFm 
Scenario IV: No AMFm
Global Subsidized ACTs Purchased (2005−2010)
Global Subsidized ACTs (2011), Including AMFm
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Modeled malaria mortality assuming no intervention
Malaria mortality including failing first-line therapy
Malaria mortality including first-line therapy and LLINs
Malaria mortality including first-line therapy, LLINs, and ACTs
Malaria mortality including first-line therapy, LLINs, ACTs w/ resistance
Assumed first widespread emergence of clinical treatment failures (2015)
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Figure 6
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Text S1: Causes and Treatments of Febrile Illnesses in Africa 
 
I) Simple African Fever Etiology  
To determine the causes of fever generally, we first took the attribution of mortality among 
African children aged 1-59 months of age from [1]. We then redistributed the causes 
proportionally after excluding those causes that are not associated with fever (injury and other 
non-communicable diseases were excluded). This analysis provides a simple etiology of fever, 
assuming that the proportions of morbidity presenting with fever correspond 1:1 to the causes of 
death by febrile illnesses. If we compare the proportion of malaria-caused fevers in this analysis 
to that predicted by the WHO for 2015 (prop_mal), we find the predicted value of 38% is much 
greater than the 24% attribution from mortality. Part of this difference (~14%) is due to 
difference of timing and analysis, but much of the difference also might relate to comorbidity. In 
the study Black et al. [1], mortality is classified by its primary cause so that diseases are not 
double-counted. However, some individuals are likely infected with malaria and bacterial 
infections, malaria and AIDS, etc., such that at time of presentation they are malaria positive, but 
their cause of death is attributed to another disease. 
 To account for comorbidity, we took the difference of prop_mal and our reattribution 
from [1] (14%) and shared this difference among the various causes of fever proportionally. 
Figure S1A provides the resulting distributions of fever in Africa. The proportions of each cause 
of fever are shown, including the fraction of comorbidity with malaria. The proportion solely 
attributed to malaria (purple) certainly has fractions of comorbidities with other diseases; this is 
simply the portion of malaria fevers attributable by the mortality data alone. If we assume that 
the attribution of causes of death is cause-neutral, then we would expect that of the 24% of 
deaths attributed to malaria, 14% in total (or 58% of malaria cases) would also have 
comorbidities with other diseases. We assume the cause-neutrality of death attributions here and 
thus assume that 58% of malaria cases have cormorbidity; however, for this 24%, malaria is the 
cause of death and not the comorbidity. 
 If we consider regional variation rather than averages, we cannot use the assumption that 
malaria causes ~24% of all deaths among febrile treatment-seeking individuals; after all, many 
areas have much less than 23% malaria prevalence. To account for those areas with low or high 
malaria, we created a function to describe the relationship between the proportion of deaths 
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caused by malaria and the proportion of treatment-seeking individuals that are malaria positive. 
The function f needed to satisfy the constraints that at f(0)=0, that f(38) = 24, and that the slope 
of f is decreasing, given that malaria is less fatal on a per treatment basis the higher the 
prevalence, due to the protective effects of immunity. Our choice of function is illustrated in 
Figure S1B. 
 
II) Treatment of Various Febrile-Illness Causes 
For pneumonia, many of the cases are caused by bacteria, some by viruses, and others are of 
unknown origin [2]; we assume that case-management and antibiotic use might prevent 36% of 
pneumonia deaths [3,4].  
 For diarrhea, there are a variety of methods used for prevention (vitamin A, rotavirus 
vaccine, breastfeeding as well as the water, sanitation, and hygiene (WASH) protocols); for 
treatment, oral rehydration salts (ORS), zinc supplementation, and antibiotics [5]. The non-
WASH interventions are estimated to cost $0.80 per capita per year [5]. Regarding effectiveness, 
Walker et al. [5] estimates that ORS is effective at averting 93% of all non-dysentery diarrheal 
deaths, antibiotics 99% effective at preventing dysentery diarrheal deaths, with zinc adding an 
additional 23% effectiveness to both. Thus, the vast majority of diarrheal deaths are preventable; 
we assume 99% are treatable.  
 For measles, two doses of vitamin A supplementation has been shown to reduce mortality 
by 62% [6,7]; two capsules cost $0.041, though the cost including delivery is higher.  
 For bacterial (N meningitidis) meningitis, intramuscular injection of ceftriaxone has been 
shown to reduce morality rates by approximately 50% [8,9], and most epidemic meningitis in 
Africa is bacterial [10].  
 For AIDS, highly active antiretroviral therapy has been shown to reduce mortality in rural 
Africa by 87% versus antibiotic prophylaxis, at a cost of ~$1,400 per person per year [11].  
 For pertussis, treatment can address either the infection or the symptoms; regarding for 
the former, “Although antibiotics were effective in eliminating B. pertussis, they did not alter the 
subsequent clinical course of the illness” [12]; for symptomatic treatment, “Much of the 
(pertussis) morbidity is due to the effects of the paroxysmal cough… insufficient evidence exists 
to draw conclusions about the effects of any intervention for the cough in whooping cough” [13]. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  As	  reported	  by	  UNICEF:	  http://www.unicef.org/immunization/files/Vitamin_A_Supplementation.pdf	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Thus, we cannot evaluate the effectiveness of interventions to prevent pertussis mortality once 
infection has presented. 
 In this paper we focus on the benefits of antibiotic treatment targeting using RDT data. 
There are other ways to bundle treatments using RDTs, by, say, pairing RDT negative diagnosis 
is delivered with either some other form of diagnostic or some type of catch-all treatment 
(antibiotic, vitamin A, ORS supplement). However, we do not consider those types of 
interventions here. 
 If we take the proportion of individuals whose cause of death is preventable upon 
presentation weighted by the proportion of febrile presentations (non-malarial causes only), we 
find that 48.7% of non-malarial febrile deaths were readily treatable (excluding AIDS, pertussis, 
and ‘other infections’) and that at least 12.5% of non-malarial febrile infections were easily 
curable by antibiotics (9.55% of febrile infections including malaria; thus 𝑝𝑟𝑜𝑝_𝑎𝑛𝑡𝑖𝑏𝑖𝑜 =0.0955), though this estimate does not include benefits from reductions in ‘other infections.’  
 However, an RDT only tells the patient whether they have malaria or not; it does not 
distinguish among the non-malarial causes. For those patients who are RDT negative, the RDT 
does not distinguish among diarrhea, measles, meningitis, or pneumonia (or whether bacterial or 
viral infection). As we have seen, the treatments for these cases differ. In clinical settings, RDT 
negative results have been shown to improve antibiotic targeting [14,15]. Indeed, antibiotics 
prescriptions increased from 19% in the RDT negative group to 45% in the RDT positive group 
in Zanzibar [22], and from 13.4% to 34.5% in Ghana [48]. This ~24% increase in antibiotic 
prescriptions likely significantly reduces mortality among the ~13% of infections that benefit 
from antibiotics; indeed, patients seek less retreatment after test-and-treat versus clinical 
diagnoses [22].  
 However, these results are valid for clinical settings, where treatment is adjusted 
conditional on a negative RDT. For individuals receiving care in the private sector, the benefits 
of a negative RDT may be more ambiguous, because these individuals are self-diagnosing, and 
because there are costs to seeking treatment multiple times, i.e., retreatment might be 
discouraged. Further, there is evidence that subsidizing ACTs may encourage antimalarial usage 
outside of the public sector, a phenomenon known as ‘crowding out’ [16]. 
 
III) Determining Total Average Levels of Mortality  
181
Assuming a revenue-neutral antibiotic prescription protocol and a 24% antibiotic targeting level, 
that RDTs save lives for a large range of RDT coverage and prop_mal pairs (Figure 3B). To 
determine the number of DALYs saved trough usage of RDTs, we can take the results from 
Figure 3B, multiplied by the probability that antibiotics will save a life; if we divide the cost of 
an RDT by this probability, we thus compute the benefit in dollars per DALY for RDTs from 
non-malarial illnesses.  
 To determine the actual probability that treatment saves a life, we need to know the 
probability of death in general. From our analysis, β6 = 0.0015 (Table 1), that is, treatment with 
an ACT has a 0.15% chance of saving a life in the absence of RDT usage. If treatment with 
ACTs saves a life that would have otherwise been lost with a 95% probability, then among 
febrile treatment seeking individuals, the probability of death from malaria is 0.158%. Using the 
estimate of malaria as a percentage of all deaths from febrile illnesses (24%), we have that the 
chance of death among all febrile treatment seekers from combined worldwide and African data 
is thus approximately 0.66% on average. Assuming independence of probabilities of receiving 
antibiotics and having a febrile illness that responds readily to them, there is thus a 0.66 ∙ 0.76 ∙0.125 = 0.66 ∙ 0.955 = 0.063% chance that an antibiotic will save the life of a person treated 
with an antibiotic for a febrile illness. 
 To determine these probabilities for RDT negative and positive individuals, we can use 
the febrile illness attribution modeling described in Section I above. We find that 3.8% of true 
malaria positive and 12.5% of true malaria negative individuals who would have died otherwise 
can avert mortality if antibiotics are given. Thus the probability that an antibiotic saves a life 
among true malaria positives and malaria negatives is 0.66 ∙ 0.038 and 0.66 ∙ 0.12, respectively. 
 To determine the number of DALYs saved trough antibiotic targeting using RDTs, we 
can take the results from Figure 3B, multiplied by the probability that antibiotics will save a life; 
if we divide the cost of an RDT by this probability, we thus compute the benefit in dollars per 
DALY for RDTs from non-malarial illnesses. 
 
IV) Analysis of RDTs Assuming Constrained ACT Supplies 
To examine the effects of RDTs on malaria mortality assuming constrained ACT supplies, 
consider the following example. Assume that there are 1 million doses of ACT available for a 
given area, and that in the absence of RDTs, the specificity of treatment (treatment of malaria 
182
positives) is 25%: without RDTs, all million doses are used, 25% of individuals are cured, and 
75% of treatment is wasted. Now assume that, using RDTs, overtreatment is reduced by 20% and 
that 24% of treatment seekers are cured (24% < 25% because of reduction of intensive margins); 
then overtreatment is 60%; and 75 ∙ .2 = 15%  of treatments are left over.  
 These remaining treatments are then given out to the next round of patients at the same 
60:24 ratio, and .15 ∙ 24 =   3.6% of patients are cured, with 0.152 or 2.25% remaining for a 
third round. The total percentage of patients cured can be expressed as 24 ∙. 15! = 24 ∙!!!!!!!.!" ~ 28.2%, i.e., the total number of cures with 1 million treatments increases from 250,000 
to 282,000 with RDTs. The number of cures per RDT is thus (32,000/1,000,000 = 0.032). 
 Following the same logic, we adjusted the effectiveness of ACTs by incorporating the 
benefits of RDTs in terms of reduced overuse under supply constraints for the entire range of 
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Figure S1. Etiology of fever and malaria mortality attribution. (A) Estimate of the distribution of febrile illnesses 
in Africa; the proportions of each cause of fever are shown, including the fraction of comorbidity with malaria. The 
proportion solely attributed to malaria (purple) has fractions of comorbidities with other diseases, but this proportion 
of febrile illness represents that propotion of mortality attributable to malaria. (B) Assumed proportion of malaria 
mortality as a function of prop_mal; non-malarial mortality is assigned proportionally according to the proportions 




Figure S2: Effects of rapid diagnostic testing on overtreatment with ACTs. We predicted the effects of rapid 
diagnostic testing (RDT) on the levels of overtreatment with artemisinin-based combination therapies (ACTs). 
We examined three compliace secenarios: ‘very good compliance’ (95% compliance with a positive RDT and 
60% compliance with a negative RDT, top surface); ‘excellent compliance,’ (95% and 80%, middle surface); and 
‘perfect compliance’ (100% and 100%, botom surface). The x-axis is the total coverage level of test-and-treat 
treatment with RDTs and ACTs; the proportion not covered is assumed to be treated presumptively. The y-axis 
is the proportion of treatment-seeking individuals with malaria (prop_mal). The z-axis represents the fold change 
in overtreatment, i.e., treatment of individuals with ACTs who do not have malaria, versus purely presumptive 
treatment. Contour lines are provided for the top surface and projected to the z=0 axis for clarity. The blue dot 
represents the effects of 80% coverage assuming the mean worldwide value of prop_mal used in the paper (~38%). 
The larger the fold decrease, the more overtreatment being averted and thus the better the outcome from a drug 
resistance perspective.
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